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The aim of these studies was to modulate d ru g  resistance in 
small cell lung cancer (SCLC) both in the laboratory and in the 
clinic with verapamil. Nine small cell lung cancer cell lines have 
been established from both pretreatm ent and relapse biopsies and 
include a pair of cell lines from the same patien t. Problems in 
establishing cell lines related to lack of viable tumour material and 
overgrowth by  fibroblasts.
All the cell lines have been characterised  and demonstrate 
features characteristic of SCLC in v itro . All cell lines expressed 
the small cell m arker enzymes dopa-decarboxylase and the BB 
isoenzyme of creatine kinase though the levels varied between cell 
lines . Pathological, immunocytochemical and u ltra s tru c tu ra l studies 
were used to identify  both epithelial and neuroendocrine fea tu re s . 
Thus the cell lines could be classified into classic or variant 
phenotypes. Detailed cytogenetic analysis of the cell lines 
confirmed the ir human origin and all were shown to contain the 3p 
deletion characteristic of lung tum ours. The modal chromosome 
number ranged from 39 to 53.
The cell lines all grow as non-adherent aggregates except for 
a monlayer varian t of LS112. Measurement of growth ra tes and 
chemosensitivity therefore proved difficult since the aggregates 
could not be dispersed into a viable single cell suspension. 
Initially measurements were attem pted by  computerised spheroid 
image analysis. This technique was slow bu t provided limited
27
information for th ree of the cell lines (LS106, LS111 and LS112FL). 
However, the other cell lines tested  did not grow well in this 
system .
A tetrazolium dye-based m icrotitration assay was therefore 
modified for use with both adherent and non-adherent cell lines. 
The assay uses as an end point the ability of live, bu t not dead 
cells, to reduce a yellow water-soluble tetrazolium dye (MTT) to a 
purple water-insoluble formazan product (MTT-formazan). Initial 
work with this assay  indicated a number of deficiencies and , in 
particu la r, at high cell density  or low pH the relationship between 
MTT-formazan production and cell number was not linear. It was 
shown th a t by  determining the optimal concentration of MTT for 
each cell line and by  addition of a bu ffer a t a high pH (10.5) to 
control the pH of the formazan product a linear relationship could 
be obtained. When in tact aggregates were incubated with MTT, 
crystals of MTT-formazan were produced by  the entire viable cell 
population of the ag g reg ate . Furtherm ore, doxorubicin was shown 
to penetrate  throughout the viable cell population of the ag g reg ate . 
Thus the assay could be applied to the in tact SCLC aggregates 
thereby  avoiding the need to d isru p t the clusters with the 
consequent loss of cell interaction and viability.
The cell lines were slow growing with doubling times of 
between 4 and 6 d ay s . There was a 60-fold range in sensitiv ity  to 
doxorubicin (IDs o , 17-5 - 1050nM). In trinsic sensitiv ity  to 
doxorubicin did not relate e ither to any specific characteristic of 
the cell lines or to the h isto ry  of the patien t from whose biopsy the 
cell line was established. However, for the pair of cell lines
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established from the same patient the line derived from the relapse 
biopsy (LS310) was five-fold more resis tan t to doxorubicin than the 
line derived from the original chemosensitive pretreatm ent biopsy 
(LS274).
For the m ultidrug resis tan t SCLC cell line, H69LX10, 
resistance modification by  verapamil was shown to be dose 
dependent and was maximal (10-fold) a t about 6-7 uM. At 
clinically achievable levels of verapamil (luM) the effect was only 
2-fold. These resu lts  indicate th a t verapamil may have limited 
activ ity  in the clinic. However, the D-stereoisomer of verapamil 
was shown to be an equally effective resistance modulator as the 
racemic m ixture. Since D-verapamil is thought to be less 
cardiotoxic than L-verapamil it is possible tha t use of D-verapamil 
in the clinic will allow increased plasma levels of the modulator 
without undue cardiotoxicity. Quinidine and bepridil were also 
identified as modulators th a t have significant activ ity  in H69LX10 
cells in the laboratory at levels achievable in the clinic.
An increase in sensitiv ity  to doxorubicin (2-3 fold) in the 
presence of verapamil (6.6uM) was dem onstrated in 5 of the 9 
newly established SCLC cell lines. The sensitising effect of 
verapamil did not relate to patien t h isto ry  or to the in trinsic 
sensitiv ity  of the cell line to doxorubicin. T hus, the most 
sensitive line (LS277) established from an un treated  patient showed 
a 2 .3-fold increase in sensitiv ity  whereas the most resis tan t line 
(LS310) from a relapse biopsy showed no change in sensitiv ity  
when co-incubated with verapamil.
In order to assess w hether verapamil might have an effect on
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relapse with resis tan t tumour in the clinic the f irs t randomised 
large-scale (comprising 226 patien ts) s tudy  of verapamil given in 
addition to combination chemotherapy in patients with SCLC was 
undertaken . All patients received four cycles of identical 
combination chemotherapy (including doxorubicin) with or without 
verapamil. Toxicity in both arms of the s tudy  was similar. In 
particu lar, there  was no undue cardiovascular toxicity. There 
were no major differences in response ra te  or in survival between 
the control and verapamil arms.
Thus the role of verapamil as a resistance modifier in the 
clinical management of small cell lung cancer remains unclear. 
Problems may relate to the relatively low levels of verapamil 
achievable in the clinic. Furtherm ore, the importance of P- 
glycoprotein expression as a resistance mechanism in SCLC is not 
clear. If over-expression of P-glycoprotein is not a common 
mechanism of d rug  resistance in SCLC, fu tu re  attem pts to modulate 
d ru g  resistance should be aimed a t o ther resistance mechanisms 
such as altered activities of d ru g  detoxification enzymes or of 
topoisomerases.
Nonetheless, this work dem onstrates for the f irs t time clear 
evidence of resistance modification by  verapamil in newly 
established SCLC cell lines and identifies two modulators, quinidine 
and bepridil, that are active at levels achievable in the clinic.
CHAPTER I
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GENERAL INTRODUCTION 
Drug Resistance in Small Cell Lung Cancer: 
The Problem in Perspective
In this co u n try , lung cancer is the commonest malignancy in 
men and second most common malignancy in women. Although the 
incidence may now be reaching a plateau, lung cancer still causes 
2,500 deaths every  year in the West of Scotland (Kemp et a l . , 
1985). Indeed the West of Scotland has the highest incidence of 
lung cancer in the Western world (Plate 1 .1 ).
Small cell lung cancer (SCLC), rep resen ts  about 25% of all 
lung tumours and is regarded as a distinct pathological en tity . It 
d iffers from the o ther histological types of lung tumour with 
respect to its biological behaviour and its usually initial, dramatic 
response to cytotoxic agents (Seifter & Ihde, 1988).
The natural h istory  of SCLC is characterised by  a 
progressive clinical course with the early  development of 
m etastases (Cohen & Mathews, 1978; Morstyn et a l . , 1984). 
Indeed in comparison with o ther types of lung cancer, patients 
p resen ting  with SCLC often have a sho rte r h isto ry  of symptoms, 
the majority have overt evidence of widespread tumour 
dissemination a t presentation and in the absence of therapy  their 
disease progresses relentlessly . Thus SCLC has come to be 
regarded  as a systemic disease at presentation.
Trachea,
Plate 1.1
Map of Scotland illu s tra tin g  the annual average incidence of 
lung  cancer p e r 100,000 population (1975-1980) (from: Kemp et a l . ,
1985).
Bronchus and Lung —  Males
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Over the last two decades it has become clear tha t SCLC is
usually responsive to a wide range of cytotoxic d ru g s. This has
led to the establishment of chemotherapy as the mainstay of
treatm ent for this disease (A isner et a l . ,  1983). Aggressive
generally
therapeutic regimes yield the best response ra tes and produce the
A
highest proportion of long-term surv ivors in SCLC (Aisner et a l . ,
1983). However despite response ra tes  of more than 80% and 
significantly improved median survival (10-12 months) with 
combination chemotherapy, at best about 10% of patients will remain 
disease-free 2 years a fte r diagnosis (Ihde, 1984; Morstyn et a l . ,
1984). The reason for such disappointing long-term  survival 
s ta tistics relates to relapse with tumour which is generally 
resis tan t to most cytotoxic agents (Aisner e t  a l . ,  1983).
Thus relapse with chemoresistant tumour is the main 
cause for treatm ent failure in SCLC. Plate 1.2 exemplifies this 
problem. This series of chest radiographs show the original 
tumour (A ), a dramatic response to chemotherapy (B ), and then 
afte r a prolonged period of remission the untreatable relapse with 
resis tan t tumour (C ).
This is not a feature unique to SCLC, and indeed is a 
problem in many other commonly occurring solid tumours such as 
b reast (Benson 111 et a l . , 1985) and ovary (Ozols et a l . , 1987A). 
Indeed the fru s tra tin g  phenomenon of relapse with chemoresistant 
tumour has been evident since cytotoxic agents capable of inducing 
effective tumour regression were f irs t used (F arber et a l . , 1948).
The nature of resistance in such tumours remains unclear. 
It is probable th a t a range of mechanisms of resistance operate.
Plate 1.2
C hest rad iograph  of m iddle-aged female with small cell lung  
cancer a t p resen ta tion  showing ex tensive left sided tum our (A).  
T here  was a complete radiological response  (confirmed b y  re -  
s tag in g  bronchoscopy) to induction chem otherapy (B) .  Tw enty- 
fou r months la te r  the pa tien t re lapsed  locally (C) .  This relapse 
tum our p roved  re s is ta n t to fu r th e r  chem otherapy.
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It may be that relapse with resis tan t tumour is a manifestation of 
resistance tha t has developed secondary to cytotoxic therapy  (so- 
called acquired resistance). Luria & Delbruck (1943) f irs t 
described acquired resistance due to selection of spontaneously 
occurring mutations in bacteriophage. Similar spontaneous 
mutations might explain resistance to cytotoxic d rugs in mammalian 
cancer cells (Isaacs & Coffey, 1981; Law, 1952). More recently  
a mathematical model for the process of spontaneous mutation 
resu lting  in acquired d rug  resistance has been developed by  Goldie 
& Coldman (1979). A lternatively, such relapse might relate to the 
overgrowth of a population of intrinsically  resis tan t tumour cells, 
p resen t from the s ta r t in the natural h isto ry  of the tumour ( i.e . 
in trinsic resistance).
Numerous studies have shown tha t there  are sub-populations 
of cells in animal tumours (Barranco et a l . , 1978; Lotan & Nicolson,
1979) and human tumours (Barranco et a l .,  1972; Trope et a l . ,  
1975) with differing susceptibilities to a varie ty  of cytotoxic 
agen ts. More recently  Tsuruo & Fidler (1981) demonstrated 
extensive differences in d rug  sensitiv ity  among cells populating 
parental tumour and metastatic sub-populations. Thus metastases 
may resu lt from the growth of selected sub-populations of cells 
th a t p re -ex is t within the prim ary neoplasm (Fidler & Kripke, 
1977; Poste & Fidler, 1980). The recognition th a t neoplasms are 
populated by cells with such diverse biological behaviour has 
prompted investigation into both the nature  of the biological 
heterogeneity  of neoplasms and also into the implications of these 
findings for therapy  (Calabresi et a l . , 1979; Fidler, 1978; Fidler
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& Kripke, 1977; Kerbel, 1979). Indeed micrometastases and 
metastases have been shown to be genetically unstable and so more 
likely to become resis tan t (Fidler, 1978).
Small cell lung cancer, by  its  very  biological n a tu re , with its 
clinical behaviour comprising a b risk  initial response to 
chemotherapy followed by  relapse with resis tan t tumour, serves as 
an ideal model for the s tudy  of d rug  resistance both in the 
laboratory and in the clinic. The s tudy  of resistance in any 
tumour model system comprises both the investigation of possible 
mechanisms of the resistance, and also the application of methods 
to t ry  and overcome such resistance. A great deal of our cu rren t 
understanding  of mechanisms of resistance and methods of 
circumventing resistance has come from laboratory models of d rug  
resis tan t tumour cell lines. Before considering what information 
has been obtained from such in v itro  models of resistance and of 
what clinical relevance these findings might be , it is f irs t 
appropriate to review the general h isto ry  of concepts of resistance 
in the clinical setting .
Theories of Drug Resistance in the Clinic
There are a number of possible components of tumour 
resistance to cytotoxic drugs in the clinic. The patient might 
handle drugs in an altered fashion in terms of d ru g  absorption and 
activation. Altered tumour vascularisation could resu lt in reduced 
penetration of d rug  into the tumour. However, most theories 
concerning tumour resistance are based on cellular mechanisms.
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This might relate to any or all of the following factors: the
proliferative state  of the cell, altered cellular biochem istry, and 
altered cellular pharmacology (d ru g  uptake and re ten tio n ). Before 
considering each of these three broad groupings it is worth noting 
th a t many cytotoxic drugs themselves are potent mutagens and may 
themselves directly  induce resis tan t mutants (Selby, 1984). 
Furtherm ore tumour cells may in teract (both in vivo and in v itro ) 
and these interactions may influence d rug  sensitiv ity  (Miller et a l . ,
1981).
Initially the popular belief was th a t the main mechanism of 
resistance related to altered cell k ine tics . The most resis tan t cell 
was thought to be the non-proliferating (Go) cell. The frequency 
of resistance in solid tumours was thought to relate to the large 
proportion of Go cells and consequent low growth fraction and long 
doubling time in these tumours. This theory  has been elegantly 
reviewed by  C arter (1984). However, there  is little evidence to 
suggest tha t initially sensitive cells may become resis tan t by  
altered proliferation kinetics.
Subsequently, a biochemical view became popularised. This 
led to the development of anti-metabolites and between 1950 and 
1970 a massive data base of "rationally designed anti-metabolites" 
was developed. In terms of tumour cell resistance, it seems likely 
th a t altered biochemistry plays a major role (see below).
More recently  a pharmacological view has been developed to 
explain the lack of activity of cytotoxic drugs in resis tan t tumour 
cells. This was based on the premise tha t a cytotoxic d rug  could 
only kill tumour cells if it reached the cell a t an adequate
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concentration and for an adequate time. This led to a great 
number of studies of the pharmacokinetics of cytotoxic agents bu t 
these only developed some post-hoc rationalisation for why one 
empirically discovered schedule was superior to others (C arte r,
1984). Nonetheless, in terms of resis tan t tumour, it seems likely 
th a t altered d rug  handling does play a role.
By the 1980s the view of cancer chemotherapy resistance was 
an integration of the pro liferative, biochemical and pharmacological 
concepts, all placed within the broad conceptual context of the cell 
kill hypothesis (C arter, 1984). The cell kill hypothesis was f irs t 
elucidated by  Skipper and Schabel (1984). This sta ted  th a t if the 
dose of cytotoxic d rug  could be increased to a sufficiently high 
level in relation to the total number of tumour cells p resen t, then 
the fractional kill would lead to the total eradication of the tumour 
mass and hence lead to cure. However, th is approach did not lead 
to cure. The paradigm to explain this failure of chemotherapy 
focuses on the problem of tumour cell resistance.
Whether this is inherent or acquired during  chemotherapy, 
a model of tumour cell resistance predicts tha t there will be a 
proportion of resistan t cells within a tumour. The final common 
pathway of all chemotherapy strateg ies is to overcome such 
resis tan t tumour cells, and completely eradicate them a t cytotoxic 
dose levels tha t are tolerated by  the host. Such a model of tumour 
cell resistance supports the administration of the h ighest possible 
dose of cytotoxic d rug  bu t does recognise th a t if resistance has 
developed, then the tumour will not be successfully eradicated 
simply by  dose escalation. This model remains an essentially
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proliferative model bu t shifts the emphasis from tumour cell 
kinetics to tumour cell resistance. However, this conceptual model 
does not consider the mechanism of tumour cell resistance or ways 
of overcoming i t ,  although it naturally  leads to such concepts. 
Nor does this model consider the possibility th a t resistance may 
relate to tumour cell dormancy. Such mitotic quiescence may relate 
to a lack of or inactivation of essential tumour growth factors. 
A lternatively some tumour cells may undergo differentiation 
associated with reversible cessation of division (Alexander, 1982; 
C arter, 1984). Tumour cell dormancy remains a potentially 
formidable problem. Nonetheless, from clinical experience it seems 
likely th a t the failure of chemotherapy to cure the vast majority of 
patients with SCLC relates to the overgrowth of resis tan t tumour 
cells.
Laboratory Models of Drug Resistance: The Role of P - glycoprotein
A number of laboratory models of d rug  resistance have now 
been developed. Tumour cell lines can be made resis tan t by 
chronic exposure to increasing doses of cytotoxic agents. This 
approach, which resu lts  in cell lines with a high degree of 
acquired resistance was followed by  a number of workers (Akiyama 
et a l . ,  1985A; Beck et a l . ,  1979; Biedler & Riehm, 1970; Ling & 
Thompson, 1974; Shen et a l . ,  1986A). Such cell lines made 
resis tan t to one cytotoxic agent often demonstrate cross-resistance 
to a broad range of s tructu ra lly  unrelated  cytotoxic drugs - so 
called m ulti-drug resistance (MDR). Although initial studies
3 7
involved resistance to actinomycin D (Biedler & Riehm, 1970) and 
vinca alkaloids and colchicine (Ling & Thompson, 1974), other 
cytotoxic agents have also been used , including etoposide (Seeber 
et a l . ,  1982) and mitomycin-C (Dorr e t a l . ,  1987). These cells 
appear to be resis tan t because they  have decreased intracellular 
cytotoxic accumulation, probably related to increased d rug  efflux 
(Fojo et a l . , 1985; Inaba & Johnson, 1978; Inaba et a l . , 1979; 
Nishimura et a l . ,  1979).
More recent work examining genetic changes in resis tan t 
cells has demonstrated tha t these m ulti-drug resis tan t cells usually 
contain a gene, termed the MDR-1 gene, which is transcribed  into 
a 4.5 kilobase messenger RNA (Gros e t a l . , 1986A; Riordan et a l . , 
1985; Scotto et a l . , 1986; Shen et a l . , 1986B; Van der Bliek et a l . ,
1986). This gene is over-expressed bu t not always amplified in 
MDR cells (Fairchild et a l .,  1987; Roninson et a l . ,  1984). The 
protein  product of this gene is a 170 kilodalton membrane 
glycoprotein, named P-glycoprotein (P for permeability) which is 
thought to act as an energy dependent d ru g  efflux pump 
(Gottesman & Pastan, 1988; Horio et a l . ,  1988). This is now the 
most clearly understood mechanism of d ru g  resistance in v itro  and 
for th is reason it is the only mechanism addressed  by the studies 
described in this thesis.
A full length complementary DNA for the MDR-1 gene from 
one of the m ulti-drug resistan t human KB carcinoma cell lines has 
been isolated and sequenced (Chen et a l . , 1986; Roninson et a l . , 
1986; Ueda et a l. ,  1987A, B). Molecular biological techniques were 
subsequently  used to fu rth e r s tudy  the function and possible
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importance of the MDR-1 gene. Although Roninson’s and Gros’s 
work initially involved resistan t animal tumour cells, Pastan and 
Gottesman focused on resistan t human tumour m utants. The gene 
sequences in these human tumour mutants were rem arkably similar 
to the DNA isolated by  Gros from resis tan t ham ster tumour ( Chen 
et a l . ,  1986; Gros et a l .,  1986A). The s tru c tu re , amino-acid 
sequence and configuration of P-glycoprotein within the cell 
membrane have now been elucidated (Plate 1.3) and its  remarkable 
resemblance to bacterial transpo rt proteins noted (Gerlach et a l . ,  
1986; Gros et a l . , 1986B). This suggests it may have a role as a 
d rug  tran sp o rt protein.
There is now evidence tha t P-glycoprotein is a member of a 
multigene family. At least two d ifferent classes of P-glycoprotein 
cDNA have been identified in ham ster (Endicott et a l . ,  1987), 
mouse (Gros et a l . , 1986A) and human (Van der Bliek et a l . , 1987) 
tum ours. Certainly amplification of o ther closely juxtaposed gene 
classes has also been detected in MDR cells, the product of one of 
which is the cytoplasmic protein , sorcin (Jongsma et a l . ,  1987).
The most dramatic evidence to suggest P-glycoprotein is 
important in m ulti-drug resistance arises from the experimental 
tra n sfe r of genetic material encoding for P-glycoprotein. F irst 
experiments involved tran sfe rrin g  genomic DNA from MDR ham ster 
cells into drug-sensitive mouse cells and with the use of species- 
specific anti-P-glycoprotein antibodies dem onstrating the presence 
of ham ster P-glycoprotein in the originally sensitive mouse tumour 
cells (Deuchars et a l . ,  1987). Resistance was also shown to be 
conferred on mouse N .I.H . 3T3 cells by  transfecting  genomic DNA
Plate 1.3
Schematic diagram  of the  P -g lycoprotein  molecule. This 
illu stra tion  em phasises the  trans-m em brane location of th is complex 
s tru c tu re , which is though t to act as an energ y -d ep en d en t d ru g  
efflux pump in MDR tum our cells. The ATP bind ing  sites (g reen) 
are  in trace llu la r, w hereas the carb o h y d ra te  g roups (pu rp le) he on 
the cell su rface , (from: K artner & L ing, 1989).
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from MDR human KB cells (Shen et a l . , 1986C). Furtherm ore, full 
length cDNAs coding for human P-glycoprotein have been su b ­
cloned into expression vectors and transfected  into d rug  sensitive 
cells (Pastan et a l . ,  1988; Ueda et a l . , 1987A,B). Thus it seems 
likely tha t P-glycoprotein can be implicated in MDR, although it 
may not be the only component of th is phenomenon. Indeed there 
is a body of evidence against P- glycoprotein being the only 
mechanism of resistance in MDR cells.
Although MDR cell lines do in general express similar 
p a tte rn s of resistance , each individual cell line displays its  own 
p a tte rn  of c ross-resistance , which may be d ifferent from p atterns 
of resistance in o ther MDR cell lines (Beck et a l . ,  1979; Fairchild 
et a l . , 1987; Riordan et a l . , 1985; Roninson et a l . , 1984; Scotto et 
a l . ,  1986). The number of d ifferent P-glycoprotein genes, even 
taking into account variation in levels of expression, seems 
insufficient to account for this d iversity  (Moscow & Cowan, 1988). 
Furtherm ore the degree of resistance of many cell lines to an ti­
cancer d rugs is not directly  correlated with the degree of 
in tracellu lar accumulation of d rug  (Chang & G regory, 1985; Louie 
et a l . ,  1986; Siegfried et a l . ,  1983; Sirotnak et a l . , 1986).
In addition some MDR cells display additional changes in 
protein expression. For example, sorcin is over-expressed  and 
amplified in a vincristine resis tan t cell line, and this suggested 
th a t th is protein might contribute to MDR. However, subsequent 
investigations indicated th a t the sorcin gene is simply a passenger 
gene (De Bruijn et a l . ,  1986; Deuchars e t a l . , 1987). Finally 
several human cell lines have recently  been described that have
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transport-m ediated defects and a m ulti-drug resis tan t phenotype, 
bu t do not over-express P-glycoprotein (Dalton et a l . , 1988; Danks 
et a l . ,  1987; Marsh & Center, 1987; Mirski et a l . ,  1987; Slovak et 
a l . ,  1988).
P - glycoprotein in the Clinic
Following the identification of P-glycoprotein in MDR 
resis tan t cells in v itro  a number of studies have investigated the 
possible role of th is protein in clinical d ru g  resistance. These 
studies have been made possible by  the development of monoclonal 
antibodies to P-glycoprotein (Bell et a l . ,  1985, Sugawara et
al.,1988) and by  the isolation of a cDNA probe th a t can detect
MDR-1 mRNA (Fojo et a l . ,  1987B).
Fojo e t al. (1987B) have shown th a t the MDR-1 gene is
expressed at a high level in normal human k idneys, adrenal gland, 
liver and colon. Moreover Thiebaut et al. (1987) have shown that 
in kidney, liver and colon, the P-glycoprotein is p resen t on the 
luminal surface of epithelial cells compatible with its  role as a 
tra n sp o rte r.
Relatively high levels of MDR-1 mRNA have been found in 
normal colon and colon cancer and adjacent "normal" colon (Fojo et 
a l . , 1987B). In 2 of 8 patients h igher levels of MDR-1 mRNA were 
seen in the tumour and the authors speculate tha t this could be 
related to the known in trinsic resistance of colonic carcinoma. In 
addition 6-fold h igher levels of MDR-1 mRNA were detected in a 
relapse tumour than in the pre-chem otherapy biopsy. Similarly
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Fojo et al. (1987A) have suggested th a t the in trinsic resistance 
seen in renal cancer is associated with expression of the MDR-1 
gene.
Bell et al. (1985), using immunocytochemical techniques 
revealed over-expression of P-glycoprotein in 2 of 5 patients with 
ovarian carcinoma. Similar techniques have demonstrated P- 
glycoprotein over-expression in 2 patients with acute non- 
lymphocytic leukaemia (Ma et a l . ,  1987). In 25 patients with 
sarcoma, Gerlach et al. (1987) dem onstrated increased levels of P- 
glycoprotein in 6 tumour samples. More recently  Goldstein e t a l . , 
(1989) measured MDR-1 mRNA levels using  a slot blot technique in 
an extensive range of tumour samples (human biopsy material and 
cell lines). They demonstrated a w ide-range of MDR-1 mRNA 
levels, ranging  from high (e .g . in colon, renal and liver cancer) 
to low/undetectable in b reast, ovary, upper gastro -in testinal, 
small cell and non-small cell lung cancer (the la tte r was studied 
only in cell lin e s ) . They did rep o rt high levels of MDR-1 mRNA in 
relapse tum ours, b u t, apart from b reast, the tumours also had 
high p re -th e rap y  levels. The authors go on to postulate th a t high 
MDR-1 mRNA levels are associated with tumours resistarit in the 
clinic.
There have been few studies of P-glycoprotein expression in 
lung tum ours. Recently Lai et al. (1989) reported  the presence of 
MDR-1 mRNA in both SCLC tumour biopsies and in cell lines 
derived from SCLC. Although the levels were low when compared 
with o ther tumour types the significance of the level of expression 
is not known. Since the technique used did not consider
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individual cells, the low levels found may rep resen t a small focus 
of resis tan t tumour cells within a population of d rug-sensitive 
cells.
It is clear th a t P-glycoprotein is an important component in 
the mechanism of MDR. It may also play a role in clinical 
resis tance , however the plethora of conflicting reports  concerning 
the presence or absence of P-glycoprotein, or variable levels of 
MDR-1 mRNA in both clinical samples and cell-lines indicates that 
the role of P-glycoprotein in clinical d rug  resistance remains 
unclear.
Modulation of P - Glycoprotein A ctivity
It has been shown in animal and human tumour models of 
m ulti-drug resistance , th a t a number of agents are capable of 
resto ring  sensitiv ity  to a range of cytotoxic drugs in MDR tumour 
cells. Such agents (termed resistance modifiers) come from various 
groups of d rugs which by  themselves are not cytotoxic. The most 
potent modifiers appear to share a common molecular s tru c tu re : 
they  are typically hydrophobic molecules with two planar aromatic 
rings and a te r tia ry  basic nitrogen atom with a positive charge at 
physiologic pH (Rothenberg & Ling, 1989).
In the last decade there  has been growing in te rest in such 
non-chem otherapeutic agents which might enhance the cytotoxicity 
of conventional chemotherapy drugs (such as doxorubicin). A 
number of calcium channel blocking drugs (typified by  verapamil 
and nifedipine) and calmodulin inhibitors (such as fluphenazine and
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trifluoperazine) have been shown to be effective in enhancing the 
cytotoxicity of natural product an ti-cancer d ru g s, prim arily vinca 
alkaloids and anthracyclines. The greatest effects of such 
resistance modifying agents have been seen in MDR tumour cell 
models, which often express increased levels of P-glycoprotein 
(Beck et a l . ,  1986; Harker et a l . ,  1986; Skovsgaard et a l . ,  1984; 
Tsuruo et a l . , 1984).
Verapamil
The earliest work describing an increase in sensitiv ity  of 
resis tan t cells in the presence of a resistance modifying agent was 
tha t reported  by  Tsuruo et al. (1981) using  verapamil. Not only 
did they  repo rt the phenomenon, bu t they  also dem onstrated tha t 
the increase in sensitiv ity  related to increased intracellular 
accumulation of cytotoxic d rug  (vincristine and doxorubicin) in the 
resis tan t cells in the presence of modifier (Tsuruo et a l . ,  1981,
1982). Resistant cells had previously been shown to have 
decreased intracellular accumulation of doxorubicin, primarily 
because of enhanced active efflux (Inaba & Johnson, 1978; Inaba 
et a l . , 1979) whereas doxorubicin en try  into cells probably relates 
to passive Fickian diffusion (Dalmark & Storm, 1981).
In teresting ly  some increase in in tracellu lar d ru g  accumulation 
in the presence of modifier was also noted in the sensitive tumour 
cells (Tsuruo et a l . ,  1982). However the sensitising effect of 
verapamil with vincristine and doxorubicin was much more marked 
in the d ru g  resis tan t model, a resis tan t P388 leukaemia cell line
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(40-fold and 10-fold respectively) than in the standard  P388 cell 
line (4-fold and 2-fold respectively). This reversal of d rug  
resistance with verapamil was subsequently  confirmed by others 
(Beck et a l . ,  1986; Slater et a l . ,  1982).
Rogan et al. (1984) dem onstrated an increase in sensitiv ity  
of human ovarian cancer cells to doxorubicin in the presence of 
verapamil. This effect was most clearly seen in resis tan t cell 
lines, bu t some sensitisation with verapamil was also noted in the 
parental cell lines. Although there  was a marked increase in 
sensitiv ity  with verapamil, with a clear dose-response effect noted, 
in highly resis tan t in vitro  models verapamil did not fully resto re  
sensitiv ity  suggesting  that other mechanisms of resistance may also 
be operating.
Although the sensitising effect of verapamil has been clearly 
established, the mechanism(s) w hereby verapamil exerts  this effect 
remain unclear. In this regard  it should be noted tha t MDR cells 
have neither inhibitable voltage dependent calcium channels (Kessel 
& Wilberding, 1985; Ramu et a l . , 1984), nor differences in 
calmodulin levels (Tsuruo et a l . , 1984). Thus the mechanism(s) 
w hereby verapamil enhances chemosensitivity must relate to other 
fac to rs .
In the case of verapamil and o ther calcium-channel blockers, 
inhibition of voltage-gated potassium channels (De Coursey et a l . ,
1985) and certain calmodulin-dependent activities (Epstein et a l . , 
1982; Janis & Scriabine, 1983) may be relevant. More recently  it 
has been shown that verapamil can compete with labelled 
vinblastine for binding to isolated plasma membrane vesicles from
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MDR cells (Cornwell et a l . , 1986A,B). Since vinblastine is known 
to bind to P-glycoprotein (Safa et a l . , 1986) this suggests tha t 
verapamil can also bind to the P-glycoprotein. Cornwell et al.
(1987) have also shown tha t verapamil is capable of competing with 
a varie ty  of cytotoxic drugs of the MDR family for the binding 
sites on P-glycoprotein. Furtherm ore recen t studies have shown 
that the phosphorylation state of the P-glycoprotein may modulate 
its  function. Studies using an MDR human leukaemia cell line 
indicate tha t agents which are capable of resto ring  d rug  
sensitiv ity , such as verapamil, cause a significant increase in 
phosphorylation of the P-glycoprotein (Hamada et a l . ,  1987).
Alternative mechanisms of action for verapamil have been 
proposed. For example, it might exert its effect by  altering  
membrane trafficking (Beck, 1987). Indeed recently  Sehested et 
al. (1987B) have shown tha t the ability of verapamil to resto re  
chemosensitivity relates to disruption of vesicular tra ff ic . Warr et 
al. (1986) suggested th a t collateral sensitiv ity  of MDR cells to 
modulators such as verapamil might relate to a general membrane 
p e rtu rb in g  effect. In this reg ard  it is worth noting th a t relatively 
high molar concentrations of "modifier” are requ ired  for an effect. 
These relatively high concentrations are also relevant to the 
application of agents identified as resistance modifiers in the 
laboratory , to the clinical setting . In particu la r, a major obstacle 
in the clinic is th a t of achieving plasma levels in patients which are 
similar to those known to be most active in the laboratory (See 
Chapter 7).
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Other Calcium Antagonists
Other calcium antagonists have also been shown to be active 
as resistance modifiers in the laboratory. Tsuruo and co-workers 
have demonstrated the circumvention of resistance to both 
vincristine and doxorubicin in v itro  and also in vivo using a 
variety  of calcium antagonists including nifedipine and diltiazem 
(Tsuruo et a l . , 1983A,B,C,D ). More recently  bepridil has been 
shown to enhance doxorubicin cytotoxicity in both anthracyline- 
resistan t and -sensitive cell lines. Moreover this effect was seen 
in vitro  a t levels th a t may readily be achieved in the clinic 
(Schuurhuis et a l . ,  1987).
R e c e n tly  an  a n a lo g u e  of t ia p a m il ,  N - ( 3 ,4 -  
d im e th o x y p h e n e th y l)-N -m e th y l-2 -(2 -n a p h th y l-m -d ith a n e -2 -  
propylamine) (DMDP), was shown to have a g rea ter resistance 
modifying effect than verapamil in a doxorubicin resis tan t P388 
leukaemia cell line (Radel et a l . , 1988). It exerted  its  modulating 
effect at half the concentration of verapamil. An important aspect 
of this work was the demonstration tha t a 24 hour exposure to 
DMDP with a short exposure to doxorubicin resu lted  in the same 
cytotoxicity as a 24 hour exposure to both agents. Moreover the 
former regime resu lted  in prolonged intracellular retention of 
doxorubicin.
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Quinidine
Quinidine has been shown to be active as a resistance 
modifying agent in laboratory tumour models (Tsuruo et a l . , 1984). 
It appears to be capable of reversing  MDR and altering  
intracellular accumulation of vincristine and doxorubicin in both 
P388 leukaemia cell lines and in the human myelogenous leukaemia 
cell line, K562. However, the effect of quinidine in vitro in the 
above models is considerably less than  th a t observed with calcium 
channel blocking d ru g s. Quinidine (like o ther antidysrhythm ics) 
may produce its  resistance modifying effect by  p e rtu rb in g  the 
organisation of membrane lipids and so non-specifically d istu rb  
various membrane-bound enzymes which are believed to be 
influenced by the physical state  of surrounding  lipids (Surewicz 
& Jozwiak, 1983). Quinidine may also affect sub-cellular calcium 
distribution and thus decrease the free in tra-cellu lar calcium level 
(Harrow & Dhalla, 1976). Quinidine is of particu lar in terest as a 
resistance modifying agent because it is active in v itro  at 
concentrations that are achievable in the clinic (Tsuruo et a l .,
1984).
Calmodulin Inhibitors
Calmodulin antagonists such as chlorpromazine and 
trifluoperazine have been shown to potentiate the cytotoxicity of 
vincristine and doxorubicin in v itro  (Tsuruo et a l . , 1983D). This 
effect appears to relate to increased accumulation of cytotoxic d rug
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in resis tan t cells following incubation with calmodulin inhibitor 
(Tsuruo et a l . ,  1982). More recently  Akiyama et al. (1986) 
demonstrated circumvention of multiple d rug  resistance in human 
cancer cells using a range of calmodulin inh ib ito rs. Working with 
a human KB carcinoma cell line made resis tan t to colchicine, and 
exhibiting a typical MDR pa tte rn  of cross-resistance , they showed 
tha t thioridazine had the g reatest sensitizing effect although 
trifluoperazine and chlorpromazine also had some sensitising effect. 
However, the calmodulin inhibitor, N -(6-am inohexyl)-5-chloro-l- 
naphthalene sulphonamide did not reverse  MDR. Thus the effect 
seen with thioridazine, trifluoperazine and chlorpromazine appeared 
not to relate specifically to calmodulin inhibition. Once again the 
enhanced d rug  efflux seen in the MDR cells was inhibited by 
thioridazine. It has been speculated th a t calmodulin antagonists 
(as indeed verapamil) may produce the ir effects by  acting on 
lysosomal function. Both verapamil (Akiyama et a l . , 1984, 1985B) 
and thioridazine (Kuratomi et a l . , 1986) have been shown to affect 
lysosomal function and delay the degradation of ligands such as low 
density  lipoproteins and epidermal growth factor in lysosomes.
Cyclosporins
Slater and colleagues (1986A,B) have shown th a t the 
immunosuppressive d rug  cyclosporin A acts as a modifier of 
resistance to daunorubicin and vincristine in Ehrlich ascites 
carcinoma in vivo and in human acute lymphatic leukaemia in v itro . 
Recent studies of cyclosporin A in a highly resis tan t small cell lung
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cancer cell line confirmed that this agent could considerably reduce 
the degree of resistance to doxorubicin and vincristine (Twentyman 
et a l . ,  1987). A close correlation was noted between the
immunosuppressive properties of natural cyclosporin analogues and 
their ability to modify d rug  resistance. Subsequently, Twentyman
(1988) showed tha t some non-immunosuppressive synthetic 
cyclosporin analogues are also highly effective as modifiers of 
resistance to doxorubicin and vincristine in the MDR small cell lung 
cancer cell line, H69LX4. Cyclosporins themselves are generally 
growth inhibitory (Saydjari et a l . , 1986). Nonetheless these 
synthetic non-immunosuppressive cyclosporin analogues do p resen t 
an exciting area of research  as they  appear to retain  their 
resistance modifying activ ity  at lower concentrations than 
cyclosporin A. This is an important observation because the 
plasma levels of cyclosporin A achievable in the clinic (1-2 ug/ml) 
(Kahan et a l . ,  1983) are considerably lower than the levels 
required  to produce significant modulation in vitro (5 ug/m l).
Amiodarone
A French group have published a repo rt indicating tha t in 
a ra t colon cancer model, amiodarone is more efficient than 
verapamil in enhancing the cytotoxic effect of 4 ^ -deoxydoxorubicin 
(C hauffert et a l . ,  1987). They also dem onstrated tha t a 1 hour 
p re-treatm ent with amiodarone produced an increased resistance 
modifying effect, whereas verapamil p re-treatm ent did not. Levels 
of amiodarone achievable in patients (up to 7 uM afte r intravenous
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dosing and up to 4 uM after oral dosing) are comparable to levels 
found to be maximally active in the laboratory (C hauffert et a l . , 
1987; Mostow et a l . , 1984).
Thus it may be seen tha t there  is great continuing in terest 
in evaluating agents in the laboratory which may be suitable as 
resistance modifiers in the clinic.
Aims of the Study
The vast bulk of laboratory work which has investigated 
possible mechanisms of resistance and has evaluated the role of 
resistance modifying drugs has used in v itro  derived resis tan t cell 
lines as models for d rug  resis tan ce . However, it is difficult to be 
certain  what relevance these laboratory derived models have to 
d rug  resistance in the clinical setting .
Therefore, the main aim of this thesis has been to establish 
cell lines from small cell lung cancer biopsies (prim ary and 
metastatic) taken from both un treated  patients and from patients 
who had relapsed following chemotherapy. It was thereby  hoped 
to obtain a group of cell lines with a range of d rug  sensitivities to 
use as the basis for studies of d ru g  resistance in this tumour 
type. Since doxorubicin is one of the most active agents in the 
chemotherapy of small cell lung cancer, the chemosensitivity of the 
newly established SCLC cell lines to th is cytotoxic d rug  was
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measured in the f irs t instance. In addition the effects of verapamil 
on the chemosensitivity of the cell lines to doxorubicin was 
assessed . Verapamil was selected as the resistance modifier as it 
is the agent which has been most widely investigated as a 
modulator, and already is used extensively in the clinic in patients 
with hypertension, ischaemic heart disease and cardiac 
dysrhythm ias.
The three principle aims of this work can be summarised as 
follows:
(1) To establish a number of SCLC cell lines from biopsies of 
patients before treatm ent and a t time of relapse following 
chem otherapy.
(2) To determine the sensitiv ity  of the cell lines to doxorubicin 
and to investigate the activity  of verapamil as a resistance modifier 
in these cell lines.
(3) To evaluate the potential role of verapamil as a resistance 
modifier in the clinic in a large-scale randomised clinical s tudy .
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Layout of the Thesis
Each Chapter includes a self-contained Introduction and 
therefore details of the rationale behind the various stages of the 
work will not be discussed here.
Chapter 2 describes the establishment of 9 SCLC cell lines. 
Their detailed characterisation is presented  in Chapter 3. The cell 
lines were established from biopsies of both un treated  and tre a te d , 
relapse patien ts. Of particu lar in terest are a pair of cell lines 
established from a single patien t, one pre-treatm ent and one post­
chemotherapy from relapse tumour.
The growth characteristics of these cell-lines p resented  
major problems in the s tudy  of growth and d rug  sensitiv ity . Since 
the cell lines all grow as non-adherent floating aggregates and 
have similar morphological characteristics to man-made tumour cell 
spheroids, the analytical methods used to s tudy  spheroid growth 
were applied to the SCLC cell lines. These studies are described 
in Chapter 4, which discusses the problems encountered with this 
approach.
Chapter 5 describes the adaptation of a tetrazolium dye- 
based chemosensitivity assay th a t can be used for both adherent 
and non-adherent cell lines. This assay  proved suitable for use 
with the SCLC cell lines and C hapter 6 details the growth rates 
and chemosensitivities to doxorubicin of the cell lines. In addition 
the effects of verapamil on the chemosensitivities of the cell lines 
to doxorubicin is described in Chapter 6. Chapter 7 describes a 
large-scale m ulti-centre randomised tria l of verapamil in addition
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to chemotherapy in patients with SCLC.
The final conclusions of this work are presented  in Chapter
8 .
CHAPTER 2
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ESTABLISHMENT OF SMALL CELL LUNG CANCER 
CELL LINES IN VITRO
INTRODUCTION
Cells growing continuously in tissue culture (cell lines) have 
been widely used as laboratory models in an increasing range of 
scientific specialities. A number of workers have established SCLC 
cell lines (Carney et a l . , 1985A; Duchesne et a l . , 1987; Gazdar et a l . , 
1980,1985; Pettengill et a l . , 1980). A major aim of th is project was to 
establish SCLC cell lines in v itro , from both the prim ary tumour site 
and metastatic deposits, from patients before treatm ent and also from 
patients who had relapsed following chemotherapy. Hence it was 
hoped to establish cell lines with a range of chemosensitivities 
(Carney e t a l . , 1983), in order to s tudy  the chemosensitivity pa tterns 
and effects of resistance modifiers in relatively sensitive and resistan t 
SCLC cell lines in v itro .
A particu lar aim was to establish cell lines from the prim ary 
tumour (biopsied using fibre-optic bronchoscopy) or from a metastatic 
deposit before any chemotherapy was given. These patients could 
then be followed-up until they relapsed with recu rren t tumour. Cell 
lines from such relapse tumour (either prim ary or metastatic) could 
then be established, and regarded  as a model for d rug  resistance in
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vitro where resistance had developed in the clinic.
Another aim of this project originally was to attem pt to establish 
a number of clonal cell lines from a single tumour biopsy, immediately 
afte r explantation. This would provide information on the possible 
existence of sub-populations of tumour cells of varying 
chemosensitivity within a tumour.
Establishment of SCLC Cell Lines In Vitro
A large number of centres have already reported  techniques for 
establishing SCLC cell lines in v itro . The f irs t repo rt came from 
Japan in the early  1970s (Oboshi et a l . ,  1971). Towards the end of 
tha t decade and into the 1980s, there  was a dramatic rise in the 
number of centres establishing SCLC cell lines. One of the most 
active in this regard  has been John Minna’s laboratory a t the National 
Cancer Institu te at Bethesda in the United States (Carney et a l .,  
1985A; Gazdar et a l . ,  1980, 1985). The major problems in
establishing SCLC cell lines cited by  this group and others (Baillie- 
Johnson et a l . ,  1985; Bepler et a l . ,  1987A,B,C; Duchesne et a l . ,  
1987; Pettengill et a l . , 1980) were the inadequacy of viable tumour 
material, infection, and difficulties associated with fibroblast 
overgrow th.
Three basic techniques have been used to t ry  and overcome the 
problem of fibroblast overgrowth. They are the use of collagenase, 
the use of feeder-layers and the use of serum -free medium, with
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appropriate supplem ents.
Collagenase is an enzyme tha t digests the collagen component 
of the extracellular matrix. In the presence of collagenase cells are 
unable to produce an extracellular matrix. Cells such as fibroblasts 
tha t are anchorage-dependent cannot proliferate in suspension. 
However many tumour cells exhibit anchorage-independent growth and 
are able to proliferate in the presence of collagenase. This approach 
has been used for small cell lung cancer biopsies (Pettengill et a l .,
1980) where agarose overlays were also used to preven t fibroblast 
attachm ent. Collagenase is also used for the enzymatic disaggregation 
of larger biopsies where physical disaggregation is inefficient. 
Recently Duchesne et al. (1987) described the use of enzymatic 
disaggregation in establishing small cell tumour biopsies in cu lture .
Feeder-layers have also been used to suppress fibroblast over­
growth. Feeder-layers may consist of STO mouse tumour cells 
exposed to Mitomycin-C, which acts as a cytostatic agent, a rres tin g  
STO cell growth, bu t maintaining cellular metabolism. Ultimately the 
STO mouse tumour cells die, as the Mitomycin-C damages the cellular 
DNA. These Mitomycin-C treated  STO mouse tumour cells recognise 
fibroblasts and this resu lts  in contact inhibition of fibroblast grow th. 
However, epithelial human tumour cells do not exhibit contact 
inhibition and may continue to grow. Thus Mitomycin-C treated  STO 
tumour cells used as a feeder-layer, suppress fibroblast overgrow th. 
In addition, because the d ru g -trea ted  STO cells remain metabolically 
active, they  may condition the medium in which the SCLC cells are
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growing (see below). Various feeder-layer techniques have been 
used in the establishment of SCLC biopsies previously. Bergh et al. 
(1985) described the use of glial cells as feeder-layers and Gazdar et 
al. (1980) have co-cultured tumour cells with mouse fibroblasts. More 
recently  the usefullness of feeder-layers has again been reported 
(Gazdar and Oie, 1986).
Serum-free medium has also been used to t ry  and suppress 
fibroblast growth. Carney at al. (1981,1985A) described the use of 
serum -free medium in establishing SCLC cell lines in v itro . Such an 
approach proved to be particularly  helpful in stemming fibroblast 
overgrowth at an early stage afte r explantation. However, it has 
been noted that for continued SCLC growth in v itro , serum 
supplementation is often required (Carney et a l . ,  1981). The 
advantages and disadvantages of serum -containing and serum -free 
medium in establishing SCLC cell lines are reviewed la ter.
In an attempt to maximise the chance of successfully 
establishing cell lines, conditioned medium has also been used. 
Gazdar et al. (1980), described the use of conditioned medium in 
SCLC in vitro in some detail and showed th a t only 2 of 21 tumour 
specimens plated out in serum-supplemented medium yielded cell lines 
b u t 6 of 11 tumour specimens plated out in medium supplemented by 
conditioned medium grew. Subsequently Minna et al. (1982) reported  
tha t medium from all SCLC cell lines stimulated colony formation of 
o ther SCLC cell lines. More recently  Carney et al. (1985A) described
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the usefullness of conditioned medium in establishing SCLC cell lines.
These various techniques were investigated in an attem pt to 
establish a panel of SCLC cell lines for studies of d rug  sensitiv ity  and 
resistance modulation.
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METHODS
Tumour Samples and Biopsy Techniques
Both prim ary and metastatic tumour samples and SCLC 
xenograft explants have been established in tissue cu lture .
Primary tumour was obtained via the fibre-optic bronchoscope. 
All bronchoscopies were performed by  myself a fte r a diagnosis of small 
cell lung cancer had already been established. A fter sedation with 
intravenous diazepam and topical anaesthesia with lignocaine (4%) the 
bronchoscope was passed via the nostril into the airways. As many 
biopsies as possible (up to a maximum of 10) were taken with alligator 
forceps, and tran sfe rred  to culture medium (see below). The 
p a tien ts , all of whom had given informed consent, invariably tolerated 
this procedure well and there were no complications.
Biopsies from metastatic deposits were obtained with myself in 
attendance by  conventional surgical techniques under s tr ic t aseptic 
conditions and with appropriate local/general (for cervical lymph 
nodes) anaesthesia. Pleural effusions were asp irated  by  myself 
according to conventional techniques, under local anaesthesia 
(lignocaine, 2%) and appropriate asepsis.
SCLC tumour xenografts established in athymic nude mice were 
removed surgically from an e ther-anaesthetised  animal. One p a rt of 
the tumour was preserved  in formal saline for subsequent histological 
examination to confirm that the tumour was SCLC. Another p art was
60
tran sfe rred  to appropriate culture medium and processed as described 
below.
All solid tumour tissue samples were tran sfe rred  to 20 mis 
culture medium (Roswell Park Memorial Institu te  [RPMI] 1640 with 10% 
v /v  foetal bovine serum) with antibiotics (penicillin [250 units/m l], 
streptomycin [250 ug/m l], gentamycin [50 ug /m l]), and an antifungal 
agent (amphotericin [2.5 u g /m l]), in a sterile universal container. 
Biopsies were then immediately transported  to the laboratory and 
processed. Pleural fluid was collected in large volume (500 mis) 
sterile plastic containers containing p reservative-free  heparin as an 
anti-coagulant (final heparin concentration 0.2 mg%) and transported  
immediately to the laboratory.
Media
Roswell Park Memorial Institu te  (RPMI) 1640 Medium (Gibco, 
Paisley, U .K .) was the culture medium generally used . A monolayer 
SCLC cell line, LS112ST, was established and this was maintained in 
Waymouth’s medium (Gibco, Paisley, U .K .) . Culture medium was 
supplemented with glutamine (2mM), and foetal bovine serum (2.5% - 
10% v /v )  and antibiotics (penicillin 250 units /ml, streptom ycin 250 
ug/m l, gentamycin 50 ug/m l), and an antifungal agent (amphotericin 
2.5 ug/m l). If fibroblast growth became excessive then medium 
containing reduced serum concentrations was used . This comprised 
RPMI 1640 as described above supplemented with 2.5% v /v  foetal
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bovine serum, with SIT additive (Sigma Co., Poole, Dorset) 
containing final concentrations of selenium (5 ng/m l), insulin (5 
ug/m l), and tran sfe rrin  (5 ug/ml) (RPMI 2.5% SIT).
Disaggregation
Samples were freed of fat and fibrous tissue and the tumour 
tissue was carefully dissected in a Petri dish using crossed scalpel 
blades to obtain fragm ents of 1 mm x 1 mm. The smaller bronchial 
biopsy specimens requ ired  less physical disaggregation than 
metastatic skin and lymph node deposits or tumour xenografts. The 
disaggregation was performed in a sterile laminar flow hood.
Pleural effusions were examined and if macroscopically bloody 
or if many red  cells were seen on microscopy, the fluid was 
centrifuged (200 g for 5 minutes) th rough  an equal volume of Ficoll- 
Paque (Pharmacia L td ., Milton Keynes, U .K .) . The red  cell pellet 
was discarded and the cells at the interface resuspended in 4 volumes 
of phosphate buffered saline (PBS) and centrifuged (200g, 5
m inutes). The resu lting  cellular pellet was resuspended in a small 
volume (5mls) of culture medium as described below.
The disaggregated tumour material was resuspended in 5 mis of 
RPMI medium containing 10% v /v  foetal bovine serum (FBS) with 
antibiotics (as above) and glutamine (2mM) [RPMI 10%] and 
equilibrated with 2% C 03 in a ir and incubated at 37“” C in a humidified 
atm osphere. Generally at least two separate 25cm:z flasks (Nunclon;
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Gibco, Paisley, U .K .) with tumour material a t relatively h igher and 
lower cell densities were established. Cells were examined 2-3 times 
p er week and the medium changed 1-2 times p e r week.
CoUagenase
Some specimens were trea ted  with collagenase. When used , 
samples were dissected into small fragm ents and the resu lting  tissue 
divided into two p a rts . One p a rt was pu t into a 25 cm3 flask 
(Nunclon; Gibco, Paisley, U .K .) in 5 mis of RPMI 10%, as described 
above. The other p a rt was suspended in collagenase (Boehringher 
Mannheim, Lewes, U .K .) 200 units/m l in RPMI 10% (5 mis) and 
incubated for 24 hours. A fter 24 hours the sample was centrifuged 
(200 g for 5 m inutes), the medium containing collagenase removed, the 
sample was washed with sterile PBS and resuspended in 5 mis of RPMI 
10%.
STO Feeder Layers
For preparation of the feeder-layers exponentially growing STO 
fibroblasts were trea ted  with Mitomycin-C. When used , STO 
fibroblast cells growing in 25 cm3 flasks, almost a t confluence, were 
exposed to Mitomycin-C, at a concentration of 2 ug/10*5 cells ( i.e . 20 
ug/25 cm3* flask ), for 24 hours. The monolayer was then washed 
twice with PBS, and could then be used as a feeder layer.
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Conditioned Medium
Conditioned medium was obtained from either more active flasks 
of the same cell line, from other actively growing SCLC cell lines or 
from the longer established SCLC cell line, NCI-H187. This was a gift 
from Dr D. Carney (NCI, B ethesda). In all cases such conditioned 
medium was filter-sterilised  using a 0.22 micron pore filter (Millipore 
U.K. L td ., London, England) to avoid cellular cross-contamination.
Maintaining Cells in Culture
In those cases where there  was evidence of cellular 
proliferation, the medium required  to be changed up to 3 times 
weekly. In the o ther cases half of the medium was replaced weekly. 
A fter 1-2 months in cu ltu re , the developing cell lines were 
tran sfe rred  to medium without antibiotics.
Specific Experiments
LS111 n Cloning"
Actively growing LS111 aggregates were d isrupted  mechanically 
and serially diluted (from 1:20 to 1:2 x 10s ) and plated out across a 
96-well plate (Linbro; Flow Laboratories, Rickmansworth, U .K .).
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The plate was examined microscopically. The two rows (16 wells) in 
which aggregates at a dilution of 1:2 x 10^ were plated had 3 
individual wells with a single small aggregate in each. These were 
monitored carefully thrice weekly and fed weekly over the next 2 
m onths. Only one aggregate ultimately s ta rted  to grow and expand . 
The aggregates from this well were tran sfe rred  to a single well of a 
24 well plate (Linbro; Flow Laboratories) and afte r a fu rth e r  few 
months they  were tran sfe rred  to a 25 cm3 flask in 5 mis of RPMI 10% 
and grown up. This process yielded the sub-line, LS111 "Clone” .
LS129
In order to attempt to establish a number of cell lines from a 
single tumour biopsy a 24 well plate (Linbro; Flow Laboratories) was 
p re-p repared  with Mitomycin-C-treated STO fibroblasts (see above). 
The biopsy material was then processed as usual bu t instead of being 
placed in 25 cm3 flasks, was plated out in small (1/24) portions onto 
the feeder lay e r. The wells were examined thrice weekly and fed once 
weekly for three months.
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RESULTS
A total of 21 SCLC biopsies were processed during  the period 
January  1986 to May 1988. The details of these biopsies and 
processing are shown in Table 2.1. These include 12 metastatic 
deposits, 7 prim ary bronchial biopsies and 2 xenograft SCLC tumours 
which gave rise to 6, 1 and 2 cell lines respectively.
It may be seen from Table 2.1 th a t 9 cell lines have been 
successfully established from both prim ary and metastatic tumour, 
from both un treated  and previously trea ted  patients and from patients 
with relapse disease. There appeared to be no relationship between 
source or h isto ry  of biopsy and the ability to establish a cell line in 
v itro . Similarly there was no clear benefit from the use of 
collagenase, STO feeder-layers or conditioned medium.
It should be noted tha t in most cases it took many months for 
the explanted SCLC material to proliferate into a cell line. Often the 
tumour aggregates would initially simply adhere to the base of the 
flask. Over a period of weeks fibroblasts would proliferate as 
outgrow ths along the base of the flasks and afte r many weeks small 
clumps of tumour cells would grow out from the nests of biopsy 
material enmeshed in the fibroblast monolayer. Ultimately, these 
tumour cells would break off into the medium as free floating tumour 
clumps (Plate 2 .1 ). These could be harvested  and tran sfe rred  to 
o ther flasks and ultimately yielded continuously growing SCLC cell 
lines in 9 cases. Although morphology varied between cell lines, all
Biopsy Sowee History
TeoiitHrtiiMtit'
fttfftftfeMKl 
Stodlum :
:::-:6WOTWQf;:
LSI 06 Bronchial Biopsy Pre-therapy, subsequent PR No No Yes Cell line
LS107 8tdn Metastasis Pretherapy Yes No Yee Failed
LS108 Pleural Effusion Pre-therapy No Yes Yee Failed
LS109 Bronchial Biopsy Pre-therapy Yes No Yes Failed
LS110 Bronchial Biopsy Pre-therapy
(same patient as LS108)
Yes No Yes Failed
LS111 Neck Node Pre-therapy, subsequent PR/CR Yes No Yes Cell line
LS112 Sldn Metastasis Pretherapy, no treatment Yes No Yes Cell line
LS124 Bronchial biopsy Pre-therapy Yes Yes No Failed
LS126 Lymph Node Pre-therapy Yes Yee No Failed
LS127 Bronchial Biopsy Pre-therapy
(same patient as LS126)
Yes No No Failed
LS126 Bronchial Biopsy Pretherapy Yes Yes No Failed
LS129 Bronchial Biopsy Pre-therapy Yes Yee No Failed
LS131 Sldn Metastasis Poet-therapy, relapse after PR 
(same patient as LB106)
Yes No No Failed
LS132 Neck Node Post-therapy, relapse after PR Yes No No Failed
LS133 Pleural Effusion Poet-therapy, unresponsive No No No Failed
LCPH2 Mouse xenograft Poet-therapy, relapse No No No Cell line
LCPH3 Mouse xenograft Poet-therapy, relapse 
(same patent as LCPH2)
No No No Cell line
LS263 Neck Node Poet-therapy, unresponsive No No No Cell line
LS274 Sldn Nodule Pretherapy, subsequent PR No No No Cell line
LS277 Sldn Nodule Pretherapy, subsequent CR No No No Cell line
LS310 Axillary Nods Poet-therapy, relapse altar PR 
(same patent as L8274)
No No No Cell line
Table 2.1
Sources of biopsies and methodology for establishing SCLC cell lines.
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Plate 2.1
Viable clumps of tum our cells a t an early  stage (weeks a fte r  
explantation) in tissue  cu ltu re . (A , LS106; B, LS112).
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grew as floating aggregates in vitro (Plate 2 .2 ).
In the case of cell line LS112, two distinct sub-populations of 
tumour cells developed. One comprised the typical SCLC floating 
aggregates, LS112 FL (Plate 2.3A). These, however, tended to 
adhere to the base of the flask and these adherent tumour aggregates 
then produced a distinct monolayer SCLC sub-line, LS112 ST (Plate 
2 .3B ). The propensity  to form an SCLC monolayer by  LS112 could be 
enhanced by  culture in Waymouth's medium with 10% v /v  FBS.
Clinical History of Cell-Lines
Cell Line LS106
56 year old male presented  with haemoptysis. Chest x -ray  
showed collapse of the left lung and bronchoscopy showed proximal 
tumour in the left main stem bronchus. Histological examination 
demonstrated small cell carcinoma of intermediate cell type. Bronchial 
biopsies yielded cell line LS106. Subsequent staging with whole body 
Gallium scan and ultrasound examination indicated that disease was 
confined to the thorax. He received 4 cycles of induction 
chemotherapy with cyclophosphamide, doxorubicin, vincristine and 
etoposide with verapamil and restag ing  indicated a partial response. 
He therefore received a course of consolidative mediastinal irradiation 
(3,000 cGy. given in 10 fractions over 2 weeks). He remained stable 
for a few months bu t then complained of malaise, weight loss and an 
abdominal wall swelling. Investigation confirmed both local (thoracic)
Plate 2.2
Cell line LS111 grows as tig h t, non -ad h eren t agg regates  of 
tum our cells.
AB
Plate 2.3
Two cell populations derived  from biopsy LS112.
LS112FL grows as loose n o n -adheren t ag g reg ates  of cells (A) and 
LS112ST, a monolayer sub-line estab lished  in selective cu ltu re  
medium ( B ) .
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relapse and abdominal wall m etastases. This was biopsied and 
established in tissue culture (LS131) bu t unfortunately did not yield 
a continuous cell line. His condition deteriorated and he died with 
extensive metastatic disease 8 months afte r presentation. Cell line 
LS106 is therefore representative of a partially  chemosensitive tumour 
in the clinic.
LS111
59 year old female smoker presented  with a righ t sided su p ra­
clavicular swelling. Chest x -ray  showed a rig h t hilar mass. 
Bronchoscopy revealed righ t sided tumour, histological examination 
of which revealed the presence of small cell anaplastic carcinoma. 
Lymph node biopsy confirmed the presence of SCLC, and this yielded 
cell line LS111. F u rther investigation, including liver ultrasound 
indicated th a t she had limited disease. There was a past h isto ry  of 
ischaemic heart disease. She showed an excellent response to her 
f irs t cycle of induction chemotherapy with cyclophosphamide, 
doxorubicin, vincristine and etoposide with dramatic regression of the 
lymphadenopathy and a marked reduction in the rig h t hilar mass on 
the chest x -ray . She developed neutropenia from which she made a 
full recovery and was re-adm itted for her second cycle of 
chemotherapy. She died suddenly of a presumed dysrhythm ia thought 
to be secondary to a recent myocardial infarction demonstrated at 
post-mortem, 5 weeks afte r diagnosis. Cell line LS111 is an example 
of a chemosensitive small cell lung tumour in the clinic.
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LS112
65 year old male smoker who presen ted  with headaches and skin 
nodules. Biopsy of the la tte r dem onstrated evidence of small cell 
anaplastic carcinoma. Isotope brain  scan suggested cerebral 
m etastases, and chest x -ray  demonstrated a central mass lesion. His 
condition was considered too frail and his disease too extensive for 
active treatm ent and he died comfortably a few weeks after 
presentation. Skin biopsy yielded cell line LS112, which represen ts 
a very  advanced small cell lung tumour in the clinic.
LCPH2 and LCPH3
33 year old male smoker who presented  with a 5 month history  
of general malaise and weight lo ss . He had extensive skin nodules at 
p resentation , with axillary lymphadenopathy and a large rig h t hilar 
mass on chest x -ray . Biopsy indicated extensive SCLC. He 
responded extremely well to initial chemotherapy with 
cyclophosphamide, doxorubicin, etoposide, vincristine and 
m ethotrexate. There was marked resolution of his skin and nodal 
m etastases. His chest x -ray  re tu rn ed  to normal and re-stag in g  
bronchoscopy showed normal endobronchial appearances. Two months 
afte r restag ing  he developed extensive lymphadenopathy which was 
shown to be due to recu rren t small cell tumour. LCPH2 was 
established from a mouse xenograft of tumour from the supraclavicular 
gland mass at time of initial relapse. His relapse was trea ted  with a 
phase I d rug  (CB3717). However, he then developed SVC obstruction
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and was treated  with mediastinal irradiation. Although the SVC 
obstruction responded to radiotherapy, his peripheral disease 
continued to progress and he was treated  with a single course of the 
alkylating agent, TGU. LCPH3 was established from a mouse 
xenograft tumour from a chest wall metastasis biopsied at a time when 
his disease was progressing  relentlessly  despite additional 
chemotherapy with TGU. His disease continued to advance with the 
development of liver m etastases, and he was therefore treated  with a 
course of Cholorambucil, Etoposide and Prednisolone. There was no 
response to this therapy  and he died 7 months a fte r his initial 
response to chemotherapy. Cell lines LCPH2 and LCPH3 are therefore 
representative of small cell lung cancer p rogressing  in the clinic.
LS263
53 year old male smoker presented  with cough and dyspnoea. 
Chest x -ray  showed a rig h t upper lobe mass with mediastinal 
lymphadenopathy. Bronchoscopy showed tumour occluding the rig h t 
main stem bronchus. Histological examination demonstrated small cell 
anaplastic carcinoma. He was trea ted  with 3 cycles of 
cyclophosphamide, doxorubicin, vincristine and etoposide with 
verapamil. Despite this he developed progressive thoracic disease 
with total collapse of the rig h t lung and he developed righ t-sided  
supraclavicular g lands. This gland mass was biopsied and yielded cell 
line LS263. Despite treatm ent with ifosphamide and carboplatin and 
local radiotherapy his disease p rogressed  and he died 4 months afte r
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diagnosis. His tumour therefore appeared intrinsically resis tan t in the 
clinic.
LS274/LS310
61 year old male smoker presen ted  with rig h t chest wall pain, 
increased dyspnoea, anorexia, weight loss and malaise. He was found 
to have extensive skin nodules and neck and groin lymphadenopathy. 
Biopsy of a skin nodule demonstrated metastatic small cell lung cancer 
and yielded cell line LS274. Chest x -ra y  showed a bulky rig h t hilum 
and righ t paratracheal lymphadenopathy. Bronchoscopy demonstrated 
tumour in the rig h t upper lobe, biopsy of which confirmed prim ary 
SCLC.
He was treated  with 4 cycles of cyclophosphamide, doxorubicin, 
vincristine and etoposide, without verapamil. He showed a partial 
response to chemotherapy. The rig h t hilar bulkiness on chest x -ray  
resolved bu t the paratracheal shadowing persis ted . There was 
complete resolution of the neck and groin lymphadenopathy and partia l 
resolution of the skin nodules. A residual nodule, although shrunk  
from 4 cm x 3 cm to 0.5 cm x 0.5 cm, was biopsied afte r completion of 
chemotherapy. Histology demonstrated persis ting  viable small cell 
tumour cells. This biopsy yielded cell line LS310. He was reluctant 
to consider fu rth e r active treatm ent and a few months la ter developed 
cerebral metastases which progressed  rapidly despite palliative brain  
irradiation. He died 6 months afte r diagnosis. It may be seen that 
cell line LS274 represen ts a partially  sensitive tumour in the clinic.
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jY line LS310 may be regarded as being representative of resistance
that had developed in the clinic.
LS277
62 year old smoker with past h isto ry  of Crohn’s disease. 
P resented with left anterior chest pain and increased cough. There 
was clinical and radiological evidence of left lower lobe collapse. 
Bronchoscopy showed tumour in the left lower lobe, biopsy of which 
revealed SCLC. An abdominal wall nodule was noted, and biopsy of 
this demonstrated metastatic SCLC. This material yielded cell line 
LS277. There was no other evidence of metastases and she was 
trea ted  with 4 cycles of cyclophosphamide, doxorubicin, vincristine 
and etoposide with verapamil. She showed a complete response to 
treatm ent radiologically and the sub-cutaneous nodule regressed  
almost completely. Restaging bronchoscopy showed no evidence of 
residual tumour. She was treated  with mediastinal irradiation. She 
developed cerebral metastases and died 6 months afte r diagnosis. Cell 
line LS277 therefore represen ts a p re-treatm ent biopsy from a patient 
who had a chemosensitive tumour.
Results of Specific Experiments
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LS111 "Cloning"
A fter two months one individual aggregate had divided 
sufficiently to allow it to be tran sfe rred  to be grown on. 
Unfortunately only a single "clone” was established from LS111 and 
thus comparisons between different "clones" has not been possible.
LS129
The attempt to establish individual lines from an early  explant 
has been described in "Methods" above. Over the next few months 
any viable tumour material that was p resen t died. This primarily 
related to paucity of tumour material at outset.
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DISCUSSION
Nine new small cell lung cancer cell lines have been successfully 
established in tissue culture. Their detailed characterisation is 
described in the next chapter. Overall this rep resen ts a success rate 
of 43%. Although this is not as high as has been previously reported 
(Carney et a l . , 1985A) it should be noted tha t the f irs t 7 biopsies 
were processed in the f irs t 3 weeks of the s tudy . Indeed there was 
a learning curve evident in the processing of samples (success rate 
of 21% for the f irs t 14 samples processed in 1986, ris ing  to 100% in the 
more recently  handled samples; LCPH2 and LCPH3 (1987) and LS263, 
LS274, LS277 and LS310 in 1988).
Adequacy of tumour material remains the most crucial factor in 
establishing SCLC cell lines. This is particu larly  the case in biopsies 
of prim ary tumour obtained via the fibre-optic bronchoscope. One 
continuous cell line has been successfully established in this way. 
Although a number of other workers have reported the establishment 
of SCLC cell lines from prim ary lung tumour this has either been from 
resected lung (ante- or immediately post-mortem) (Carney et a l . ,  
1985A) or from specimens taken via the rigid bronchoscope (Postmus 
et a l . ,  1988) which allows larger biopsies to be taken bu t has the 
disadvantage of requiring general anaesthesia. The difficulty of 
establishing SCLC cell lines from prim ary tumour is confirmed by  the 
large number of authors who have been unable to establish SCLC cell 
lines from prim ary tumour (Baillie-Johnson et a l . ,  1985; Duchesne et
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a l . , 1987; Pettengill et a l . , 1980). In a series of 50 cell lines Carney 
et al. (1985A) described 6 established from prim ary lung tissue , bu t 
these were all derived from material from a single tumour biopsy.
The difficulties of establishing prim ary SCLC tumours in culture 
underline the importance of obtaining adequate tumour material at 
ou tset. In restrospect therefore the division of biopsy material to 
treatm ent with or without collagenase and to co-culture with feeder- 
layer or not may have been erroneous as this will have reduced the 
tumour density  in any given flask. This impression is corroborated 
by  the higher success ra te  of establishing cell lines from more recent 
biopsies, which were not sub-divided a t time of explantation.
The decision to plate initial biopsy material in culture medium 
containing 10% v /v  foetal bovine serum was based on a number of 
prem ises. Most early  researchers and a number of recent workers 
involved in establishing SCLC cell lines used medium containing serum 
(Bergh e t a l . ,  1985; De Leij et a l . ,  1985; Gazdar et a l . , 1980; 
Pettengill et a l . ,  1980). Moreover, although Carney et al. (1981, 
1985A) have described the use of serum -free medium in successfully 
establishing SCLC cell lines, they  did indicate that serum 
supplementation was often requ ired  for continued SCLC growth in 
v itro  especially a fte r the f irs t few months (Carney et a l . , 1981). 
Indeed, a recent s tudy  comparing serum -free and serum-supplemented 
medium by  Carney et al. (1985A) indicated th a t although 22 out of 31 
SCLC biopsies could be established in serum -free medium, 19 out of 
31 could be established in serum -containing medium. Thus
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almost as many lines could be established in serum -containing medium 
as serum -free medium. Therefore, the use of serum -free medium 
based on earlier work by  Hayashi and Sato (1976), and subsequently  
elaborated by  Bottenstein et al.(1979) which described the addition 
of hydrocortisone, insulin, tran sfe rrin , estradiol and selenium to 
serum -free culture medium, and which had proved particularly  helpful 
in stemming fibroblast overgrowth a t an early  stage afte r explantation 
was not routinely employed in this s tudy . Similarly o ther trace 
substances previously employed as possible additives (Minna et a l . ,  
1982; Simms et a l . , 1980) were not routinely used in this s tudy . 
Although the possibility tha t serum contains inhibitory factors to 
SCLC cells has been raised (Gazdar and Oie, 1986), this did not 
appear to be the case in this s tudy .
The major disadvantage with plating the explant into serum- 
containing medium related to overgrow th of fibroblasts. Generally 
fibroblasts did develop and grow in the flasks containing explanted 
biopsy material. Initially often this proved helpful as the fibroblast 
monolayer acted as a bed for the tumour material to settle onto and 
form nests of tumour. However, in the case of the f irs t biopsies 
handled, the fibroblasts often overgrew to the detrim ent of the 
tumour cell population. In an attem pt to overcome this Mitomycin-C- 
trea ted  STO mouse fibroblasts were used for two reasons - f i r s t l y  to  
suppress the growth of fibroblasts from the biopsy itself and secondly 
in the hope th a t the feeder layer would condition the medium 
especially in the early  stages a fte r explantation (see also below).
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However, the use of feeder-layers did not prove helpful in 
establishing new SCLC cell lines. This was partly  because the mouse 
fibroblasts sometimes continued to grow and ultimately became 
detached from the base of the flask , and partly  because the tumour 
material did not always settle onto the monolayer. A fter biopsy LS129 
the use of feeder-layers was therefore discontinued. This resu lted  
in g rea ter ra th e r than reduced success ra tes for establishing cell 
lines, probably because the biopsy material was not sub-divided 
between so many flasks a t the time of explantation.
The other approach used to suppress fibroblast overgrowth was 
the use of col lagenase  . Generally the effectiveness of collagenase 
proved disappointing. Sometimes it appeared somewhat toxic to the 
tumour cells as shown by the healthier condition of the tumour cells 
in flasks which did not contain collagenase. Recently therefore (since 
biopsy LSI33) the use of collagenase was discontinued. This has 
allowed the initial explanted material to be maintained a t high cell 
density  in ju st one or two 25 cm3 flasks, and this approach appears 
to have been more fru itfu l.
In contrast to the disappointing resu lts  with the use of feeder- 
layers and with collagenase, the use of conditioned medium proved to 
be helpful, although not essential. Carefully filter-sterilised  
conditioned medium both from other longer established SCLC cell lines 
and from more active flasks of the same cell line was particularly  
useful in the early  stages afte r explantation. At this stage biopsy 
material contains a relatively small number of metabolically active cells
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and so the culture medium remains relatively alkaline, despite 
equilibration with 2% C 03 in a ir. Conditioned medium can therefore 
be helpful in adjusting the pH of the culture medium (although this 
could also be achieved by  the use of HEPES b u ffe r), bu t more 
importantly may supply growth factors to stimulate tumour cell growth 
(Minna et a l .,  1982).
It is worth re ite ra ting  a t this stage tha t SCLC biopsies can take 
many months to develop into cell lines. This slowness to generate 
tumour lines has been noted by  many workers over the years ( Carney 
et a l . ,  1985A; Oboshi et a l . , 1971; Ohara & Okamoto, 1977).
Specific Experiments
An aspect of the initial project was to t ry  and isolate separate 
cell lines from a single biopsy a t an early  s tag e , in order to determine 
whether a single SCLC biopsy could give rise to a range of 
phenotypically d ifferent cell lines. Although theoretically this concept 
appeared a ttrac tive , in realistic terms it was a mistaken approach. 
Indeed one biopsy (LSI29) which was plated out at time of 
explantation into a 24-well plate which had been p re-p repared  with 
feeder-layer failed to show any active growth. On the other hand 
once a biopsy sample had become established in tissue culture it was 
possible to isolate a separate cell line from a single floating ag g reg ate , 
as was the case with LS111 and the sub-line LS111 ’’Clone” . This of 
course is not a tru e  clone, bu t given the problem of successfully
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completely disaggregating individual SCLC aggregates it r e m ains  the 
model most like a clone realistically achievable. The similarities and 
differences between LSI 11 and its derivative LSI 11 ’’Clone” will be 
discussed in Chapter 3.
Summary
Nine new SCLC cell lines have been established from a total of 
21 small cell lung cancer biopsies. Although conditioned medium was 
sometimes helpful in establishing SCLC cell lines, a large amount of  
tumour t i s s u e  in the i n i t i a l  biopsy was cer ta in ly  h e lp fu l .  The reduced 
tumour cell density  which resulted  as a consequence of sub-dividing 
biopsy material to treatm ent with and without collagenase and as a 
consequence of fu rth e r  sub-dividing material into flasks with and 
without feeder layers (and occasionally also into flasks containing 
different media) probably explains the relatively disappointing early 
resu lts  from this work. These new cell lines will form the basis for 
the laboratory studies of d rug  resistance in SCLC in the la ter p a rt of 
this thesis . The characterisation of the 9 newly established SCLC cell 
lines is now described.
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CHAPTER 3
CHARACTERISATION OF NEWLY ESTABLISHED 
SMALL CELL LUNG CANCER CELL LINES
INTRODUCTION
The original papers where detailed characterisation of newly 
established small cell lung cancer cell lines was undertaken came from 
the United States, from the National Cancer In stitu te , Bethesda 
(Gazdar et a l . , 1980) and Darmouth Medical School (Pettengill et a l . ,
1980). However since that time there has been an enormous increase 
of in terest in the study  of the biology of SCLC and a number of 
European Centres (Baillie-Johnson et a l . ,  1985; Bergh et a l . ,  1982, 
1985; De Leij et a l . , 1985) have reported  the ir experience establishing 
and characterising SCLC cell lines in v itro .
Classification of SCLC into Classic & Variant Sub-Groups
A range of characteristic features of small cell lung cancer have 
been identified. Recently more detailed studies of established cell 
lines has allowed the identification of two broad sub-types of human 
SCLC cell lines in v itro , based on morphological, biochemical and 
genetic characteristics (Carney et a l . , 1985A,B; Gazdar et a l . , 1985). 
The so-called "classic” cell lines grow as tightly  packed floating
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cellular aggregates, have long doubling times and low colony forming 
efficiencies and have a distinctive biochemical profile, with the 
presence of L-dopa-decarboxylase (DDC), bombesin-like immuno- 
reactiv ity  (BLI), neurone specific enolase (NSE), and high 
concentrations of the brain iso-enzyme of creatine kinase (CK-BB). 
On the other hand the so-called "varian t” cell lines grow as ra th e r 
loosely-packed aggregates , have more rapid doubling times and higher 
colony forming efficiency. They also have reduced or absent DDC 
and BLI and have lower concentrations of NSE. These variant cell 
lines demonstrate amplification of the C-myc oncogene and exhibit 
relative radio-resistance (Carney et a l . ,  1983).
The Heterogeneity of Lung Cancer
Various features have been reported  as characteristic for small 
cell lung cancer. However, with increasingly sophisticated methods 
being applied to the histological investigation of tum ours, the fact 
tha t lung cancers are often made up of heterogeneous tumour cell 
populations (Dunnill & G atter, 1986) is gradually gaining general 
acceptance.
Using electron microscopy Auerbach et al. (1982) found 
evidence of a second cell type in nine out of 35 cases of lung cancer. 
In examining 61 tumours that had been classified as adenocarcinoma 
Rainio et al. (1983) analysed mucus histochem istry and u ltra s tru c tu re  
and found evidence of a second cell type in 18%. Saba et al. (1983)
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using both electron microscopy and an immunoperoxidase method for 
detecting keratin  noted both glandular and squamous differentiation 
in 17 out of 52 lung carcinomas. Furtherm ore, both McDowell & 
Trump (1981) and Horie & Ohta (1981) described carcinomas which on 
electron microscopy showed not only dense core granules bu t also foci 
of squamous differentiation together with areas of glandular 
differentiation associated with in tra - and extra-cellu lar secretion of 
mucus. Even when using only light microscopy Hirsch et al. (1983) 
found 13% of 200 patients with lung cancer had features of more than 
one cell type in their tumour.
The advantage of immunocytochemistry in examining tumours is 
that a much larger sample is studied than with electron microscopy. 
Even so it is often very  small when compared with the size of the 
whole tumour. Thus it might be expected tha t if tumours are 
examined by light and electron microscopy together with 
immunocytochemistry a h igher percentage of mixed tumours would be 
found than if only one or two of these methods were used , and this 
has proved to be the case.
It is noteworthy tha t biochemical investigation of lung tumours 
may reveal ectopic hormone production by  all classes of tumour. 
Merrill & Bondy (1982) described vasopressin in both small cell 
carcinoma and adenocarcinoma of lung and calcitonin in all varieties 
of lung cancer. Even more strik ing  was the investigation by  B erger 
et al. (1981) in which L-dopa-decarboxylase, histaminase, B- 
endorphin and calcitonin were measured in 50 lung cancers. They
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found no single marker separated SCLC from the re s t. Instead they 
discovered that there  were quantitative differences between various 
histological types and concluded tha t the major forms of lung cancer 
"represented  a continuum of differentiation with a common cell 
lineage".
Microscopic evidence of cytological heterogeneity is not found 
in all cases bu t this may well be due to the necessarily small sample 
examined in an individual tumour. Yet it seems probable tha t all lung 
cancers in fact contain elements of several cell types though in the 
majority one type dominates the histological p ictu re . This has 
profound consequences when considering the histogenesis of lung 
cancer. Yesner & C arter (1982) in reviewing the pathology of lung 
tumours suggested tha t small cell carcinoma as well as squamous and 
adenocarcinomas were derived from primitive endoderm. They based 
this opinion on the observation th a t all varieties of lung cancer may 
occur within a single tumour and suggested tha t all lung cancers are 
p a rt of a spectrum of differentiation.
In the past it has been suggested tha t small cell carcinomas 
were derived from Kultschitzsky type cells in the bronchial mucosa 
which were considered to have a neuroectodermal origin. This view 
as to the origin of these cells is now somewhat discredited as the 
u ltras tru c tu ra l studies described above and others (McDowell & 
Trump, 1981; Raikhlin et a l . ,  1979) have shown features 
characteristic of small cell carcinoma together with those of 
adenocarcinoma and squamous carcinoma in the same tumour.
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Thus the evidence seems to point to all lung cancers being 
heterogeneous. In the case of SCLC this point has recently  been 
highlighted by  Engelholm et al. (1986). In an extensive s tudy  
comparing the histological, electron microscopic and flow cytometric 
characteristics in a model system of metastatic SCLC (tumour biopsy 
material, cell lines and xenografts) it was found tha t although 
tumours in the various components of the model system preserved  the 
characteristics of SCLC, there was evidence of inherent heterogeneity
l
and genetic instability . Thus the main cell population in the patient 
tumour may not necessarily dominate in vitro  or in nude mice. 
Similarly using flow cytometric DNA analysis it was found that the 
tumour cell sub-populations obtained by  in v itro  growth did not 
always reflect the composition of the original tumour. Indeed sub­
populations, undetectable in the original tumour were found in a 
number of cell lines. Despite this heterogeneity , a number of 
features are said to be characteristic for SCLC and these are now 
review ed.
Light Microscopy
The vast majority of small cell lung cancer cell lines grow as 
floating aggregates of cells in v itro  (Carney et a l . , 1985A; Gazdar et 
a l . ,  1980). It has been suggested th a t this phenomenon may relate 
to a lack of glycoprotein attachm ent factors (Baylin et a l . ,  1982). 
The morphological characteristics have been used to sub-divide SCLC
8 4
cell lines into ’’classic” ( i.e . tigh t clusters of cells) and ’’varian t” 
( i.e . loose aggregates of cells) categories (Carney et a l . ,  1985A ).
The characteristic features of SCLC in tissue culture on light 
microscopy have been extensively described and are similar to those 
features seen in human small cell lung tumours (Matthews & Hirsch,
1981). In particu lar the cells are small with meagre cytoplasm. 
Nuclear chromatin may be seen d istribu ted  uniformly throughout the 
nuclei. Nucleoli are small and indistinct. Mitoses are numerous. 
Spindle and fusiform cells are also seen. These features should be 
p resen t when newly established SCLC cell lines are examined by light 
microscopy.
Electron Microscopy
Small cell lung cancer specimens frequently  exhibit 
characteristic features on electron microscopy. In particu lar the 
presence of membrane limited dense core granules (DCGs) has been 
widely reported  in SCLC biopsies and cell lines. These are thought 
to rep resen t a cellular neurosecretory  function (Pettengill et a l . , 
1980). More recently  it has been reported  that some variant SCLC 
cell lines do not have DCGs p resen t (Carney et a l . ,  1985A). 
Furtherm ore, De Leij et al. (1985) not only reported  that DCGs were 
absent in 3 variant cell lines bu t commented on the fact that all 
showed features of epithelial differentiation, manifest by  the presence 
of desmosomes and other less tigh t adhesion specialisations. Indeed
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some cell lines were seen to have villous process formation, which in 
addition to apical tigh t junctions and secretory  organelles are 
suggestive of adenodifferentiation. In this regard  it is in teresting  to 
note th a t Mooi et a l . , (1986) were only able to demonstrate the 
presence of DCGs in 42 of 54 clinical SCLC cell specimens examined 
u ltra s tru c tu ra lly . Another group has also reported features of 
epithelial differentiation on u ltra s tru c tu ra l examination of clinical 
SCLC specimens (Iglehart et a l . , 1985).
Thus, a number of u ltras tru c tu ra l characteristics have been 
described in small cell lung cancer specimens and cell lines . Although 
the most characteristic feature is the presence of dense core 
granules, a number of other features may also be seen.
Immunocytochemistry
In 1981 a method for producing monoclonal antibodies with a 
specificity for human lung cancer was described (C uttitta  et a l .,  
1981; Minna et a l . ,  1981). In recent y ears, researchers have 
examined the significance of a wide range of antibodies in SCLC (De 
Leij et a l . , 1984; Postmus et a l . ,  1988). Consequently there have 
been many reports  of positive antibody reactions in small cell lung 
cancer. Many researchers have reported  positive reactions with CAM
5.2 in SCLC. This is an antibody directed against low molecular 
weight cytokeratin and indicates an element of epithelial 
differentiation (Bernal et a l . , 1983; Makin et a l . , 1984; van Muijen et
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a l . , 1984). The antibody directed against the human milk fat globulin 
antigen (HMFG2), expressed on epithelial cells (Burchell et a l . , 1983,
1984) and consequently also a marker for epithelial differentiation has 
also recently  been reported to be positive in SCLC (Allan et a l . ,  
1987). On the other hand Bergh et a l . , (1984) did not find a positive 
reaction against cytokeratins in SCLC. To fu rth e r complicate the 
issue some workers have demonstrated the presence of neurofilaments 
in SCLC (Bergh et a l . ,  1984; Lehto et a l . ,  1983). Recently Broers 
and associates have tried  to resolve this issue by  suggesting that 
classical SCLC cell lines have cytokeratins bu t no neurofilaments 
(Broers et a l . ,  1985), whereas variant SCLC cell lines usually have 
neurofilaments and always contain vimentin intermediate filaments 
(Broers et a l .,  1986).
In terms of specific biochemical m arkers, antibodies directed 
against both bombesin (C uttitta  et a l . , 1985) and neurone specific 
enolase (NSE) (Sheppard et a l . ,  1984) have given strong  positive 
reactions, which are regarded as pointers to a diagnosis of SCLC.
More recently  there  has been increasing in te rest in the use of 
antibodies (both monoclonal and polyclonal) to t ry  and detect other 
antigenic determinants in SCLC. A variety  of antibodies have been 
identified and shown to give varyingly positive reactions to a range 
of antigenic determ inants. These antibodies include the anti-SCLC 
antibody, 123C3, which probably identifies SCLC neurofilaments 
(Schol et a l . , 1988), an antibody directed against the C-myc oncogene 
product (Sikora et a l . ,  1985), and EGFD10, an antibody thought to
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react with the cytoplasmic portion of epidermal growth factor receptor 
(Gullick et a l .,  1986).
In summary a range of antibodies have been identified as useful 
in characterising SCLC. These include the epithelial markers CAM
5.2 and HMFG2 as well as the enzyme markers bombesin and NSE.
Cytogenetic Characteristics
Detailed cytogenetic analyses have been extensively 
undertaken, not only in fresh  small cell lung tumour biopsy material 
bu t also in SCLC cell lines. The most widely reported  specific 
chromosomal abnormality in SCLC cell lines and fresh  tumour material 
is deletion of the short arm of chromosome 3, the so-called 3p 
deletion, f irs t described by Whang-Peng and associates (1982) and 
subsequently  reported by many other workers (Bepler et a l . , 1987B; 
De Leij et a l . , 1985; Falor et a l . , 1985; Postmus et a l . , 1988; Yunis, 
1983).
In contrast Bergh et al. (1982) did not find this chromosomal 
abnormality in their cell lines. Similarly Wurster-Hill et a l . ,  (1984) 
reported  tha t only 20% of SCLC cell lines demonstrated the 3p 
deletion. More recently deletion of a DNA sequence at the 3p 21 
chromosome region has been identified using highly specific molecular 
biological techniques. This abnormality has now been noted in all 
major types of lung cancer (Kok et a l . , 1987). Thus it may be that 
by  using  more specific technology, the 3p deletion can be identified
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in all SCLC specimens examined, as some are probably sub- 
microscopic. This loss of heterozygosity of 3p alleles has led to the 
suggestion tha t a recessive cancer gene, analagous to tha t proposed 
for the retinoblastoma locus on chromosome 13, may be located in this 
region. The loss of alleles in SCLC has also recently  been 
demonstrated for loci on chromosome 13 (Harbour et a l . ,  1988) and 
chromosome 11 (Shiraishi et a l . , 1987). Both are at or near sites of 
recessive cancer genes and their loss of heterozygosity has been 
observed in several types of tumour suggesting a role in tumour 
p rogression .
A host of additional chromosomal defects have been reported . 
Buys et al. (1983) described over-representation of chromosomes 13 
and 20 and ex tra  genetic material on 14p in 2 of 3 cell lines. One of 
their cell lines also had ex tra  material a t 12q similar to tha t previously 
reported by  Bergh et al. (1982). Other abnormalities including 
deletion at 6q and an aberran t chromosome 12 have also been reported 
(Bepler et a l . ,  1987B).
In summary, a variety  of karyotypic abnormalities have been 
described in SCLC. The commonest, deletion of p a rt of the short arm 
of chromosome 3, is probably p resen t, at least sub-microscopically, 
in all cases.
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Enzyme A ctivities
Since the f irs t reports of hormone production by  small cell lung 
cancer cell lines (Pettengill et a l . , 1977; Sorenson et a l . ,  1981) a 
large number of substances have been reported to be secreted by 
SCLC in v itro , including calcitonin, ACTH, parathormone, glucagon, 
oestradiol, LH, somatostatin and neurotensin (Bepler et a l . ,  1987B; 
Moody et a l . ,  1985; Pettengill et a l . ,  1985). Indeed Pettengill et al. 
(1985) not only demonstrated the presence of many hormones and 
enzymes in SCLC cell lines bu t also suggested that apart from 
differing concentrations between cell lines (e .g . ACTH levels in 
DMS53 and DMS79), concentrations might also vary  in the same line 
over a period of time (e .g . calcitonin levels in cell lines DMS53 and 
DMS153). There has been particu lar in te rest in measurement of levels 
of the enzyme neurone specific enolase (NSE) in the laboratory 
(Bepler et a l . , 1987B; Marangos et a l . , 1982). Indeed NSE has been 
regarded  as a marker enzyme for SCLC. However, until recently , 
those enzymes regarded as the most constant markers for SCLC were 
L-dopa-decarboxylase (L-DDC) (Baylin et a l . , 1980) and bombesin 
(Moody et a l . , 1981). Recent work has demonstrated the BB 
isoenzyme of creatine kinase (CK-BB) to be the most consistently 
p resen t enzyme in SCLC cell lines and this should now be regarded 
as the definitive marker enzyme for SCLC (Gazdar et a l . , 1985). The 
MM isoenzyme of CK has also been identified in SCLC cell lines (De 
Leij et a l . ,  1985; Postmus et a l . ,  1988).
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In summary, a host of substances produced by SCLC have been 
identified. The more widely used marker enzymes include NSE, 
bombesin, L-DDC and the BB isoenzyme of creatine kinase.
The newly established SCLC cell lines were therefore 
characterized by  morphological, u ltra s tru c tu ra l, immunocytochemical, 
cytogenetic and enzymatic analyses.
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METHODS 
Cell Lines
The cell lines examined are those whose establishment has been 
described in Chapter 2. NCI-H69 was used as a reference cell line 
for some of the studies. This cell line grows as floating aggregates 
in RPMI 1640 medium supplemented with 10% v /v  foetal bovine serum 
and glutamine (2 mM). This cell line was kindly donated by  Dr D. 
Carney, NCI, Bethesda, U .S.A .
Light Microscopy
Exponentially growing tumour cell aggregates, 24 hours a fte r 
feeding with fresh  medium, were washed once in phosphate buffered 
saline (PBS) and then fixed in formal saline (10% formaldehyde in 
PBS) for 24 hours. The fixed aggregates were embedded in paraffin 
wax, and four micron thick sections were cu t, stained with 
haematoxylin and eosin and examined by  light microscopy.
Electron Microscopy
Samples were taken from tissue culture and fixed in 4% 
glutaraldehyde buffered with Sorensen’s phosphate buffer (pH7), 
post-fixed in osmium tetroxide in aqueous osmium, dehydrated with
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absolute ethanol and embedded in Emix (Biorad L td . , Watford). One 
micron sections from 3 to 4 blocks were stained with toluidine blue and 
examined by light microscopy (Philips EM 301G microscope). All 
grids were stained with uranyl acetate and lead citrate (Reynolds, 
1963). All preparations were examined by transmission electron 
microscopy (EM) by at least two observers. Once a suitable area was 
identified on light microscopy 2 blocks were trimmed and u ltra -th in  
sections were cut at a thickness of 50 nm and mounted on copper 
g r id s . Each observer looked for the presence or absence of 
membrane-limited dense core granules (neuro-secretory  g ranules), 
tonofilament bundles, true  desmosomes, and other less well developed 
adhesion specialisations, microvillous profiles, mucin granules and 
basal lamina formation. The abundance of specialised features was 
assessed and scored as one plus if they were unequivocally presen t 
bu t scanty  in number, and as two p lus, if the ir presence was 
prom inent.
Immunocytochemistry
Cells were trypsinised if necessary  (LS112ST) using 0.25% 
trypsin/EDTA solution, then pelleted and washed twice in phosphate 
buffered saline. The pellet was resuspended in human plasma and 
then thrombin added which caused a clot to develop. The pellet/clot 
was then fixed in buffered formal saline for 24 hours, before being 
processed to paraffin wax. Four to five micron sections were cu t,
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dewaxed in xylene and rehydrated . The sections were stained using 
a standard  indirect immunoperoxidase method for CAM 5.2 (Becton 
Dickinson L td ., Oxford, U .K .) and N .S .E ., (Dako L td ., High
Wycombe, B ucks., U .K .) and using a standard peroxidase an ti­
peroxidase (PAP) method for the other antibodies [bombesin (NCI, 
B ethesda); HMFG2 (ICRF, London); EGFD10 (ICRF, London); C-myc 
(Ludwig Institu te , Cambridge) and 123C3 (Sera Lab L td ., Crawley 
Down, S ussex)]. In all cases endogenous peroxidase activity was 
blocked with fresh ly  prepared 0.3% hydrogen peroxide in methanol, 
for 30 minutes. Slides were then washed in tris-bu ffered  saline (pH
7 .4 ). Antigen recognition was enhanced by  trypsinisation (0.1% 
Sigma crude trypsin  in 0.01% EDTA) prio r to incubation with
antibodies (except for NSE).
The epithelial marker HMFG2 was used as undiluted
supernatan t. The other epithelial m arker, CAM 5.2 was used in a 
1/10 dilution. The polyclonal antibody, neurone specific enolase was 
used in a dilution of 1/500. Bombesin and C-myc monoclonal 
antibodies were used at optimal dilutions (1/20 and 1/200 
respective ly ). EGFD10 and the anti-SCLC antibody, 123C3 were both 
used in a 1 in 10 dilution. The antigenic determ inants of the specific 
antibodies and their sources are detailed in Table 3.1.
T hereafter, for those sections stained using the PAP technique 
a standard  3-step peroxidase anti-peroxidase technique (Dako L td ., 
High Wycombe, Bucks.) was applied. In such cases, background 
staining was reduced by the use of sheep serum (1:5 dilu tion). In all
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cases, the peroxidase end-product was developed using 
diaminobenzidine tetrahydrochloride / H^03 , followed by haematoxylin 
counter staining.
Reactions with the CAM 5.2 and NSE antibodies for each cell 
line studied have been graded depending on the number of cells with 
positive reaction and the in tensity  of the staining. All slides were 
examined by the same experienced pathologist, and graded according 
to the scale shown in Table 3.2.
In collaboration with Dr F . Hay ( I . C . R . F . ,  Medical Oncology 
Unit, Western General Hospital, Edinburgh) the cell lines were 
screened for cellular antigens that have previously been reported  to 
react with a range of monoclonal antibodies (Table 3 .1 ). Again each 
preparation was examined by an experienced researcher who scored 
the reaction according to the number of cells showing uptake and the 
in tensity  of uptake. In this case uptake has been expressed in 
percentage terms bu t the ” grading" equivalents as described above 
(Table 3.2) are also shown.
Cytogenetic Analyses
Flasks of cells were fed with fresh  medium 24 hours p rio r to 
harvesting  for chromosome preparations. The harvesting  protocol 
differed between cell lines in order to obtain optimum resu lts . The 
period of exposure to 0.02% colchicine varied between 1 and 3 hours, 
p rio r to a 0.075M KC1 hypotonic treatm ent time of 10 to 15 minutes.
Grade Percentage of Cells 
Showing Uptake
Description 
of Staining
-ve Nil None
+ <5% Modest
+ + 5 - 50% Moderate
+ + + >50% Intense
Table 3.2
Grading systems used to quantify antibody staining.
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Cells were then fixed in two changes of methanol: acetic acid (3:1) and 
stored overnight a t 4 °C . The next morning the fixative was changed 
once more and cells were dropped from varying heights onto clean, 
cold, wet slides. Preparations were also made from the monolayer 
SCLC cell line, LS112ST, by trypsin ising  the cells with 0.25% 
trypsin/EDTA solution and washing in complete medium prio r to 
hypotonic treatm ent.
Fifty cells from each cell line were analysed afte r staining with 
Giemsa and /o r Trypsin-Giemsa banding. The chromosome count, 
specific chromosomal re-arrangem ents and the presence of s tru c tu res  
which may rep resen t sites of gene amplification [ i.e . homogeneous 
staining regions (HSRs), abnormally banding regions (ABRs) and 
double minute chromosomes (DMCs)] were noted. Analysis was 
performed at x 1280 magnification, using a Zeiss photomicroscope and 
photographed with Kodak Technical Pan Film.
Estimation of Dopa-decarboxylase (DDC) A ctivity
Principle
DDC activity is measured by  the ra te  of conversion of ~'H-L- 
Dopa to ^H-dopamine and C 03 . ^H-dopamine is separated from "*H- 
L-dopa by liquid cation exchange.
1. Sample Preparation
The cells were centrifuged at 200g for 5 minutes and the
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supernatant discarded. The cell pellet was washed twice in PBS, 
resuspended in 2 mis of borate buffer and lysed by freezing and 
thawing three times in solid CO= in methanol and a 37°C water bath . 
The lysates were centrifuged in an Eppendorf centrifuge (13,000 rpm) 
for 5 minutes to remove particulate material.
2. DDC Assay
The reaction mixture consisted of a borate buffer (Borax 0.025 
M + KH3  PO^ 0.05M, pH 7.0) containing nialamide (125uM), EDTA 
(1.5mM), L-Dopa (1200 uM) and ^H-L-Dopa (30 uCi/ml). A 
concentrated stock solution of the reaction mixture was prepared  and 
45 ul placed in 15 ml stoppered glass centrifuge tubes. These were 
incubated at 37°C for 5 minutes. Samples were mixed with pyridoxal- 
5-phosphate (1,200 uM) to give a final pyridoxal-5-phosphate 
concentration of 400 uM. Fifteen ul of this solution was added to the 
reaction mixture in the glass tubes. Samples were incubated for 1 
hour a t 37°C and the reaction was stopped by  addition of 5 mis ice- 
cold sodium phosphate buffer (10 mM, pH 6 .5 ). The tubes were 
tran sfe rred  to ice and 1 ml of heptan-3-one containing 25 mg sodium 
tetraphenylboron was added . The two phases were mixed by  shaking 
for 1 minute and then separated by centrifugation at 1500g, 4°C for 
5 minutes. The lower aqueous phase was removed and the organic 
phase was washed with 2 mis of sodium phosphate buffer (10 mM, pH
7.4) containing 1 mg of sodium tetraphenylboron. Tubes were shaken 
and centrifuged at 1500 g , 4°C for 5 minutes. A sample (0.5ml) of
97
the organic phase was tran sfe rred  to a scintillation vial and 10 mis of 
Ecoscint (National Diagnostics, Somerville, New Jersey , U .S .A .) 
added. Samples were shaken and counted for 10 minutes in a 
scintillation counter (Packard Liquid Scintillation Counter; Canberra 
Packard, Pangbourne, U .K .).
Some ^H-L-Dopa was extracted  into the organic phase and 
hence control tubes containing the reaction mixture bu t not sample 
were processed to estimate the reagent background counts. 
Extraction efficiency for riH-dopamine was determined by  extraction 
of known amount of '^H-dopamine. A sample of the reaction mixture 
was counted to determine the specific activity  of 3 H-L-Dopa. This 
value was used to convert counts p er minute (cpm) to umol of 
dopamine. DDC activity  is expressed as International Units/mg 
protein , where 1 I.U . = 1 umol of dopamine formed, p er minute under 
the specified reaction conditions.
Estimation of Creatine Kinase (CK) Activity
Principle
The principle of this assay is to measure the ability of CK to 
catalyze the reaction between creatine phosphate and ADP to creatine 
and ATP. The ATP so produced reacts with glucose in the presence 
of hexokinase to produce ADP and glucose-6-phosphate. This 
glucose-6-phosphate (G6P) is converted to 6-phosphogluconate and 
NADH by G6P dehydrogenase. NADH formation is measured by  the
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absorbance at 340 nm. The rate of change in absorbance is directly  
proportional to CK activity.
CK Assay
Creatine kinase (CK) reagent (Sigma Diagnostics, St. Louis, 
U .S .A .) is reconstituted with deionized water and mixed by 
inversion. This reagent not only contains creatine phosphate (the 
substra te  for CK) bu t also NAD (2 mmol/1), ADP (2 mmol/1), 
hexokinase (yeast) (3000 u/1) and glucose-6-phosphate dehydrogenase 
(2000 u/1) which are all components of the chain reaction described 
above. The reagent also contains N-acetyl-L-cysteine (20 mmol/1) 
incorporated to activate the CK. One ml of the CK reagent and 0.02 
ml of supernatant from the sample (prepared  as above in methods for 
DDC estimation) were incubated at 30°C for 3 minutes. Absorbance 
at 340 nm was then read versus water as reference; this rep resen ts 
initial absorbance. The incubation was continued for a fu rth e r  2 
minutes and a fte r this time absorbance was again measured (final 
absorbance). CK activity  was then calculated from the change in 
absorbance at 340 nm and expressed as units of activity  where one 
unit is defined as the amount of enzyme which produces one micromole 
of NADH p er minute under the specified conditions.
CK Isoenzyme Analysis
Creatine kinase isoenzyme (CK-BB, CK-MM, CK-MB) profiles 
were determined electrophoretically. Samples were diluted such that
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the activity  was less than 0.7 IU/ml and lu l was loaded onto a 
preformed agarose gel film (1% w /v , Corning Diagnostics L td ., 
Halstead, Essex). The separating buffer was 3-(N-morpholino)-2- 
hydroxypropane sulphonic acid (MOPSO, 0.05M, pH 7.8) and the gel 
was run  for 20 minutes at 9V/cm. Following electrophoresis the film 
was overlaid with creatine kinase substra te  solution (Corning 
Diagnostics L td .) and incubated for 20 minutes at 37” C. The gel was 
then dried . The substra te  solution was similar to that used for the 
estimation of CK activity and the presence of the CK isoenzymes was 
detected by  the production of NADH. This was quantified with a 
scanning fluorimeter (Helena Densitometer) a t an excitation 
wavelength of 365 nm and an emission wavelength of 460 nm. The 
position of the bands in the samples was compared with that of a 
standard  preparation (3 in 1 Level 11 Electrophoresis Control, 
Corning Diagnostics L td .) . The relative proportions of the 3 
isoenzymes was determined by  the relative area under the curve of 
the densitometer trace estimated as half base x height.
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RESULTS 
Light Microscopy
All the cell lines demonstrate typical morphological features of 
small cell lung cancer and grow as floating aggregates in v itro . On 
histological examination of sections of the SCLC aggregates nuclear 
chromatin was seen d istributed uniformly in a stippled p attern  
throughout the nuclei. Nucleoli were small and indistinct. Mitoses 
were numerous. The majority of cells had meagre cytoplasm. Spindle 
and fusiform cells were also seen (Plate 3 .1 ). In some of the larger 
cell aggregates central necrosis could be seen. This was particularly  
seen in the larger aggregates of cell line LS111.
In the two cell lines established from mouse xenografts, light 
microscopy revealed typical areas of small cell lung carcinoma, bu t 
also areas of b izarre , giant cells.
Electron Microscopy
The u ltra -s tru c tu ra l features of the 5 cell lines studied to date 
are detailed in Table 3.3. Membrane-bound dense core granules were 
convincingly apparent in 3 of the cell lines (Plate 3 .2 ). In co n tras t, 
features of epithelial differentiation such as desmosomes, tonofilaments 
and microvillous processes were only weakly expressed , if at all, 
certainly indicating no significant level of squamous or glandular
Plate 3.1
Section of LSI 11 tumour cell agg reg ate , stained with 
haematoxylin and eosin. In th is re la tively  small aggregate  th e re  
is no evidence of cen tral necrosis. The charac te ris tic  fea tu res of 
SCLC on light microscopy can be observed .
C eS tlne DerteeCot»  
O ranges
AditMtoit
Spedeftifttfon
Tenafliamefit
Btwdto*
f^roVttloUS
PWMtttft*
LS106 _ +
LS111 + +
- - _
LS111 Clone + +
- -
LS112FL + + + -
LS112ST - - - -
LCPH2 - + - -
LCPH3 + - - -
+  = present but scanty. 
+ +  =  abundant
Table 3.3
Ultra8tructural features in SCLC cell lines.
Plate 3.2
Transm ission electron m icrograph p rep ared  from cell line 
LS111. Membrane-bound dense core granules are  clearly  seen 
w ithin the cytoplasm (arrow ed).
differentiation in the material examined.
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Immunocytochemi at-ry
The resu lts  of the immunocytochemical studies are shown in 
Table 3.4. The reaction with the epithelial marker CAM 5.2 (raised 
against the cytokeratin cellular epitope) was most marked in cell lines 
LS112 and LS263 (Plate 3 .3), and least marked in the small cell lines 
obtained from mouse xenograft and the reference cell line, NCI-H69. 
There was no reaction with CAM 5.2 in 3 of the 4 most recently  
established cell lines. On the other hand reaction with the NSE 
monoclonal antibody was more marked in the reference SCLC cell line 
and the xenograft lines, although positive staining was seen in all cell 
lines examined.
It may be seen that there was a spectrum of reactiv ity  to a 
range of antibodies. The epithelial marker antibody HMFG2 was most 
strongly  reactive with cell lines LS106 and LS112 (FL and S T ). Again 
less reaction was noted with the cell lines obtained from mouse 
xenograft. Staining with EGFD10 was most marked in the two cell 
lines from mouse xenograft. Bombesin reactiv ity  was most marked in 
cell line LS111. The reference cell line (NCI-H69) and LS106 showed 
the weakest reaction with bombesin. Studies using the monoclonal 
antibody raised against the C-myc oncogene were negative in 5 of the 
8 new SCLC cell lines tested  and weakly positive with LS112ST, LS263 
and LS277, as well as the reference cell line NCI-H69.
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wPlate 3.3
A paraffin  section of cell line LS263 stained with the 
an tibody CAM 5.2 directed  against an epithelial an tigen . S trong 
positive stain ing  is observed (+++, 90%).
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Cytogenetic Analyses
All the cell lines had human karyotypes. Cell lines had modal 
chromosome concentrations (5 or more cells with the same chromosome 
count) ranging from 39 to 53 chromosomes. Two cell lines (LS106 and 
LS277) had a bimodal distribution due to the presence of polyploid 
cells. Karyotypes of all cell lines were complex and no cells with a 
normal karyotype were found (Table 3 .5).
Abnormalities of chromsome 3 (short arm deletions) were found 
in all 9 cell lines. These included both in terstitial deletions (LS111 
and LS111 "Clone” , LCPH2, LCPH3 and LS263) and isochromosomes for 
the long arm (cell lines LS106, LS274, LS277 and LS310). S tructures 
which may contain amplified gene sequences (HSRs, ABRs, and DMCs) 
were found in 3 cell lines [LS112 (FL and ST), LS263 and LS277]. 
Cell line pairs (LS111 and LS111 "Clone” , LS112FL and LS112ST, 
LCPH2 and LCPH3, LS274 and LS310) showed only minor karyotypic 
differences. The karyotype of LS111 is shown in Plate 3 .4 , which 
dem onstrates the characteristic 3p deletion.
Measurement of Enzyme Activities
The results of the enzyme assays for L-dopa-decaroboxylase 
(DDC) and for creatine kinase (CK) and its isoenzyme profile are 
shown in Table 3.6. All the newly established small cell lung cancer 
cell lines exhibit activity of the SCLC marker enzyme DDC with a wide
c d iy p * Lessor G&iri Of 
ItfowrtaJ Chromosomes
8tftietur#l$>str#tJeri*
LS106 -1 ,-3,-4.-t-8,-9,-10,-13, 
-15,+18,-21 ,-22
LS111 -3,-5,-5,-10,-13,+21
LS111 (Clone) -3,-5,-5,-10,-13,+21
LS112FL -1,-2,-3,-4,-5,-6,-7,+8,
-10,-12,-13,-14,-15,-15,
-16,-17,-17,-18,-19,-19,-21
*HSR (Chromosomes 11 +12) 
+ 8 markers
LS112ST -1,-1 ,-2,-3,-4,-5,-5,-7,+8, 
-10,-11,-12,-13,-14,-15,-16, 
-17,-17,-18,-19,+20,-21 ,-22,-X
HSR (Chromosomes 11 +12) 
+6 markers
LCPH2 -3,-4,-5,-6,+7,+14,+18,+X
LCPH3 -3,-4,-5,-6,+7,+13, +14,+18,+X
LS263 -3,-4l-4,‘5 l-6l-7l-8l-9l-12,
-13,-13,-14,-14,-16,-18,-19,-20,-21
HSR (Chromosomes 14+20) 
**ABR (Chromosomes 11 +14) 
+2 markers
LS274 -3,-3,-6,-11 ,-12,-13,-13,-14,-17, 
-18,-18,-19
LS277 -3,-4,-5,-10,-15 ***DMC + 2 markers
LS310 +1,-3,-3,-11,-12,-13,-13,-14, 
-15,-18,-19,-22
* Homogeneously staining region (HSR)
** Abnormally bonding region (ABR)
*** Double minute chromosome (DMC)
Table 3.5
Chromosomal characterisation of SCLC cell lines.
K AR Y OG R A M
n  It u  6 i' *
4* US • 41 4 «  M
'  * — ♦  *  *  «  * « - * ■ ■ :  4 a '
ft
    (f ’ 1   •  '  •    > - --------------  ^  ' ^ ' 
D M R . 1 1 7 .
Plate 3.4
Karyotype of a rep resen ta tive  metaphase of cell line LSI 11. 
The charac te ris tic  deletion of the sh o rt arm of chromosome 3 is 
a rro w ed .
OefiUrra
BB MB MM
LS106 66,311.9* ±  9022 8.4 ± 1.1 93.5 0.0 6.5
LS111 1,5503 ±  197.8 5.0 ± 0.8 100.0 0.0 0.0
LS111 Clone 2,272.7 (n«2) 5.9 (n - 3 100.0 0.0 0.0
LS112FL 2220.8 ±  773.9 0.4 ± 0.2 54.8 0.0 45.4
LS112ST 2,857.4 ±  1372.5 0.4 ± 0.1 40.9 0.0 59.1
LCPH2 N.D. N.D. - - -
LCPH3 2,224.6 ±  185.7 10.0 ± 2 2 97.7 0.0 2.3
LS263 1,117.3 ±  208.8 0.78 ± 0.1 922 0.0 7.8
LS274 14275.4 ±  2012.5 4.5 ± 1.1 73.6 19.9 8.5
LS277 450.4 ±  4.1 0.8 ± 0.1 79.4 8 2 12.4
LS310 11,7983 ±  1703.8 5.1 ± 1.0 89.5 7.0 3.5
N.D.»  not done.
Values are mean +/- SEM of 4 observations.
Table 3.6
Activities of the marker enzymes Dopa-dscarboxylase (DDC) and Creatine Kinase 
(CK) In newly established SCLC oeN Knee.
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range in activity . In the case of creatine kinase, activity is similar 
for all cell lines except for LS112 (both FL and ST), LS263 and LS277 
where levels of activity are much lower, although still p resen t in 
significant quantity . With regard  to the CK isoenzyme profile all cell 
lines expressed the BB isoenzyme. This was the dominant form 
except for cell line LS112 (FL and ST) where there were equal 
proportions of the MM and BB isoenzymes. It is also of note tha t the 
MB isoenzyme was present in 3 of the cell lines (LS274, LS277 and 
LS310).
There did not appear to be any specific relationship between 
DDC and CK enzyme activities in the new SCLC cell lines. For 
example, LS112 with low CK activity had intermediate levels of DDC 
activ ity  whereas LCPH3 with the highest levels of CK activity also had 
intermediate levels of DDC activity.
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DISCUSSION
These resu lts  show that the established cell lines are of human 
small cell lung cancer origin in all cases. This has been shown to be 
the case not only on pathological (light, u ltras tru c tu ra l and 
immunocytochemical) examination and on karyotypic analysis bu t also 
by  the activity  of the small cell marker enzyme CK-BB (Gazdar et a l . ,
1985). All the above charactersistics have been well described by 
previous workers as detailed in the introduction of this Chapter, as 
has the spectrum of characteristics seen in newly established SCLC 
cell lines.
On the basis of morphological appearance and biochemical profile 
the 9 cell lines which have been established demonstrate a range of 
biological characteristics ranging from classical (LS111) to variant 
(LCPH3) bu t with a number of cell lines that fall into an intermediate 
category. As can be seen from Table 3 .7 , each characteristic has 
been divided into categories. Although these divisions are quite 
a rb itra ry  it has allowed a satisfactory categorisation of these newly 
established SCLC cell lines (Table 3 .8 ). It may be seen tha t each cell 
line did not show a homogeneous pa tte rn  of classic or variant 
characteristics, unlike the work described by Carney et a l . , (1985A ). 
However this categorisation did allow identification of predominantly 
classic (LS111), intermediate (LS106, LS112) and variant (LS263) cell 
lines. Ultimately it was intended to s tudy  each specific phenotypic 
characteristic of each cell line individually to assess if there was any
Cia*4te(<$ totamtsdlats (J)
Morphology Tight Intermediate Loose
aggregate aggregates aggregates
Oopa-decarboxylase 
(ulU/mg protein)
> 10,000 1,500 - 9,999 < 1,500
Bombesin-like + + + + + +
Immunoreactivity (BU) (>50%) (10-50%) (<10%)
Neurone Specific + + + + + +
Enolase (NSE) (>50%) (10-50%) (<10%)
Table 3.7
Parameters used to categorise SCLC cell lines Into Classic, Intermediate 
and Variant sub-groups.
tf&Q)
m  tm
LS106 l/C c V V I
LS111 c i c c c
LS111 Clone c i c I l/C
LS112FL i i I V I
LS112ST V i I I I
LCPH2 I *ND I c I
LCPH3 V I _ I I
LS263 V V I c IN
LS274 V C I c l/C
LS277 I V I c I
LS310 V c I c l/C
* ND -  not done.
Teblo 3.6
Classification of the newly established 6CLC cell lines in terms of the parameters defined In Table 3.7 
The cell lines are divided Into classic (C), Intermediate (I) and variant (V) phenotypes on the 
basis of morphology, enzyme activity and immunocytochemlcal features. The final column summarises 
the overall predominant phenotype of the cell One.
relationship to chemosensitivity.
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Light Microscopy
Light microscopy of sectioned tumour cell aggregates confirmed 
appearances of human small cell lung cancer. In the two cell lines 
established from mouse xenograft b izarre large cells were also 
p resen t, and these probably represen t transform ed residual mouse 
stromal cells. Indeed, previous workers (Gazdar et a l . ,  1980) have 
also reported  that successful replication of cell lines derived from 
tumours in athymic nude mice may be dependent on the presence of 
mouse stromal cells for periods of up to 24 months.
Electron Microscopy
The u ltrastru c tu ra l features seen in SCLC cell lines have 
already been described in the Introduction. In summary, although 
dense core granules (DCGs) have been described as characteristic 
more recent work has shown that they are not always presen t (Carney 
et a l . , 1985A; De Leij et a l . ,  1985) and features of epithelial 
differentiation (De Leij et a l . ,  1985; Iglehart et a l . ,  1985) and 
adenodifferentiation (Mooi et a l . , 1986) have also been found. Indeed 
the difficulty of always finding DCGs in SCLC has recently  been 
highlighted (Dunnill & Gatter, 1986).
Clear evidence of dense core granules were found in the most
1 0 6
classic SCLC cell line, LS111 (Plate 3 .2 ). There was evidence of 
DCGs in 2 of the other 4 cell lines examined. Thus DCGs were not 
identified in the preparations examined from 2 of the cell lines (LS106 
and LCPH2). This is not entirely unexpected, particularly  as these 
two cell lines fall into an interm ediate/variant classification and the 
absence of DCGs in variant SCLC cell lines has been previously 
described (De Leij et a l . , 1985). There were also features of 
epithelial differentiation and adenodifferentiation in 3 and 2 of the cell 
lines respectively (Table 3 .3).
The immunocytochemical studies undertaken have been useful 
in confirming the epithelial features of the newly established cell lines 
with varying positivity with CAM 5.2 and HMFG2 noted. Such a 
spectrum of positivity to markers of epithelial differentiation has been 
noted previously, as described in the Introduction to this Chapter. 
In addition a spectrum of immunoreactivity was seen with antibodies 
directed against the SCLC marker enzymes bombesin and neurone 
specific enolase (NSE). Using the antibodies raised against bombesin 
and against NSE along with biochemical estimation of dopa- 
decarboxylase it has been possible to classify the cell lines into 
classic, intermediate and variant categories. In general terms there 
was a good correlation between those cell lines with classical 
biochemical profiles and those with classical (or intermediate)
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immunocytochemistry. However cell line LS106 was an exception to 
this ru le , with high DDC activity bu t low NSE and bombesin-like 
immunoreactivity (BLI). In addition cell lines LS263 and LS277 had 
low levels of DDC, and intermediate BLI bu t high levels of NSE 
activ ity  on immunocytochemical testing . Similarly there was an 
association between cell lines with variant biochemical profiles and 
with variant (or intermediate) immunocytochemistry. Thus these 
immunocytochemical studies have not only proved useful in 
characterizing the cell lines bu t also in corroborating the resu lts  of 
biochemical analyses.
Studies using recently raised antibodies also proved useful in 
the fu rth e r  characterisation of the cell lines. HMFG2 appeared in 
general to be similar in reactivity  to CAM 5.2 except for cell lines 
LS111 and LS263. This is what one might expect given that both are 
epithelial m arkers. In contrast, EGFD10 generally showed only weak 
activ ity , if any, and did not appear to mirror CAM 5.2 and HMFG2 
activities. The anti-SCLC marker (123C3) probably directed against 
SCLC neurofilaments was only strongly positive in LCPH3, which was 
the most variant of all the cell lines. This finding would corroborate 
those of Broers et a l . , (1985) who suggested tha t variant SCLC cell 
lines usually have neurofilam ents. Three of the newly established cell 
lines showed a weak positive reaction with the C-myc antibody. The 
significance of this remains uncertain.
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Cytogenetic Analyses
The various cytogenetic abnormalities reported in SCLC have 
been described in detail in the Introduction to this Chapter. 
Abnormalities of the short arm of chromosome 3 were found in all 11 
cell lines and sub-lines (LS111 and LS111 "Clone"; LS112FL and 
LS112ST) studied. In 9 of these (6 patients) the characteristic 3p 
deletion (Whang-Peng et a l . , 1982) was detected. A host of additional 
chromosomal defects were found with chromosome numbers ranging 
from 39 to 53 and over-representation of chromosome X and ex tra  
material on chromosome Y (Table 3.5 and Plate 3 .4 ). There was an 
under-representation  of chromosome 13 in 6 cell lines from 4 patien ts. 
Such an under-representation  presumably includes not only 
chromosome loss bu t s truc tu ra l rearrangem ents of chromosome 13 that 
are masked within the complexity of the karyotype and both could be 
a mechanism for the loss of alleles. In all published cases where 
detailed karyotypic data on SCLC is given, 37 of 63 cell lines (59%) 
have shown an under-representation of chromosome 13.
Considering the 9 cell lines analysed, there were 4 cell line 
pairs in which each pair had been established from the same patient 
(LS111 and LS111 "Clone", LS112FL and LS112ST, LCPH2 and LCPH3, 
and finally LS274 and LS310). Of these , the f irs t two pairs had a 
common tumour origin and the la tte r two were established from tumour 
biopsies from the same patient a t two stages of their disease. Very 
few karyotypic alterations between each member of a pair were
109
apparent even though they had been separated for many months in 
tissue culture. Not only did they exhibit karyotypic stability , bu t 
even separate tumours from the same patient (LCPH2 and LCPH3, 
LS274 and LS310) had a large proportion of their chromosome 
aberrations in common, showing that these had probably arisen in 
v ivo, during tumour formation and were not artefacts of tissue 
cu lture . The pair of cell lines LS112FL and LS112ST have different 
growth morphologies and it is in teresting  to speculate that these 
differences could resu lt from the additional 3 marker chromosome 
found in the monolayer culture, LS112ST.
In summary, it has been confirmed that all the cell lines are of 
human tumour origin. The karyotypic data obtained from these cell 
lines confirms the consistent deletion of material from the short arm 
of chromosome 3 and suggests a possible role for this and the loss of 
material from chromosome 13 in tumour progression in SCLC.
Biochemical Studies
The biochemical analyses proved useful in confirming the nature 
of the origin of the cell lines, with all demonstrating significant 
activ ity  of the SCLC marker enzyme CK-BB. Indeed in the majority 
of cases, high levels of CK-BB activity were found. A number of cell 
lines demonstrated CK-MM, as well as CK-BB activity . This has 
previously been reported (De Leij et a l . , 1985; Postmus et a l . , 1988) 
bu t the significance of this finding remains uncertain.
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The spectrum of activity of L-dopa-decarboxylase proved useful 
in categorising the cell lines into classic, intermediate and variant. 
As discussed above this characteristic showed good general agreement 
with the resu lts  of immunocytochemical studies.
S u m m a ry
Nine small cell lung cancer cell lines have been established and 
characterised . Pathological studies, including light and electron 
microscopy and immunocytochemistry, and cytogenetic analyses, as 
well as biochemical analyses have clearly demonstrated tha t these lines 
are of human small cell lung cancer origin. A spectrum of 
characteristics, ranging from classic to varian t, with the majority of 
cell lines having intermediate features have been found.
These cell lines form the basis of the studies of d rug  sensitivity  
and modulation in v itro . However, the SCLC cell lines all grow as 
floating aggregates in vitro and this resulted  in difficulties in 
studying  their growth and chemosensitivity. The problems 
encountered and the means developed to overcome them are discussed 
in the next section of this thesis.
I l l
CHAPTER 4 
ESTIMATION OF GROWTH RATE AND CHEMOSENSITIYITY 
BY AGGREGATE GROWTH AND GROWTH DELAY ANALYSIS
INTRODUCTION
A major aim of this project was to establish new small cell lung 
cancer cell lines in the laboratory to use as models for studies of d rug  
resistance. Thus having successfully established and characterised 
9 SCLC cell lines in v itro , an assay for measuring drug  sensitivity  in 
these cell lines was required . Because of the large number of cell 
lines established and in view of the fact that ultimately it was 
intended to assess a range of cytotoxic d rugs, the assay chosen for 
measuring growth and chemosensitivity had to be relatively simple, 
reproducible and sensitive enough to be capable of detecting small 
changes in d rug  sensitivity. This la tte r point was particularly  
important as the model system established would also be used to 
assess the activity  of a number of resistance modifying ag en ts .
All the newly established small cell lung cancer cell lines 
described in the preceding Chapters grow as floating aggregates in 
suspension. This is a characteristic of almost all SCLC cell lines that 
grow continuously in vitro (Carney et a l . ,  1985A; Gadzar et a l . ,  
1980). This very  fact however poses major problems in the study  of 
these lines in the laboratory, for it renders them unsuitable for
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assessm ent of both growth and chemosensitivity using conventional 
a ssay s .
Clonogenic Assays
The majority of workers in this field have attempted to s tudy  
growth and hence chemosensitivity in both fresh  biopsies and in 
established cell lines using a form of clonogenic assay ( Carney et a l .,  
1980, 1983; Hamburger & Salmon, 1977; Hamburger et a l . , 1978; Kahn 
et a l . ,  1986; Sarosdy et a l .,  1986). Gazdar and associates (1985) 
from the National Cancer Institute popularised the use of this system 
in SCLC. However, they themselves have highlighted the problem of 
obtaining a satisfactory single cell suspension from floating 
aggregates (Carney et al, 1983). Indeed the problem of clumping in 
studies of both fresh  biopsies (Alley & Lieber, 1984; Bertoncello et 
a l . ,  1982; Hamburger et a l .,  1982; Twentyman, 1985) and in cell 
lines (Ruckdeschel et a l .,  1987; Walls & Twentyman, 1985) has never 
been satisfactorily overcome. Recently Ruckdeschel et a l .,  (1987) 
dem onstrated significant cell death when try ing  to obtain a single cell 
suspension from SCLC cell lines. Furtherm ore, even when the 
technical problems are minimised, such assays are limited by the poor 
colony forming efficiency of lung cancer cells in vitro (Gazdar et a l . , 
1983; Salmon & Von Hoff, 1981; Von Hoff et a l . ,  1981). In any case 
it seemed more appropriate to study the intact aggregate as this is 
more analogous to the in vivo situation (Plate 4 .1).
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Moreover the relevance of the clonogenic assay has been 
questioned (Weisenthal & Lippman, 1985). In particular tru e  tumour 
stem cells may be non-dividing (Go) cells and therefore clonogenic 
cells may not represen t tumour stem cells. Indeed growth kinetic 
studies have suggested that tumours in vivo are made up of a mixture 
of dividing cells and temporarily non-dividing (Go) cells (Gabutti et 
a l . ,  1969; Saunders e t a l . ,  1969). In addition Suda et al. (1983), in 
studies of normal murine haematopoeisis, have shown that stem cells 
do have long variable Go periods, compared to cells committed  to 
terminal differentiation, with purely  random activation of stem cells 
from this population. Suda et al. (1983) went on to show that 
reversib ly  non-dividing Go cells may not be assayed using a 
clonogenic system and re-itera ted  that these are probably tru e  stem 
cells. Moreover it has been shown that cells which are committed to 
differentiation can form colonies in vitro (Mackillop et a l . , 1983).
It has been postulated that it may be the failure to kill Go cells 
th a t is partly  responsible for the ineffectiveness of chemotherapy in 
human cancers (Drewinko et a l . , 1981). Certainly concerns about the 
clonogenic assay in terms of clinical credibility have often been 
expressed . Not only because of the artificial environment and 
abbreviated and a rb itra ry  d rug  exposure (Selby et a l . , 1983) which 
are indeed criticism of any in vitro assay, bu t also because by  using 
a clonogenic assay to predict for survival one ignores the problem of 
resis tan t tumour sub-populations (Skipper & Schabel, 1984; Stephens 
et a l . ,  1984; Tofilon et a l .,  1984).
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For these reasons it was felt that an alternative approach to 
studying  growth and chemosensitivity in the SCLC cell lines was 
needed, and the various possible non-clonogenic assays are briefly  
reviewed here to indicate why the system selected was chosen.
Alternative Techniques for Measuring Growth and ChemosPTmitivity
By fa r the simplest way to measure growth is to count 
increasing cell number over a period of time. This can most easily be 
performed by  counting single cells obtained after trypsinisation in a 
coulter counter. However, for reasons stated above it seemed likely 
tha t the cell line aggregates might prove difficult to disperse into tru e  
single cell suspension.
An alternative method to assess growth might be to perform 
protein assays over time (Bradford, 1976; Lowry et a l . , 1951). Such 
assays however measure dead as well as live cells. Moreover protein 
production is not a constant. Measurement of total DNA (Labarca & 
Paigen, 1980) is another technique which has been used to estimate 
cell grow th. However, again this assay would measure DNA in dead 
as well as live cells. Furthermore the amount of DNA per tumour cell 
is not constan t. Hence neither protein assays nor DNA assays seemed 
app rop ria te .
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Proliferation Assays
Assays which measure the uptake of a radioactive labelled 
p recu rso r are often used to measure chemosensitivity. These assays 
are based on the premise that living but not dead cells will take up 
radioactive labelled precursors (Volm et a l . , 1979). Specific examples 
include tritia ted  thymidine or leucine (Morgan et a l . , 1983). Over the 
last decade a number of workers have reported the usefulness of 
m easuring tritia ted  nucleotide incorporation to measure 
chemosensitivity (Ballou & Tseng, 1986; Sanfillipo et a l . ,  1986; 
Silvestrini et a l . ,  1985). However, tritiated  thymidine is only taken 
up by  some cells in tissue culture and then only by cells in S-phase. 
Although tritia ted  leucine is taken up by all cells it effectively 
measures protein turnover, which will be variable depending on the 
stage of the cell cycle. Furtherm ore, techniques involved in 
assessing  growth using tritia ted  leucine uptake are labour intensive 
and time consuming. In addition the time of performing the labelling 
assay afte r the noxious insult is critical. If nucleoside label 
incorporation is estimated too early then specific problems will occur. 
This relates to artefactual alterations in nucleoside intracellular pool 
sizes (Nakata & Bader, 1969). In addition the problem of salvage 
versus de novo dTMP synthesis has to be considered (Wolberg, 1972).
It has been shown that some cells have a long cycle time 
(Livingston et a l .,  1980). Indeed Raich (1978) demonstrated that 
acute myelogenous leukaemia blasts may have a cycle time of up to 70
116
hours. Furtherm ore it has been shown that many samples of tumour 
do not incorporate sufficient amounts of ^H-thymidine to allow 
accurate measurement and comparisons (Bech-Hansen et a l .,  1976, 
1977). In addition Hamburger (1981) has pointed out that p recurso r 
incorporation into cells may be temporarily stopped due to damage to 
cells during  the period of handling in the experiment. She also re ­
emphasized the profound effects of anti-cancer drugs on nucleotide 
synthesis which can therefore artefactually decrease estimates of DNA 
sy n th esis .
A final problem often faced by  those using labelled p recursor 
uptake studies to measure tumour growth and chemosensitivity is that 
of differentiating between tumour and non-tumour uptake. Some 
researchers have applied autoradiographic techniques to overcome this 
difficulty (Livingston et a l . , 1980; Sky-Peck, 1971; Weisenthal et a l . , 
1984). Although this la tter difficulty is not a specific problem in the 
new SCLC cell lines, it does underline the importance of critical 
consideration before an appropriate assay is finally chosen. Thus 
these techniques did not seem suitable for estimating the 
chemosensitivities of the SCLC cell lines.
Metabolic Assays
The possibility of measuring growth and chemosensitivity using 
changes in cell metabolism as an end-point was considered. Changes
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in oxygen consumption (Laszlo et a l .,  1958) and measurement of 
labelled C 03 released into the gas phase of culture bottles containing 
C labelled glucose (Scheithauer et a l . , 1986) are very  sensitive to 
culture conditions and therefore difficult to control.
A ssays of the Entire Cell Population
An alternative approach is to look for gross cell damage in the 
entire population in morphological terms. Weisenthal & Lippman (1985) 
have suggested that very  gross early evidence of cell damage in the 
whole tumour may correlate with a multiple log cell-kill in that 
population of tumour cells which is responsible for sustained tumour 
growth. Studies of tumour growth in vivo as xenografts (Fergusson 
et a l . , 1986) or using a sub-renal capsule assay (Bogden et a l . , 1984; 
Bogden & Van Hoff, 1984) would achieve this objective, although the 
importance of histological examination for tumour cell damage (and not 
simply tumour size) has been emphasized (Dumont et a l . ,  1984; Levi 
et a l . ,  1984). Such techniques are expensive, labour-intensive 
(especially when histological tumour examination is perform ed), 
requ ire  the presence of an animal house facility and most importantly 
take a longer period of time to obtain meaningful resu lts.
Cell Membrane Function Assays
Assays based on changes in cell membrane function have also
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been used to s tudy  chemosensitivity. This approach assesses damage 
to cells by  the inability of injured cells to exclude a dye as f irs t 
described by  Kaltenbach et al. (1958). Subsequently a number of dye 
exclusion assay s , using eosin Y, erythrocyin B , nigrosin and trypan  
blue, with or without internal standards, have been described 
(Durkin et a l .,  1978; Roper & Drewinko, 1976,1979; Tsukeda et a l .,  
1978; Weisenthal et a l .,  1983A,B). An alternative is to estimate 
in ju ry  by  the ability of viable cells to retain a dye such as fluorescein 
(Rotman & Paperm aster, 1966). D iffere n tial staining assays of cell 
suspensions (Bird et a l . , 1986; Weisenthal et a l . , 1983B) and of fixed 
cells (Kornblith & Szypko, 1978; Leu & Herriott, 1984; Mealey et a l . , 
1974) have also been described.
In recent years there has been a rekindling of in terest in this 
technique (Weisenthal et a l .,  1983B). Such assays are quick and 
relatively simple and require less cells than cloning a ssay s . 
Furtherm ore they detect cell-kill in the Go fraction of cells. Most 
im portant perhaps is that such dye assays do not require a s tric t 
single cell suspension. However, there are problems as recently  
reviewed by  Weisenthal & Lippman (1985). For example, whilst 
allowing sufficient tim e for damaged membranes to lose their in teg rity , 
the surv iv ing  cells may continue to proliferate (Hamburger, 1981). 
Most im portantly however is the labour intensive nature of scoring 
damaged cells (Ruckdeschel et a l . , 1987). Given the large number of 
cell lines to be studied and the range of cytotoxic drugs and 
resistance modifiers to be screened, a simple, quick assay that could
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be semi-automated was required.
A number of other short term assays of drug-induced in jury  
have also been described including those based on dehydrogenase 
activ ity  a fte r insult (Di Paolo, 1965) and more recently the s is te r 
chromatid exchange assay (Tofilon et a l . , 1984) has been shown to be 
able to detect small changes in drug induced cytotoxicity. This la tte r 
assay is ra th e r  complex and again depends on analysis of individual 
cells.
Spheroid Growth Studies
One of the more promising approaches used previously was 
based on changes in the measurement of the total tumour cell 
population in v itro . For example, B erry et al. (1975) examined 
changes during  the continuous short term exposure of mono-layer 
cultures exposed to cytotoxic drug . Specifically with regard  to the 
SCLC aggregates, in the last decade there has been a great increase 
in in te re st in measuring changes in multicellular tumour aggregates 
(or spheroids) both to measure growth per se and to quantify toxic 
in ju ry  by  measuring the growth delay induced by such insult. This 
la tte r approach seemed to be particularly promising and from the 
lite ra tu re  it seemed feasible to study the newly established SCLC 
aggregates in the sort of system that had previously been described 
(Sutherland & Durand, 1984; Yuhas et a l .,  1978). Such
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measurements can be performed, over a period of time using a tele­
visual system interlinked to a computer. The computer can be used 
to convert area measurements to volume (Wheldon et a l . , 1987). This 
system has the advantage that effects of drug on defined growth 
p a tte rn s  can also be measured (Nederman & Twentyman, 1984), while 
p reserv ing  cell-cell contact and interactions (Miller et a l . , 1984; 
Weisenthal & Lippman, 1985).
It seemed likely that spheroid growth studies to define normal 
growth and to determine the effects of cytotoxic damage might be a 
valid method to s tudy  growth and chemosensitivity in the new SCLC 
cell lines. Such an approach has been previously described in SCLC 
(Douple et a l . ,  1985). Moreover this approach avoids the need to 
obtain single cell suspensions thus avoiding cell in jury  from 
disruption of the aggregates and so allowing the maintenance of cell­
cell interactions within the spheroid during cytotoxic d rug  exposure. 
Clearly th is is more analagous to the in vivo situation (Miller et a l . , 
1984). Since the necessary apparatus and expertise was readily 
available spheroid growth studies were assessed for their application 
to the measurement of growth and chemosensitivity of the recently  
established small cell lung cancer cell line aggregates.
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METHODS 
Growth Studies
Small spheroids (approximately 50-100 microns in diameter) were 
tran sfe rred  under microscopic examination to individual wells of a 24 
well te s t plate (Linbro; Flow Laboratories, Rickmans w orth, U .K .) 
using glass Pasteur p ipettes. The individual wells were agar base- 
coated with 0.5 ml of 1.25% agar made up with RPMI 2.5% SIT.
Spheroid size was monitored twice weekly by measurement of 
cross-sectional areas of individual spheroids using a 
micromeasurements image analysis system coupled via a television 
camera to an inverted optical microscope (Wheldon et a l . , 1987) (Plate 
4 .2 ). These area measurements were subsequently converted to 
volumes assuming spherical geometry and graphs constructed of 
median log volume growth of spheroid against time.
Cytotoxicity Assays
Exponentially growing tumour cell aggregates in 25 mis of 
medium from 75cm ^  flasks were sub-divided into six 25 cm3 flasks, 
each made up to 10 mis with medium. The following day the medium 
was carefully removed and medium containing drug  at various 
concentrations added. For these experiments the cytotoxic d rug  
used, doxorubicin (Farmitalia Carlo Erba, St Albans, H erts.) was
Plate 4.2
The image analysis apparatu s used  to measure aggregate  
c ross-sectional a rea . Individual tum our cell aggregates contained 
in the  wells of a 24-well plate are viewed u n d er phase con trast with 
an in v e rted  microscope. A television camera linked to the 
microscope eye-piece relays the image to the screen of the image 
analysis system . The surface area of the  aggregate  image is used  
to estim ate volume, assum ing spherical geometry.
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fresh ly  p repared  and diluted using fresh  medium (RPMI 2.5% SIT) to 
obtain a final concentration range of doxorubicin of 1.6 x 10_53M to 
2 x 10- ^M. A ggregates were exposed to doxorubicin for 24 hours at 
37°C . The d rug  containing medium was removed and the aggregates 
were then carefully washed once with fresh  medium at room 
tem perature to remove residual d ru g . Individual spheroids were then 
tran sfe rred  into agar-coated 24-well plates and studied as described 
above. For each d rug  concentration in each experiment at least 12 
individual aggregates were studied. Graphs of median log volume 
against time were obtained for each concentration of doxorubicin.
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RESULTS 
Growth Studies
The f irs t 5 of the newly established SCLC cell lines were 
studied using  this system (LS106, LS111, LS112FL, LCPH2 and 
LCPH3). However, only 3 of the 5 cell lines studied were found to 
grow satisfactorily  when plated out as individual aggregates in 24 well 
p lates. These comprised cell lines of either classical (LS111) or 
interm ediate (LS106 and LS112FL) morphology. The growth curves 
are shown in Figures 4.1 and 4.2. It can be seen that the growth 
curve for the cell line with the most classic ( i.e . spheroidal) 
morphology had by  far the tigh test 95% confidence limits (Figure 
4 .1A ). For cell lines with intermediate or variant morphology e rro rs  
in volume measurements were encountered due to the non-spheroidal 
geometry of the aggregates (for example LS112FL, Figure 4 .IB ). It 
may also be seen that the slope of the growth curves remains similar 
in cell line LSI06 in which growth studies were repeated afte r an 
in terval of 4 months (Figure 4.2A).
The cell lines with variant morphology (LCPH2 and LCPH3) 
could not be studied using this system. LCPH2 did not grow at all 
when plated out individually, perhaps an indication of its relatively 
young age in tissue culture when studied. LCPH3 did show some 
grow th, bu t this followed a protracted lag phase of 10 days (Figure 
4 .2 B ). The estimated volume doubling times for the 3 cell lines that
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A ggregate volumes estimated at various times after plating 
out single aggregates into each well of a 24-well plate. Volume of 
the aggregate was estimated by a computerised tele-visual analysis 
system and values are the median + 95% confidence limits of 24 
aggregates. Results are shown for cell lines LS111 (A) and 
LS112FL (B ).
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Figure 4.2
A ggregate volumes estimated at various times after plating 
out individual aggregates of cell lines LS106 (A) and LCPH3 (B) 
into each well of a 24-well plate. Values are the median + 95% 
confidence limits. For cell line LS106 (A) results of two separate 
experim ents are shown.
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did grow satisfactorily  in this system are shown in Table 4.1. 
Cytotoxicity Assays
Despite the limited number of cell lines that did grow in this 
system a number of cytotoxic drug exposure experiments were 
perform ed, principally with cell lines LS111 and LS112FL. Two 
represen tative experimental resu lts are shown in Figure 4.3. At low 
d rug  concentrations (1.6 x 10 “ ^M) little growth delay was seen, 
except in the case of individual small aggregates (Figure 4.3A). At 
interm ediate d ru g  concentrations (8 x 10“ 9M and 4 x 10“ **M) a 
distinctive growth delay pattern  was seen (Figure 4.3A, B). At the 
top d ru g  concentration the tumour aggregates died completely and 
d isin tegrated  by  Day 10 (Figure 4.3A). The growth delays produced 
in each cell line for each cytotoxic d rug  concentration are shown in 
Table 4.1.
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Figure 4.3
A ggregate volumes estimated at various times after exposure 
of cell-lines LS111 (A) and LS112FL (B) to doxorubicin for 24 
hours. Values are the median (n=24).
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DISCUSSION
It was a disappointment to find that only some of the newly 
established cell lines grew well in this system. The failure of some 
cell lines to proliferate may have been a reflection of their early age 
in tissue cu ltu re . A lternatively this may have been an indication of 
the requirem ent for the presence of mouse fibroblast (stromal) cells 
in the case of LCPH2 and LCPH3, as discussed in the preceding 
Chapter. A final possibility is that the aggregates required the 
presence of o ther aggregates in close proximity to stimulate continued 
growth, perhaps by  means of unspecified growth factors (Minna et 
a l .,  1982).
Even in those cell lines where cytotoxicity testing  was possible 
a number of problems became apparent. F irstly , in terms of setting  
up and runn ing  an experiment, the study of spheroid growth and 
growth delay was labour intensive. Secondly, the chemosensitivity 
tests  were time consuming, lasting at least 3 weeks. Clearly this 
would not be ideal for the study of a large number of cell lines, 
d ifferent cytotoxic drugs and a number of resistance modifying 
ag en ts .
In addition for any given cytotoxic drug  concentration, the 
amount of growth delay appeared to be dependant on the s ta rtin g  size 
of the spheroid. Smaller spheroids appeared to be more sensitive to 
a given d ru g  concentration. This point is emphasized in Figure 4.3A 
which shows similar growth delay in cell line LSI 11 at two different
drug  concentrations (8 x 10~^M and 4 x lCT^M). This apparent 
d iscrepancy may perhaps be explained by the smaller median starting  
size of the spheroids at the lower drug concentration. Of course 
these comments relate to only a few observations but do serve to 
emphasize some of the apparent limitations of this technique. 
Certainly theoretically relatively small spheroids will have a greater 
proportion of cells in the outer region of the spheroid and cells in 
this region have been shown to be more sensitive to doxorubicin using 
a tritia ted  thymidine suicide technique in SCLC spheroids (Kwok & 
Twentyman, 1987). Despite many attempts (including the use of an 
eye-piece graticule) it proved very  difficult to select constantly sized 
aggregates. This is simply a reflection of the spectrum in size of 
these natu ra l SCLC aggregates at any one time. This is in contrast 
to the relatively  uniform size of multi-cellular tumour spheroids 
generated artificially using agar-based flasks.
In addition, only SCLC aggregates from cell line LS111 had 
true ly  spherical geometry. Aggregates with intermediate or variant 
morphology grew in various branching shapes (Plate 4 .3). Thus 
volume estimates became inaccurate. Moreover when the aggregates 
were killed by  high drug  concentrations, they became flat and 
although they  appeared damaged, still generated a signal in the 
televisual computer system, so again leading to possible inaccuracies 
(Plate 4 .4 ).
However, most of the above problems do not apply when this 
system is used to s tudy  laboratory generated multicellular tumour
Plate 4.3
A tum our a g g re g a te  from cell line LS112FL. I t can be seen 
th a t th is  re p re se n ta tiv e  a g g reg a te  does not possess spherica l 
geom etry .
/Plate 4.4
Estim ation of th e  volume of an  ag g re g a te  from cell line LS111 
following ex p o su re  to  doxorub icin  (2 x  10_ 'H\I). A lthough the  
a g g reg a te  co n sis ts  of dead  cells, th is  s tru c tu re  s till g enera tes  a 
signal.
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sphero ids. They possess spherical geometry, grow readily  and 
rapidly  in agar-coa ted  plates and th is allows accurate measurement of 
radiation and cytotoxic damage (Jones et a l . , 1982; Sutherland e t a l . , 
1979; West e t a l . , 1980).
Thus th is  system  did not appear suitable for the rapid  and 
simple s tu d y  of grow th and chem osensitivity in a range of newly 
established SCLC lines. It was therefore necessary  to re-consider 
some of the o th er system s used  to measure chemosensitivity described 
in the In troduction  to th is  ch ap te r, in o rder to identify  an assay  th a t 
was suitable to m easure the grow th and chemosensitivity of the new 
SCLC cell lines. The adaptation of the metabolic (tetrazolium dye- 
based) a ssay  chosen is described  in the next Chapter.
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CHAPTER 5 
ADAPTATION OF A TETRAZOLIUM DYE-BASED ASSAY 
TO MEASURE CHEMOSENSITIVITY
INTRODUCTION
The difficulties of study ing  growth and chemosensitivity in cell 
lines which grow as floating aggregates were discussed in the 
previous C hap ter. Recent studies from the National Cancer In stitu te  
of America rep o rted  the  use of a tetrazolium dye-based assay in th e ir  
d ru g  screen ing  programme (Alley et a l . , 1988; Carmichael e t a l . ,
1987). This a ssay  seemed particu la rly  a ttractive  because it does not 
req u ire  d isru p tio n  of aggregates into single cells, is rapid  and easy 
to perform  and  can be semi-autom ated. It appeared to be 
reproducib le and  capable of detecting small changes in 
chem osensitiv ity . I t therefo re  seemed suitable for adaptation to 
enable the  s tu d y  of growth and chemosensitivity in the newly
established SCLC cell lines.
The assay  is based  on the  principle th a t living metabolically
active cells, b u t not dead cells, can reduce a w ater soluble yellow- 
coloured tetrazolium -dye (3-[4,5-dim ethylthiazol-2-yl] 2,5 diphenyl 
tetrazolium  brom ide, MTT) to a w ater insoluble purple formazan 
p roduct (M T T -F). The molecular s tru c tu re s  of the tetrazolium dye
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and the reduced  form are shown in Figure 5.1. The tetrazolium rin g  
is cleaved, p robably  b y  in tracellu lar dehydrogenases (Hess & P earse, 
1963; S later e t a l . ,  1963; Sowerby & Ottoway, 1962). This reduction 
produces the  p u rp le  coloured MTT-formazan product.
Since the  su b s tra te  (MTT) and the product (MTT-F) absorb  at 
v ery  d ifferen t w avelengths no washing steps are requ ired  a fte r  
removal of the  aqueous medium before solubilisation of the MTT- 
formazan p ro d u c t. This is a clear advantage over those assays which 
use isotope incorporation as an end point, particu larly  when dealing 
with n o n -ad h eren t cell lines.
History of Tetrazolium Dyes in Science
The tetrazolium  salt MTT was f irs t  used almost 40 years ago to 
s tu d y  the  metabolism of normal and tumour tissues both in v itro  and 
in vivo (Sm ith, 1951). O ther w orkers subsequently  used reduction 
of MTT b y  liv ing cells to s tu d y  metabolism in normal and tumour 
tissue (Black e t a l . , 1953). Over the last two decades, many w orkers 
have used  MTT reduction  to determ ine the metabolic activ ity  of viable 
cells (Schaeffer & F riend , 1976). Along with this use of MTT 
reduction  to m easure cell v iability , went the assessm ent of toxic 
in ju ry  to cells b y  m easuring decreases in MTT-F production. Black 
& Speer (1953) stud ied  the activ ity  of cytotoxic d rugs in slices of 
excised tum our tissu e  u sing  MTT reduction as an end-poin t. 
Herrmann e t al. (1960) used  MTT to detect v irus induced
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Figure 5.1
The s tru c tu re  of the tetrazolium d y e , 3-(4,5-dim ethylthiazol- 
2 -y l)-2 ,5 -d ipheny lte trazohum  bromide (MTT) and the reduced 
formazan p ro d u c t.
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cytopathology in v itro  and in 1967, Kondo & Ohkubo used MTT in a 
te s t to p red ic t the effects of cytotoxic agents in v itro .
D uring the  1980s th ere  was increasing in te re st in the use of 
MTT as a possible method of estim ating cell in ju ry  in v itro . Mosmann 
(1983) and Green e t al. (1984B) described how m easuring the 
reduction in MTT-F production allows quantitation of cell damage 
following toxic in ju ry . Alley has also described the use of MTT, 
initially to m easure d rug-induced  cytotoxicity in soft agar colony 
forming assays (Alley e t a l . , 1982) and in prim ary soft agar cu ltures 
of solid human tum ours (Alley & Lieber, 1984). More recen tly  he has 
been involved with w orkers a t the National Cancer In stitu te  to 
validate an autom ated m icroculture tetrazolium assay  to s tu d y  the 
grow th and  d ru g  sen sitiv ity  of human tumour cell lines (Alley et a l . ,
1988). However, th is  assay  was designed for speed and simplicity in 
p reference to accuracy .
The assay  as originally described  b y  Mosmann (1983) has been 
modified b y  a num ber of w orkers (Carmichael et a l . ,  1987; Denizot & 
Lang, 1986) and  recen tly  Twentyman & Luscombe (1987) described a 
num ber of variab les which affect the  assay . In spite of these 
modifications a num ber of problems remain. In particu lar previous 
au thors have failed to dem onstrate a linear relationship between MTT- 
F production  and  cell num ber a t high cell densities ( Carmichael et a l . ,  
1987; Cole, 1986; Mosmann, 1983). In fact Ruben & Neubauer (1987) 
have recen tly  h ighlighted  th is problem. They a ttrib u te  th e ir  non­
linear (hyperbolic) cu rves to reduced  metabolic activ ity  in wells which
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have reached confluence. This point is particu larly  im portant since 
the h ighest cell num bers occur in the control, un trea ted  wells and 
these are  u sed  to determ ine the param eters of sensitiv ity  to the 
cytotoxic d ru g .
O ther problems with the assay  relate  to the  need to rationalise 
and define a tim e-course fo r the assay . This is particu larly  im portant 
with re g a rd  to th e  d rug -ex p o su re  period and the subsequent recovery  
period. The facto rs which have to be considered include the 
mechanism of action of the d ru g  and its  stab ility  in cu lture conditions. 
The recovery  period is req u ired  to allow for damage which does not 
kill the  cells b u t p rev en ts  cell division.
The modification of the tetrazolium  assay  is described in th is 
C hapter. In o rd e r to s tu d y  a num ber of variables adheren t non-small 
cell lung  cancer cell lines were used  for the initial characterisation of 
the assay . The re su lts  from these cell lines were then, extended to 
include well estab lished  non-adheren t SCLC cell lines th a t could be 
d isaggregated  and  counted. Finally, the modified assay  was adapted 
for stud ies  of the  newly estab lished  small cell lung cancer cell lines.
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METHODS
Cell Lines
Four non-sm all cell and two readily  disaggregable small cell lung 
cancer cell lines were u sed  initially to develop the assay . The non­
small cell lines u sed  w ere: L-DAN, a squamous lung cancer cell line 
established  in  our own laboratory ; A549, a broncho-alveolar 
carcinoma cell line and  SK-MES, a squamous lung carcinoma cell line 
both  obtained from th e  American Type Tissue Collection and WIL, an 
adenocarcinoma cell line obtained from the Ludwig Institu te  for Cancer 
R esearch, S u tton , S u rrey . These lines were maintained in a m ixture 
of Ham’s F10 and Dulbecco’s Modified Eagle’s Medium [DMEM] (50:50; 
Gibco L td . ,  Paisley , Scotland) supplem ented with glutamine (2mM) 
and foetal bovine serum  (10% v /v )  [F10/DMEM10%].
The two SCLC lines used  were GLC4, kindly gifted b y  Dr E. de 
V ries, D epartm ent of Clinical Oncology, U niversity  of Groningen, The 
N etherlands and  NCI-H187, (C arney et a l . ,  1985). These lines were 
maintained in  RPMI 1640 (N orthum bria Biologicals L td . , Cramlington, 
N orthum berland, England) supplem ented with glutamine (2mM) and 
foetal bovine serum  (10% v /v )  [RPMI 10%].
The cu ltu re  conditions of the newly established SCLC cell lines 
have been described  prev iously  (C hapter 2).
Determination of Absorption Spectra
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MTT and MTT-formazan (Sigma Chemical Company, Poole, 
D orset) were dissolved in dimethylsulphoxide (DMSO) (BDH, 
T hornliebank, Glasgow). The absorbance was then scanned between 
w avelengths of 350nm and 700nm using  a Gilford spectrophotom eter. 
MTT-formazan produced b y  cells was obtained by  incubation of cells 
(L-DAN) in the  p resence of MTT (5 mg/ml) for 4 h ours, in the dark  
at 37°C in an atm osphere of 2% CO3  in a ir . Any remaining MTT was 
removed and the formazan crysta ls  were dissolved in DMSO and 
absorbance m easured as described above.
Determination of Optimal MTT Concentration
Cells were p lated  out into 96 well plates in 200 ul of medium at 
a concentration of e ith er 10"* cells p e r  flat bottomed well (A549 and L- 
DAN; Linbro from Flow Laboratories, Irv ine, Scotland) or 5 x 10"* 
cells p e r  round  bottomed well (GLC4 and NCI-H187; Nunclon from 
Gibco, Paisley , S co tland). Cells were incubated for 24 hours a t 37°C 
in an atm osphere of 2% CO3 in a ir to allow attachm ent an d /o r grow th. 
Subsequently  MTT (a t concentrations of between 0 and 5 mg/ml) was 
dissolved in PBS and 50 ul was added to each well, 8 wells p e r 
concentration. Plates were wrapped in aluminium foil and incubated 
for 4 hours a t 37°C . Medium and any remaining MTT was carefully  
removed a t the end of the incubation. P rior to removal of the medium
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plates containing non-adheren t cells were centrifuged a t 200 g for 5 
m inutes. The formazan crysta ls  produced were dissolved in 200 ul of 
DMSO. In some experim ents 25 ul of Sorensen’s glycine b u ffer (0.1M 
glycine + 0.1M NaCl equilibrated to a pH of 10.5 with NaOH 0.1N) was 
added a t th is  s tage . The absorbance values were recorded using  an 
ELISA plate read er (Model 2550 EIA Plate Reader; B io-rad 
Laboratories, W atford, England) a t a wavelength of 570 nm.
Determination of Optimal Incubation Time
The non-sm all cell lung cancer cell lines A549 and SK-MES were 
plated out in 96 well m icrotitre plates and incubated for 24 hours as 
described above. MTT at the optimal concentration for each cell line 
(4 mg/ml fo r A549 and 4.25 mg/ml for SK-MES) was dissolved in PBS 
and 50 ul was added to each well. Plates were incubated for 1 ,2 ,3  or 
4 hours and  th en  processed  as described previously.
Relationship between MTT-Formazan Production and Cell Number
Cells (A549, L-DAN, GLC4 and NCI-H187) were diluted to a 
concentration of 2.5 x 10s  cells p e r  ml. Various volumes of th is cell 
suspension (20 ul-200 ul) were plated out in duplicate 96 well 
m icrotitre p lates (8 wells p e r  volume), the final volume always being 
made up to 200 ul with fre sh  medium. Plates were then incubated for 
24 hours a t 37°C in an atm osphere of 2% COz  in a ir . The duplicate
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plates were then  processed  as follows. To one plate 50 ul of MTT in 
PBS (concentration  depending on cell line) was added and the plate 
incubated fo r 4 hours and processed as described above. The medium 
was removed from the  o ther plate and 50 ul trypsin/ED TA  
(0.25%/lmM) was added to each well. A fter incubation a t 37°C fo r a 
few m inutes the  cells from 4 replicate wells were pooled and counted 
with an electronic counter (Coulter Electronics, Luton, England).
Growth Rates
Cells were p lated  out in 200 ul of medium at a concentration of 
10^ p e r  well ( i .e .  5 x lO^/ml for A549 and L-DAN) or 5 x 1031 p e r 
well ( i .e .  2.5 x 10^/m l fo r GLC4 and NCI-H187). More than one cell 
line was p lated  out in each plate and separate plates were p repared  
for each time po in t. Plates were fed daily with fresh  medium and 
every  2nd day one row (com prising eight wells) from a plate was 
trypsin ized  and  counted as described above. MTT (50 u l, 
concentration depending on cell line) was added to a second row and 
the p lates p rocessed  as above.
Chemosensitivity Measurements
M icrotitre A ssay
A dherent cells (A549, L-DAN) were plated out a t a 
concentration of 10^ p e r well in 200 ul of medium ( i.e . 5 x 10
cells/ml) and  allowed to a ttach  and grow for 2 to 3 days. The medium  
was then  removed from the wells and replaced with 200 ul of medium 
(for the  control wells) or 200 ul of drug-contain ing  medium. The 
cytotoxic d ru g s  used  were doxorubicin (Farmitalia Carlo Erba, St 
A lbans, H e r ts .) ,  and vincristine (Sigma Co. L td .,  Poole, D orset). 
D rug was always fre sh ly  made up and diluted in culture medium. 
Cells were incubated  with d ru g  for 24 hours a fte r which the d ru g - 
containing medium was replaced b y  d ru g -free  medium. Plates were 
then fed daily w ith 200 ul of fre sh  medium for 2 days. On the fifth  
day following d ru g  addition the cells were fed with 200 ul of fresh  
medium containing HEPES b u ffe r (lOmM, pH 7.4) to maintain a 
constant pH d u rin g  MTT incubation. MTT (50 ul of a pre-determ ined 
concentration) was added to the wells and the plates were incubated 
and p rocessed  as described  previously . In all experim ents in which 
chem osensitivity was measured b y  m icrotitre assay , d ru g  sensitiv ity  
was defined as th a t concentration of d ru g  requ ired  to reduce 
absorbance to 50% of control absorbance (IDS o ) .
For the non-adheren t cell lines (GLC4 and NCI-H187) 
exponentially grow ing cells were plated  out a t a concentration of 5 x 
10^ cells p e r  well in 100 ul of cu lture medium. D rug was added 
immediately in a volume of 100 ul a t twice the desired  final 
concentration. Cells were exposed to d ru g  for 24 hours and then  fed 
and p rocessed  as described  above. Plates containing the non­
adheren t SCLC aggregates had to be centrifuged a t 200g for 5 minutes 
every  day  p r io r  to feeding.
137
Clonogenic A ssay
Cells (A549 and L-DAN) were plated out at a concentration of 
7.8 x 10^ cells p e r  25 cm2  flask (Nunclon; Gibco, Paisley, U .K .) . 
This gave the  same cell density /cm 3  as was used for the m icrotitre 
assay . The cells were allowed to a ttach  and grow for 2 to 3 days. 
Flasks were then  fed with 5 mis of fresh  medium or medium containing 
d ru g  and incubated  fo r 24 h o u rs . The medium was then removed and 
the cells washed with 5 mis of trypsin/ED TA  (0.25 %/lmM) and 
incubated fo r a few minutes a t 37°C . Cells were then  resuspended  
in 10 mis of fre sh  medium and the cells in the control, un trea ted  
flasks counted . They were diluted to 100 cells p e r ml and 5 mis was 
plated out into each of 4 P etri Dishes (6 cm, Nunclon; Gibco, Paisley, 
S co tland). Cells from the d ru g -trea ted  flasks were diluted in the 
same way as the  control flask and plated out as above. The dishes 
were incubated  a t 37°C in an atmosphere of 2% CO^ in a ir for 10 
days. Medium was then  removed, the P etri dishes were washed with 
PBS, fixed in methanol and stained with crysta l violet. Colonies of 
g rea te r th an  50 cells were counted.
Effect of Time after Drug Exposure on the Apparent Chemosensitivity 
of the Cells
Cells (A549) were plated out, and exposed to various 
concentrations of doxorubicin for 24 hours, as described above. 
T h e reafte r, p la tes were fed daily for 24-96 hours. Residual cell
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viability was estim ated by  MTT reduction as previously described , at 
24,48,72 and 96 hours a fte r  d ru g  exposure.
Doxorubicin Penetration into and MTT-FormftsaTi Production by  
Aggregates from Newly Established SCLC Cell Linen
A ggregates from each of the newly established SCLC cell lines 
were incubated  with e ith er doxorubicin (10- e M) or MTT (5mg/ml) for 
4 h o u rs . The agg regates  were then  washed once with cold PBS and 
then mounted in OCT (BDH L td .,  Thornliebank, Glasgow) on 
cryotome blocks re s tin g  in d ry  ice. Frozen sections (5 micron) were 
p rep ared  with a c ry o sta t. These sections were observed unmounted 
to assess  the  viable cell population. Subsequently sections were 
mounted in "U V Inert"  (BDH L td .,  Thornliebank, Glasgow). Those 
incubated in  doxorubicin were mounted in glycerol and viewed by  
fluorescent microscopy. Those aggregates incubated in MTT were 
examined b y  ligh t microscopy.
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RESULTS 
Spectral Analysis
The absorp tion  spec tra  of MTT and MTT-formazan are shown in 
Figure 5 .2 . Also shown is the absorption spectrum  for MTT-formazan 
produced b y  cells incubated in the presence of MTT. For MTT there  
is a single absorp tion  maximum at a wavelength of 410 nm. Pure 
MTT-formazan obtained from the m anufacturing chemist exhibits two 
absorption maxima a t w avelengths of about 510 nm and 570 nm. In 
co n trast, MTT-formazan produced b y  cells (4 x lO^/well, L-DAN) 
incubated with MTT (5 mg/ml) dem onstrates a single absorption 
maximum a t a w avelength of about 570nm.
Determination of Optimal MTT Concentration
Figure 5 .3A shows the  amount of MTT-formazan produced when 
the cell line L-DAN is incubated with various concentrations of MTT. 
MTT-formazan production increases with increasing MTT concentration 
up to 4.5 mg/ml. For A549 a plateau of MTT-formazan production is 
reached with an MTT concentration of 4.2 mg/ml (data not shown). 
For the two SCLC cell lines MTT-formazan production was maximal at 
much lower MTT concentrations (1.8 mg/ml for GLC4, Fig 5.3B, and 
1.2 mg/ml fo r NCI-H187, Fig 5 .3C ). In no case were MTT 
concentrations of up to 5 mg/ml toxic to the cells.
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Figure 5.2
A bsorption sp ec tra  of MTT and commercially p repared  MTT- 
formazan dissolved in DMSO. Also shown is the spectrum  of MTT- 
formazan p roduced  b y  incubation of L-DAN cells (4,000 p er well) 
with MTT (5mg/ml) fo r 4 hou rs.
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Figure 5.3
Effect of MTT concentration on MTT-formazan production. 
Cells, L-DAN (A ), GLC^ (B) or NCI-H 187 (C) were plated out at 
a density  of 5 x 10"* p e r  well and allowed to grow for 24 hours. 
MTT (50ul of a solution of 0 to 5 m g  I ml) was added (8 wells p er 
concen tra tion), and the plate was incubated for 4 hours. The 
medium was rem oved, and the MTT-formazan crystals were 
dissolved in DMSO. Values are  the mean + Standard E rror of the 
Mean (SEM) of 8 observations.
Determination of Optimal Incubation Time
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Figure 5.4 shows th a t for both cell lines studied [A549 (A) and 
SK-MES (B )] the  amount of MTT-formazan produced increases du ring  
the f ir s t  3 hours of incubation. MTT-F production then appears to 
p la teau .
Relationship between MTT-Formazan Production and Cell Numhoi*
The relationship  between MTT-formazan production and cell 
num ber fo r the cell lines L-DAN (A) and GLC4 (B) is shown in Figure 
5.5. A lthough th e re  is a clear linear relationship up to a cell number 
of about 2 x 10^ cells p e r well, in neither case does the regression  
line ex trapo late  th ro u g h  the origin.
Effect of Cell Number on the Absorption Spectrum of MTT-Formazan
Figure 5.6 shows the absorption spectrum  of MTT-formazan 
produced b y  cells following incubation of A549 cells with MTT (5 
mg/ml) fo r 4 hours a t low (4 x 10^ cells/well) and high (1CT* 
cells/well) cell densities. For low cell numbers the spectrum  shows 
a single absorp tion  maximum a t a wavelength of about 570 nm. In 
co n trast, a t h ig h er cell num bers the peak is much broader with the 
absorption maximum a t a w avelength of about 510 nm and a shoulder 
in th is  peak a t about 580 nm.
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Figure 5.4
Determination of optimal incubation time for MTT. Cells, 
e ither A549 (A) o r SK-MES (B) were p lated out a t a density  of 10^ 
p e r well and allowed to grow fo r 24 h ours. MTT (50ul) a t the 
optimal concentration fo r each cell-line (4 mg/ml for A549 and 4.25 
mg/ml fo r SK-MES) was added to each well and plates were 
incubated fo r 1-4 h o u rs. The medium was removed, and the MTT- 
formazan c ry sta ls  were dissolved in DMSO. Values are the mean 
+ SEM of 8 observations.
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Relationship between MTT-formazan production and cell 
number fo r the  cell lines L-DAN (A) and GLC^ (B ). Cells were 
plated out a t a range  of concentrations and incubated for 24 h o u rs . 
Cell num ber was then  estim ated e ither b y  counting following 
trypsin  trea tm en t if req u ired  or b y  incubation with MTT (L-DAN, 
5mg/ml; GLC^, 2 mg/ml) for 4 h ou rs.
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Figure 5.6
A bsorption spectrum  of MTT-formazan produced by  
incubation of A549 cells with MTT (5 mg/ml) for 4 hours at low (4 
x 10^ cells p e r  well) and high (lCT* cells p e r well) cell densities. 
MTT-formazan c ry sta ls  were dissolved in DMSO.
Effect of pH on MTT-Formazan Absorbance
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Figure 5.7 shows the spectra l analysis of solutions of MTT- 
formazan in DMSO (200 ul) in the presence of glycine b u ffer (25 ul) 
equ ilib rated  a t a range of pH v a lu es . Addition of bu ffer resu lted  in 
increased  absorbance values for the MTT-formazan in all cases. The 
increase was small a t physiological pH (7 .4 ). At h igher pH values the 
absorbance increased  with increasing  pH, and reached a maximum at 
a pH of 10.5. T here was no fu r th e r  increase in absorbance a t pH 
values g re a te r  than  10.5
Effect of Buffer Addition on the Relationship between M T T - F o r m a  
Production and Cell Number
Figure 5.8 shows the relationship between MTT-formazan 
production and cell num ber fo r the cell line A549 both before (open 
circles) and a f te r  (closed circles) addition of bu ffer to the wells (25 
ul, 0.1M, pH 10 .5 ). The absorbance values are increased for all cell 
num bers b u t the  increase is most marked a t high cell num bers. 
Furtherm ore, following addition of b u ffer the regression  line 
ex trapolates th ro u g h  the origin.
HEPES b u ffe r  (10 mM, pH 7.4) was added during  the period of 
incubation with MTT to control the pH. This did not a lte r the 
g rad ien t of the  line b u t did reduce the sca tte r of points about the line 
(F igure 5 .9 ) .
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Figure 5.7
A bsorption spectrum  of a solution of commercially p repared  
MTT-formazan in DMSO (200ul) or in DMSO (200ul) plus glycine 
b u ffer (25ul) equ ilib rated  a t a range of pH values. For pH 7.5 , 
a phosphate b u ffe r  was used .
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Figure 5.8
Effect of b u ffe r  addition on the relationship between MTT- 
formazan production  and cell num ber. Cells (A549) were plated 
out a t a range of concentrations and allowed to adhere for 24 
h o u rs . Cells were then  e ith er trypsin ized  and counted or 
incubated  with MTT (5mg/ml) for 4 h ours. Medium was removed, 
and MTT-formazan c ry sta ls  were dissolved in DMSO, and the 
absorbance was recorded  a t 570 nm (O ). Buffer (25ul, 0.1 M 
glycine, pH 10.5) was added to each well, and the absorbance was 
again recorded  a t 570 nm ( • ) .
A549
Eco
LO
oc
CtijQ
o
CO
.O
<
y = 0.0585x + 0.0323
•  F10/DMEM
° F10/DMEM + HEPES lOmM
0.0
0 5 10 15 20 25
Cells/well (x10 '3 )
Figure 5.9
Effect of addition of HEPES b u ffe r du ring  MTT incubation. 
Cells (A549) were p lated  out a t a range of concentrations and 
allowed to adhere  fo r 24 h o u rs . Cells were then e ither trypsin ized  
and counted o r incubated  with MTT (5 mg/ml) for 4 hours with (O) 
or w ithout ( • )  HEPES b u ffe r (10 mM, pH 7 .4 ).
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Effect of Culture Medium on MTT-Formaran Pradu^tion
Table 5.1 shows the effect of d ifferent volumes of cu lture 
medium (F10/DMEM 10%) on the absorbance of a s tandard  solution of 
MTT-formazan. Addition of cu ltu re  medium resu lts  in an increase in 
the absorbance of the  MTT-formazan. In teresting ly  the increase in 
absorbance values is g rea te r  fo r small additions than for large 
additions of medium.
This table also shows the absorbance values obtained a fte r  
addition of b u ffe r  (25 ul p e r  well, 0.1M, pH 10.5) to the same p late. 
Although th e re  is still a sligh t increase in absorbance in the presence 
of 5 ul of cu ltu re  medium, addition of up to 50 ul of medium resu lts  
in only a v e ry  small reduction in MTT-formazan absorbance. It 
should be noted th a t the addition of bu ffer alone to MTT-formazan 
resu lted  in a marked increase in the absorbance value.
Growth Studies
Growth cu rves for the non-small cell (L-DAN, A) and small cell 
(GLC4, B) lung  cancer cell lines are  shown in Figure 5.10. Doubling 
times of 24 hours fo r both  cell lines compare well with those obtained 
by  cell coun ts.
A 2 . 0 L-DAN
Ecoh-in
CDocco_Q
o
CO
JD
<
. 0
. 1
0 2 4 6 B
B
Eco
LO,
CDOc
CO
1_ow
<
GLC10
1
1
8 10 12 14620 4
Time (days)
Figure 5.10
MTT-formazan production p e r  well determined a t various 
times a f te r  p la ting  out L-DAN cells (A) and GLC„ cells (B) a t a 
density  of lO3 cells/w ell in 96-well p la tes. Cells were fed daily 
and a t specified times MTT (50ul; 5mg/ml for L-DAN, 2mg/ml for 
GLC^) was added to one p la te . MTT-formazan crysta ls  were 
dissolved in DMSO, and a fte r  addition of b u ffer (25ul, 0.1M 
glycine, pH 10.5) absorbance was noted at 570 nm. Results are 
the mean of 8 wells.
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Figure 5.11
MTT-formazan production p e r  well determined 3 days a fte r 
exposure of cells (L-DAN) to various concentrations of doxorubicin 
for 24 h o u rs . MTT-formazan crysta ls  were dissolved in DMSO, and 
the absorbance noted before ( • )  and a fte r (O) addition of b u ffer
(25ul, 0.1M glycine, pH 10.5). IDS« indicated ( ------) , rep resen ts
th a t concentration of doxorubicin requ ired  to reduce absorbance 
values by  50%. Values are  the mean of 8 wells.
Itecovarytircs
(days)
IDSD (nto)
1 140 ±  28
2 120 ±  22
3 38 ±  7
4 38 ±  6
T ab le  5 .2
S en sitiv ity  o f A 5 4 9  to  d o x o ru b ic in  (ID50, nM) d e ter m in ed  b y th e  
m icrotitration  a s s a y  a n d  e s t im a te d  at v a rio u s t im e s  after d ru g rem oval. 
R e su lts  a re  th e  m e a n  + / -  SEM  of 6  e s tim a tio n s .
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Figure 5.12
Effect of time a fte r  d ru g  exposure on the apparen t 
chem osensitivity of tum our cells. Cells (A549) were plated out at 
a d ensity  of 10~* p e r  well and were allowed to a ttach  and grow for 
2 d ays. Cells were then  exposed to vary ing  concentrations of 
doxorubicin (8 x 10-CJ,M - 5 x 1 0 '^ ’M) for 24 hours. Drug 
containing medium was then  removed and cells were fed daily for 
1-4 days. Residual cell viability was estim ated by  MTT reduction 
at specified times a f te r  d ru g  exposure. Values are the mean of 8 
w ells.
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Effect of B uffer Addition on the Apparent Chemose11 tiv ity  to 
Doxorubicin
Figure 5.11 shows MTT-formazan production p e r well 4 days 
a fte r  exposure of L-DAN cells to various concentrations of 
doxorubicin fo r 24 h o u rs . When the MTT-formazan crysta ls  were 
dissolved in DMSO and absorbance values were measured a t 570 nm, 
the ID so  was 1.8 x 10_ ^M. However, following addition of b u ffe r (25 
ul p e r  well, 0.1M, pH 10.5) the absorbance a t 570 nm was g reatly  
increased  in the  control (u n trea ted ) wells and in those wells exposed 
to a low d ru g  concentration; in th is case the IDs o  was 1.1 x 10" ** M 
indicating  an app aren t increase in the sensitiv ity  of the cells to 
doxorubicin .
Effect of R ecovery Time on Chem osensitivity
Table 5.2 shows the sensitiv ity  to doxorubicin determ ined by  
m icrotitration assay  fo r the cell line A549. Cells were exposed to 
d ru g  fo r 24 hours and  MTT was added a t various times a fte r  d ru g  
exposure. The apparen t sensitiv ity  of the cell line increases with 
increasing  recovery  time over the f irs t  3 days a fte r d ru g  removal. 
A fter 3 days th e re  is no fu r th e r  increase in sensitiv ity . Figure 5.12 
shows the  absorbance p e r well determ ined at various times a fte r  
removal of th e  cytotoxic d ru g  (doxorubicin) for A549 cells. At low 
d ru g  concentrations (6 .4  x lO- 1 1  - 8 x 10-S*M) the cell number and
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grow th ra te  is the  same as for the control un trea ted  cells. There is 
a significant reduction  in cell numbers 24 hours a fte r d ru g  removal at 
all h ig h er d ru g  concen tra tions. Although some growth is observed at 
4 x 10-e *M and 2 x 10“ ^M of doxorubicin, the growth ra te  is much 
slower than  fo r the  control cells. At all h igher d ru g  concentrations 
no grow th or cell death  is observed.
Determination of Chem osensitivity by the Microtitre Assay and 
Correlation with a Clonogenic Assay
Figure 5.13 shows rep resen ta tive  chem osensitivity profiles to 
doxorubicin fo r the  cell lines L-DAN (A) and GLC4 (B ). Table 5.3 
shows the  chem osensitivities of the two SCLC cell lines to 
doxorubicin. Also shown in Table 5.3 are  the sensitivities of the two 
non-small cell lung  cancer cell lines to both  doxorubicin and 
v incristine  determ ined bo th  b y  the  m icrotitration assay  and b y  the 
s tan d a rd  clonogenic assay  described  above. The s tandard  e rro rs  for 
the two assays are  similar and th e re  is close agreem ent between the 
two assays fo r bo th  cell lines and fo r bo th  d ru g s . The overall e rro r  
of the  estim ates in the m icrotitre assay  is small (Co-efficient of 
Variation = 19%, Table 5 .4) and is similar for both the adheren t and 
non-adheren t cell lines.
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Figure 5.13
Determ ination of chem osensitivity to doxorubicin for L-DAN 
(A) and GLCU (B ). For L-DAN, cells were plated out (10ri p er 
well) and allowed to a ttach  and grow for 2-3 days, and then 
exposed to various concentrations of doxorubicin for 24 hours. 
For GLC^,, cells were plated out (5 x 10r'  p e r well) and exposed to 
various concentrations of doxorubicin for 24 hours. Subsequently 
d ru g  containing medium was removed, and cells were fed daily. 
On the  fifth  day following d ru g  addition remaining viable cell 
num ber was estim ated by  MTT reduction . Values are the mean + 
SEM of 8 observations.
ID50 (nM)
Drug Cell Line Mlcrotitretfon C lonogenic
Doxorubicin NCI-H187 36* ±  2 (6)** -
GLC4 12 ±  3 (6) -
L-DAN 23 ±  4 (7) 24 ±  7 (6)
A549 23 ±  4 (7) 38 ±  7 (6)
WIL 5 7 ±  6 (7) 34 i  8 (4)
SK-MES 33 +. 2 (10) 21 ±  7 (4)
Vincristine L-DAN 12 ±  1 (6) 12 ±  2 (6)
A549 44 ±  10 (5) 22 +. 4 (5)
WIL 4 1 + 4  (7) 20 ±  8 (4)
* M ean +_ SEM
** N um bers in p a ren th e se s , num ber of estim ates
Table 5 .3
C hem osensitiv ity  (ID50, nM) to doxorubicin and vincristine estim ated  by the 
microtitration a s s a y  and  by clonogenic assay .
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4 2
3 5
27
3 4
3 2
38
20
M ean =  3 2 .9  nM
S tan dard  deviation  =  6 .3 3 2  nM
C o-effic ien t of variation =  19.3%
T able  5 .4
C o-effic ien t o f Variation for microtitre a ssa y . T he resu lts for 10 sep a ra te  
estim a tio n s  of th e  sensitiv ity  of ce ll line SK-MES to ex p o su re  to  
d oxoru bicin  (ID50, nM) for 2 4  hours are sh ow n .
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Doxorubicin Penetration and MTT-Form a ran Production in A ggregates 
from Newly Established SCLC Cell T . i t i p k
The d istribu tion  of doxorubicin and of MTT-formazan in 
sections of small cell lung  cancer cell line aggregates are shown in 
Plate 5.1 (LS111) and Plate 5.2 (LCPH3). The aggregates were f irs t  
observed b y  ligh t microscopy (A ). Doxorubicin fluorescence was 
observed th ro u g h o u t the  aggregates (B ). Similarly MTT-formazan 
cry sta ls  were seen to have been produced by  all the cells throughout 
the ag g reg ates  ( C ) . The only exception observed was for the la rg e r 
aggregates  of LS111. Direct examination of sections from such 
aggregates indicated  th a t the viable cells appeared to be located in 
the o u ter layers  of the  ag g reg a te . This viable cell area corresponded 
to the  region of doxorubicin fluorescence and MTT-formazan 
production . A few cells in the cen tre  of these la rg er aggregates 
showed doxorubicin fluorescence and similarly a few cells in the 
cen tre  of the aggregates were associated with MTT-formazan 
p ro d u c tio n .
cPlate 5.1
P en e tra tio n  of doxorub icin  in to  and  M TT-formazan production  
by  SCLC tum our a g g re g a te s  from cell line LS111. For doxorubicin 
p en e tra tio n  s tu d ie s  cells w ere in cu b ated  w ith doxorubicin  (10-<r>M) 
fo r 4 h o u rs . For M TT-form azan p roduction  s tu d ies  cells were 
incu b ated  w ith MTT (5mg/ml) fo r  4 h o u rs . Frozen sections were 
p re p a re d  and  o b serv ed  unm ounted to  a sse ss  the  viable cell
( 3 )
population* S u b seq u en tly  sec tions w ere m ounted in "UV in e r t” . 
Those a g g re g a te s  in cu b ated  w ith doxorubicin  were viewed b y  
flu o rescen t m icroscop}^ Those in cu b ated  w ith MTT w ere examined 
b y  lig h t m icroscopy^
Plate 5.2
P en e tra tio n  of doxorubicin  in to  and M TT-formazan production  
by  SCLC tum our a g g re g a te s  from cell line LCPH3. For doxorubicin  
p en e tra tio n  s tu d ie s  cells were incu b ated  w ith doxorubicin  (10_ *^ M) 
fo r 4 h o u rs . For M TT-formazan p roduction  s tu d ies  cells w ere 
in cu b ated  w ith MTT (5mg/ml) fo r 4 h o u rs . Frozen sections were 
p re p a re d  and  o b serv ed  unm ounted to assess  the  viable cell 
population^?* S u b seq u en tly  sections w ere mounted in MUV in e r t” . 
Those a g g re g a te s  in cu b ated  w ith doxorubicin  w ere viewed by  
flu o rescen t microscopy[. * Those incu b ated  w ith MTT w ere examined 
by  lig h t microscopy?*
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DISCUSSION
The end point of any chemosensitivity assay  is usually  an 
estim ate, e ith e r d irec t or ind irec t, of surv iv ing  cell num bers. The 
tetrazolium  dye assay  relies on the ability of cells to reduce dye in a 
quan tita tive m anner and fo r there  to be a linear relationship between 
cell num ber and dye reduction .
It was shown th a t when cells are incubated with MTT, the 
amount of MTT-formazan produced depends upon the concentration of 
MTT in  the  incubation medium. MTT-formazan production increases 
with increasing  MTT un til a concentration is reached a t which MTT- 
formazan production  p lateaus. This optimum concentration varies 
widely betw een cell lines. In the SCLC cell lines (NCI-H187 and 
GLC4) a concentration of 2 mg/ml (fined concentration 0.4 mg/ml) 
gives maximal MTT-formazan production. However, for some of the 
non-small cell lung  cancer cell lines a concentration of up to 5 mg/ml 
(final concentration  1 mg/ml) is requ ired  for maximal absorbance 
rea d in g s .
The concentration of MTT used in previous assays has varied 
widely. Indeed , the  original assay  as described by  Mosmann (1 9 8 3 )  
and the  more recen tly  rep o rted  screening  assay (Carmichael e t a l . ,  
1987) use final MTT concentrations of only 0.4 mg/ml. From the 
re su lts  of th is  s tu d y  it  appears th a t th is would be insufficient for 
maximal formazan production in all cell lines. Denizot & Lang (1 9 8 6 )  
rep o rted  th a t in a T -cell lymphoma cell line, a final MTT concentration
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of 1 mg/ ml was req u ired  for maximal formazan production. The failure 
to determ ine the  optimal concentration of MTT requ ired  may, in p a r t ,  
account fo r the  failure of previous attem pts using  tetrazolium dye 
reduction  to dem onstrate a linear relationship between the amount of 
dye reduced  and cell number (Carmichael et a l . ,  1987; Cole, 1986; 
Mosmann, 1983).
With reg a rd  to the duration of incubation with MTT it is 
im portant to allow sufficient time for maximal reduction of MTT to 
MTT-F. The m ajority of w orkers have used a defined 4 hour 
incubation (Carmichael et a l . , 1987, 1988A; Green et a l . ,  1984B; 
Mosmann, 1983; Ruben & Neubauer, 1987) although Cole (1986) used 
only a 3 hour incubation. Twentyman & Luscombe (1987) showed th a t 
MTT-F continues to be produced fo r up to 6 hou rs, although the vast 
majority has appeared  within 4 h o u rs . Similarly in the non-small cell 
lung cancer cell lines, MTT-F production appeared to plateau a fte r  3 
hours (F igure 5 .4 ) . Thus 4 hours appears sufficient time to allow 
most of the  tetrazolium  dye to be reduced , and hence was chosen as 
the defined incubation time fo r th is  assay .
U sing the  appropria te  concentration of MTT for the cell line 
being stud ied  and an appropriate  incubation period , a linear 
relationship  betw een cell num ber and dye reduction was dem onstrated, 
up to a cell num ber of 2 x 10^ cells p e r well (Figure 5 .5 ). However, 
when the  reg ressio n  line is ex trapolated  it does not pass th rough  the 
orig in . Indeed in F igure 5.5 it appears th a t MTT-formazan is 
produced in the absence of any  cells. Since both medium and MTT
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are u sed  to estab lish  background absorbance values for read ing  the 
plate th is  observation  suggests  th a t the relationship may not be 
linear. It is in te re s tin g  to note th a t although Cole (1986) has claimed 
a linear re lationship  fo r the a ssay , a curve would clearly be a b e tte r  
fit (see F igure 1, Cole, 1986).
To t r y  and explain th is non-linearity  the spectral analysis of 
MTT and MTT-formazan produced commercially as well as produced by  
cells a t low and h igh  cell density  was s tu d ied . Commercially p rep ared  
MTT-formazan when dissolved in DMSO is not the same colour as th a t 
produced b y  incubation of cells in the presence of MTT. This 
observation  was confirmed b y  spectra l analysis of the two MTT- 
form azans. Commercially p rep ared  MTT-formazan exhibits a major 
absorp tion  maximum a t a wavelength of 510 nm and a shoulder in the 
peak which may rep re sen t a second absorption maximum a t 560-580 
nm. On the  o ther h and , MTT-formazan produced by  cells (4000 cells 
p e r well) exh ib its  a single absorption maximum a t 560-570 nm (F igures 
5.2 and 5 .6 ) . This difference has been reported  previously  (Alley et 
a l . , 1988) and has been a ttrib u ted  to the presence of serum when 
MTT-formazan from cells is dissolved in DMSO. This can not be the  
explanation because it was shown th a t a t high cell density  (10^/well) 
the absorp tion  spectrum  of the MTT-formazan product resembles th a t 
of the  commercially p rep ared  MTT-formazan, despite the presence of 
contam inating serum .
Nonetheless medium does in te rfe re  with the measurement of 
absorbance (Table 5 .1 ) . If a small volume (5-10ul) of medium is
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added to a solution of MTT-formazan there  is a marked increase in the 
absorbance re a d in g s . On the o ther hand if la rger volumes of medium 
(20 ul - 50 ul) are  added th ere  is only a modest increase in 
absorbance values. A lthough it has been suggested th a t th is effect 
is due to the  p ro te in  p re sen t in the medium it is not clear why a small 
amount of p ro te in  would increase the absorbance more than  a la rg e r 
am ount.
It is , how ever, known th a t pH can influence absorption 
sp ec tra . Denizot & Lang (1986) suggested  th a t the formazan 
absorp tion  spectrum  may be sh ifted  b y  changes in pH . At an acid pH 
(3 .5) the absorption  spectrum  of cellular MTT-formazan resembles 
th a t of commercially p rep ared  MTT-formazan in DMSO alone and thus 
the absorbance m easured a t 570 nm is low. However, if the pH of the 
solubilised cellular MTT-formazan is increased, the spectrum  
approaches th a t of the MTT-formazan produced by  cells a t low density  
(4,000 cells p e r  well, F igure 5.6) and thus the absorbance a t 570 nm 
is m arkedly increased . This increase in absorbance a t 570 nm with 
increasing  pH reaches a plateau value a t a pH of 10.5, when the MTT- 
formazan absorp tion  spectrum  exhibits only a single peak, a t 570 nm 
(Figure 5 .7 ).
pH Dependence of the MTT A ssay
It is difficult to explain the pH dependence of the absorption 
spectrum  of MTT-formazan. When MTT is reduced , the tetrazolium
r in g  is opened, and the q u a te rn ary  amine is reduced to a te r tia ry  
amine. A second te r tia ry  amine (which originally formed one of the 
bonds to the  q u a te rn a ry  amine) therefore becomes bonded to a 
hydrogen  atom. I t could be hypothesised th a t at a high pH th is 
hydrogen  is removed and so the te r tia ry  amine is fu r th e r  reduced to 
a secondary  amine with a lone pa ir of electrons which could delocalise 
to give a resonance form of MTT-formazan. Hence th is resonance 
form would account fo r the absorption maximum at 570 nm, whereas 
the species in which the hydrogen ion is p resen t as p a rt of a te r tia ry  
amine might account fo r the  absorption maximum at 510 nm. Whatever 
the explanation, these  spectra l sh ifts  produce a real problem when 
dye reduction  is used  to estimate cell num bers. At low cell numbers 
the absorp tion  maximum is a t 560 - 570 nm whereas a t high cell 
num bers th e re  a re  two peaks; the la rg e r a t 510 nm and a smaller peak 
at 570 nm. Thus measurement of absorption a t a single wavelength is 
in ap p ro p ria te . To t r y  and overcome the problem of spectral sh ift with 
vary ing  pH , the  pH of the  MTT-formazan product was raised  to a pH 
of 10.5. At th is  pH a single peak a t 560 - 570 nm is observed 
regard less  of cell num ber or the p resence of "contaminating" cu lture 
medium. I t was found th a t addition of a small quan tity  of bu ffer a t 
pH 10.5 to the  solubilised MTT-formazan product resu lted  in a 
significant increase in absorbance readings a t 570 nm for wells with 
a high cell d en sity . For example, a 50% increase was seen in the 
absorbance read in g  fo r A549 cells a t a density  of 3 x 10 cells p e r 
well (F igure 5 .8 ) . Furtherm ore it can be seen from Figure 5.8 th a t
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addition of b u ffe r  (pH 10.5) resu lted  in a clear Unear relationship 
between cell num ber and MTT-formazan production up to cell numbers 
of 4 x 10^ p e r  well and absorbance readings of 1 .5 . This range is 
well w ithin the  limits req u ired  for a chemosensitivity assay , even for 
cell Unes with rap id  doubhng tim es. It is in teresting  to note th a t a 
s tro n g  base has prev iously  been used to enhance the sensitiv ity  of 
the n itroblue tetrazohum  te s t b u t in th is instance it was claimed th a t 
the base was u sed  to increase the solubiUty of the formazan product 
in DMSO (Rook e t a l . , 1985).
The im portance of these observations is obvious when MTT 
reduction is u sed  to estim ate ceU numbers in a chemosensitivity assay . 
If the  MTT-formazan crysta ls  are  dissolved in DMSO alone, then  the 
control cell num ber will be markedly underestim ated and so the  IDs o  
overestim ated and th u s  is not similar to the IDs o  obtained b y  a 
s tan d a rd  clonogenic assay . On the o ther hand, addition of b u ffer 
(pH 10.5) to these  same weUs resu lts  in a significant increase in 
absorbance ( i .e .  estim ated cell number) in the control wells and in 
wells exposed to low concentrations of doxorubicin, such th a t the 
ap p aren t IDs o  is similar to th a t obtained by  the clonogenic assay  
(F igure 5.11, Table 5 .3 ).
A nother im portant aspect of the dependence of the MTT- 
formazan absorp tion  spectrum  on pH relates to the effects of cu lture 
medium on absorbance read ings. It was observed tha t MTT-formazan 
absorp tion  is g rea tly  increased  in the presence of 10 ul or less of 
cu ltu re  medium b u t is only sligh tly  increased in the presence of 10 ul
to 40 ul of medium. This phenomenon has been reported  previously  
(Twentyman & Luscombe, 1987). However, addition of b u ffer a t pH 
10.5 causes a significant increase in the absorbance of MTT-formazan, 
and overcomes most of the  variability  in absorbance readings caused 
by  the  p resence of cu ltu re  medium (Table 5 .1 ). This is an im portant 
observation , especially for chem osensitivity testin g  in non-adheren t 
cell lin e s . With such  lines it is impossible to remove all of the cu ltu re  
medium from the  wells p rio r to the addition of DMSO. Thus if b u ffer 
is not added a significant source of e rro r  could re su lt. In th is 
reg a rd  it is in te re s tin g  to note th a t Carmichael e t al. (1987) repo rted  
a g re a te r  variab ility  between wells fo r non-adherent cell lines in th e ir  
screen ing  assay , and  th ey  suggested  th a t residual medium in the wells 
might have been responsib le . No increase in variability  with non­
adheren t cell lines was noted in th is s tu d y  and this could be explained 
by  the  inclusion of b u ffe r  a t the  final stage of the assay . It was also 
found th a t b y  controlling the pH with the incorporation of HEPES 
b u ffe r d u rin g  the  MTT incubation period , the variability  in MTT- 
formazan production  between wells was decreased (Figure 5 .9 ).
Chem osensitivity T esting
A nother im portant aspect of the modified assay  is the defined 
d ru g  exposure period . This is clearly an a rb itra ry  period. One 
req u ires  long enough exposure to the toxic agent for cellular damage 
to occur (Twentym an, 1980). Cole (1986) showed th a t the apparen t
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sen sitiv ity  of cells was increased, a fte r a 24 hour exposure compared 
to a 1 h our exposure . However, a 72 hour exposure (without 
refeed ing  with d ru g  a t 24 and 48 hours) did not cause a fu r th e r  
increase in sen sitiv ity . Hamburger (1981) alluded to the problem of 
calculating an appropria te  d ru g  dosage in v itro  (concentration and 
exposure time) to re flec t the situation in vivo. Indeed she pointed 
out th a t te s ts  in v itro  do not take into account differences in host 
conversion and detoxification or tissue specific accumulation. Given 
these considerations a 24-72 hour exposure was felt most analagous to 
the situation  in v iv o . Although Ruben & Neubauer (1987) defined a 
72 hour continuous d ru g  exposure and Carmichael et al. (1987) used 
a 4 day continuous d ru g  ex p o su re , th is length of exposure , if coupled 
with an ap p ro p ria te  recovery  period (see below), would make the 
assay  unnecessarily  long.
A lthough a 24 hour d ru g  exposure was u sed , the period could 
be varied  to su it a lte rna tive  experim ental protocols. Previous rep o rts  
which described  tetrazolium  based  assays designed to be used in d ru g  
screen ing  programmes have emphasised the importance of speed and 
automation (Alley e t a l . ,  1988; Carmichael et a l . ,  1987). Because of 
th is , these  assays have included a continuous d rug  exposure for a 
period of up  to 11 days. In one a limit of 7 days was chosen in o rder 
to avoid the  need to feed cells du rin g  the assay  (Carmichael e t a l . , 
1987). Thus the  d ru g  exposure time and growth period were 
combined.
The d isadvantage of continuous d ru g  exposure, relates to the
fact th a t it takes no account of d ru g  stab ility  or of d ru g  metabolism, 
the p roducts  of which may be e ither active or inactive. The half-life 
of some mitomycins in tissue  cu lture medium is about 2 hours and th a t 
of doxorubicin is only about 15 hours (Beijnen et a l . , 1986). As most 
of these  chem osensitivity studies have been based on the effects of 
doxorubicin th is  may be re levan t. It has been suggested  th a t 
doxorubicin may a lte r  the activities of mitochondrial enzym es, and so 
cause cardiac toxicity  (P raet e t a l . ,  1986). Although the exact site 
or sites of MTT reduction  in in tact cells rem ain(s) to be ellucidated, 
it is known th a t mitochondrial dehydrogenase activities can reduce the 
dye (Hess & P earse , 1963; S later e t a l . , 1963). Thus with continuous 
d ru g  exposure any  residual doxorubicin could in terfere  with MTT 
reduction d u rin g  the  incubation period as a re su lt of non-lethal 
damage to the  cells. Furtherm ore, the absorption maximum for 
doxorubicin is betw een 500 nm and 600 nm and so any residual 
doxorubicin may contribu te  to absorbance measurements a t 570 nm, as 
has been rep o rted  previously  (Carmichael et a l . , 1987). For these 
reasons th ere fo re  a defined d ru g  exposure time with a d ru g -free  
recovery  period  was used .
For stud ies  of d ru g  sensitiv ity , particu larly  where small 
changes in  sen sitiv ity  are  critica l, a growth period is essential. It 
allows fo r e limin a t io n  of cells killed by  d ru g  and distinguishes clearly 
between those cells which surv ive d ru g  treatm ent b u t can no longer 
pro liferate  and those which continue to proliferate. The importance 
of th is  is dem onstrated b y  a decrease in the ID s o  over the f ir s t  3
1 5 5
days a f te r  d ru g  exposure (Table 5 .2 ). Another advantage is th a t 
d ifferences in cell su rv ival a t d ifferent d ru g  concentrations are  
amplified. This effect is maximised if the cells are fed daily so th a t 
grow th is not limited b y  n u trien t supply.
Previous work has shown th a t predictions of chem osensitivity 
based on observations of less than  one cell cycle, both  in HeLa cells 
(F reshney  e t a l . , 1975) and in glioma cells (Morgan & F reshney , 1979) 
can be m isleading. Indeed some drugs may cause death only a fte r  
several cell cycles (Morgan e t a l . ,  1983). Weisenthal e t al. (1983A) 
have shown th a t cell su rv ival assessed  b y  dye exclusion in leukaemia 
cells decreased  over a period of 6 days a fte r  a 1 hour exposure to 
doxorubicin. Thus it is im portant to allow sufficient time fo r damage 
to be m anifest and fo r the control cells to replicate exponentially.
It has been s ta ted  th a t some w orkers used non-clonogenic 
viability  te s ts  too soon a fte r  noxious in su lt. Bhuyan et a l . , (1976) 
m easured viability  b y  dye exclusion immediately a fte r  d ru g  ex p o su re , 
and th is  would certa in ly  not allow sufficient time for membrane 
function to be d istu rb ed  (Weisenthal & Lippman, 1985). On the o ther 
hand it  is im portant to assay  before cell division in the control wells 
has become contact inhibited (Ruben & N eubauer, 1987). Thus the 
time of assessm ent of viability a fte r  d ru g  exposure may profoundly 
affect the  re su lts  obtained. This time schedule dependency has also 
been described  in the clonogenic assay  system (Barranco & Townsend, 
J r . ,  1986; Matsushima e t a l . ,  1985). A 3-day recovery  period 
(approxim ately 3 cell doubling tim es), with daily feeding to ensure
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cells were in exponential growth, was therefore used when th is assay  
was applied to rap id ly  growing cell lines.
In term s of analysis of the data the IDs o  was specified as the 
param eter fo r comparative purposes - both for comparing the 
sen sitiv ity  in d iffe ren t cell lines and also for studying  the effects of 
verapamil on chem osensitivity (C hapter 6). The IDs o  lies on the 
steep linear portion  of the classic sigmoidal d rug  dose-response curve 
of log d ru g  concentration versus response. Therefore the IDs o  
allows a reasonable estimation of d ru g  potency with a limited num ber 
of d ru g  concentrations and so provides a point th a t is easily 
reproducib le (Ruben & N eubauer, 1987).
T h u s, although the modifications made to the tetrazolium assay  
d e trac t somewhat from its  ability to be automated it appears suitable 
for s tu d y in g  the grow th and chemosensitivity of the newly established 
SCLC cell lines. This was confirmed by  dem onstrating th a t 
doxorubicin p en e tra ted  into and MTT-formazan was produced b y  all 
the viable cells th roughout the tumour aggregates (Plates 5.1 and 
5 .2 ). Because of the difficulties encountered in attem pts to obtain an 
even d istrib u tio n  of aggregates from the newly established SCLC cell 
lines across the  96 well p late , individual aggregates were tra n sfe rre d  
by  p ip e tte  into each well. This process was time-consuming b u t 
resu lted  in  small in ter-w ell variability  in absorbance values.
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Solvents Used
Although a num ber of w orkers have reported  light sca tte r  
in te rference  caused b y  an opaque alcohol-induced pro tein  p recip ita te  
which forms in the presence of serum concentrations of g rea te r  than  
10%-15% (Denizot & Lang, 1986; Green e t a l . , 1984B) th is was not a 
problem in these  stud ies as medium containing serum concentrations 
g rea te r  th an  10% was not used and DMSO and not an alcohol was used 
in the  solubilisation step  of the assay .
The solvents used to solubilise the MTT-F product have varied  
widely. The original paper b y  Mosmann (1983) described the use of 
isopropanol which had been acidified with hydrochloric acid to acidify 
the phenol red  indicator in the cu lture medium (RPMI) to minimize 
in te rference  w ith absorbance read in g s . Acidified isopropanol was also 
used  b y  Green e t al. (1984B) and Ruben & N eubauer (1987). 
However acid isopropanol has been found to be slow to dissolve the 
formazan c ry sta ls  (Twentyman & Luscombe, 1987). Furtherm ore it 
may cause precip ita tion  of pro tein  in the medium resu lting  in high 
background absorbance values (Twentyman & Luscombe, 1987).
A lternative agents investigated  include ethanol (Denizot & 
Lang, 1986) and mineral oil (Carmichael et a l . , 1987; Twentyman & 
Luscombe, 1987). However, mineral oil is not suitable as it again is 
slow to dissolve the formazan crysta ls  and in terferes with absorbance 
read ings (Twentyman & Luscombe, 1987). This is particu la rly  
im portant when s tudy ing  cell lines which grow as floating a g g reg a te s ,
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as in such cases th ere  will inevitably be a small volume of medium 
rem aining.
For these  reasons the most widely used solvent is dimethyl 
sulphoxide (DMSO). This solvent has now been adopted by  the 
majority of w orkers (Alley e t a l . ,  1988; Carmichael et a l . ,  1987; 
Scudiero e t a l . , 1988; Twentyman & Luscombe, 1987). T herefore , 
DMSO was chosen as the solvent fo r th is assay  also.
Scudiero e t al. (1988) have recen tly  investigated the use of an 
a lternative  tetrazolium  dye (XTT) th a t is reduced to a w ater soluble 
formazan p ro d u c t th u s  eliminating the need for a solvent. However, 
XTT is metabolised much less efficiently than  MTT and therefore a 
ca ta ly st, phenazine m ethosulphate (PMS), is added during  the assay . 
Moreover, th is  technique sometimes resu lts  in crystal formation and 
therefo re  req u ires  th a t each well is individually examined. 
Furtherm ore PMS was found to cause non-specific deposition of 
formazan. Thus XTT is not a suitable alternative to MTT.
Limitations of the A ssay
This a ssay , like many o ther non-clonogenic assays, is not 
w ithout in h e ren t lim itations. I t can not d istinguish  between cytostatic 
and cytocidal effects (Carmichael e t a l . ,  1987; Ruben & N eubauer, 
1987). Thus it  is unable to d istingu ish  between cells within a 
population and the  degree of response of each cell; for example, 50-8 
inhibition of all cells and 100% inhibition ( i .e .  death) of 50% of cells
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would give the same re su lt. By incorporating a defined cell growth 
("recovery") period in the absence of cytotoxic d ru g  it has , in p a r t ,  
been possible to circum vent th is problem (Ruben & N eubauer, 1987). 
N onetheless the  problem th a t the MTT assay  can not quan tify  
individual cell response remains.
A lthough th is  assay  has not specifically been compared in detail 
with many of the  available alternative assays, a good correlation of 
absorbance measurement with both  cell counting and cloning was 
found. Previous w orkers have addressed  th is comparison in g rea te r  
d e ta il, in ea rlie r work to validate the tetrazolium assay . For example, 
Heeg e t al. (1985) compared the MTT assay  with 3 H-thymidine uptake 
using  In terleuk in -2  producing helper T -cells. More recen tly  
Carmichael e t al. (1987) used  both  a clonogenic assay  and the dye 
exclusion assay  described  b y  Weisenthal et al. (1983B) to validate 
th e ir tetrazolium  based  chem osensitivity assay .
Summary
A tetrazolium  dye-based  chem osensitivity assay which can be 
used fo r bo th  adheren t and non-adherent cell lines has been 
developed. The resu lts  obtained with th is assay  agree closely with 
those obtained b y  a s tan d ard  clonogenic a ssay . Cells are exposed to 
d ru g  fo r a defined period and then  allowed to grow in d ru g -free
medium fo r 2 to 3 cell doubling times. MTT is used to assess 
su rv iv ing  cell num bers and the MTT-formazan product is measured at 
a h igh  pH so th a t all the MTT-formazan product is detected . This 
assay  is also applicable to cell lines which grow as floating 
a g g re g a te s . Thus th is  assay  may be used for studies of growth and 
chem osensitivity in  the  new SCLC cell lines in v itro . This work is 
p resen ted  in the  nex t C hapter, along with studies of the activ ity  of 
verapamil in the  newly established SCLC cell lines.
CHAPTER 6
RESISTANCE MODULATION IN LUNG CANCER CKT.T. LINES
INTRODUCTION
The tetrazolium -dye based assay  has been modified and 
refined  as described  in the p receding  C hapter. This assay  is now 
suitable fo r the s tu d y  of the grow th and chem osensitivity of the 
newly estab lished  SCLC cell lines. The aim of th is s tu d y  was to 
determ ine the  sen sitiv ity  of the cell lines to doxorubicin and to 
examine w hether chem osensitivity in v itro  reflects e ither the 
clinical h is to ry  of the  patien t from whose biopsy material the cell 
line was estab lished  or the morphology or o ther characteristics of 
the cell line. In addition the  activ ity  of verapamil in the new
SCLC cell lines was investigated  to determine w hether it has any 
effect on the  sen sitiv ity  of these laboratory  models of small cell 
lung cancer.
Verapamil is a calcium antagonist and is known to have 
significant effects on membrane ion flux (Kohlhardt et a l . ,  1972). 
Verapamil modulates the slow calcium -dependent inward cu rren t 
system s and  is u sed  in the clinical se ttin g  to tre a t sup raven tricu lar 
tachydysrhythm ias (Waxman et a l . ,  1981) and angina pectoris 
(Simoons e t a l . ,  1980). As previously  described (C hapter 1) it 
has also been shown to rev erse  d ru g  resistance in v itro  in a 
number of cell types (Beck e t a l . , 1986; Slater e t a l . , 1982; 
Tsuruo e t a l . , 1982). Because of th is attem pts have been made to
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use verapam il in  combination with chemotherapy in cancer patien ts 
(Benson III e t a l . , 1985; Dalton et a l . , 1989; Ozols et a l . , 1987A). 
However, use in pa tien ts  is accompanied by  dose limiting 
hypotension and h e a rt block (Ozols e t a l . , 1987A; Singh et a l . ,  
1978). As a re su lt plasma levels achieved in patients are between 
3 and 12 times lower than  the most effective concentration in v itro  
(Benson III e t a l . ,  1985; Dalton e t a l . ,  1989; K err et a l . ,  1986). 
For example, pharm acokinetic studies have shown th a t a fte r an 
acute oral dose a peak verapamil plasma concentration of up to 
1000 ng/m l ( 3 uM) can be achieved. However in daily dosing or 
with an in tra -v en o u s infusion, the sustained plasma concentration 
achieved is only 200-500 ng/m l ( 0 .6 -1 .5  uM) (Benson III e t a l . ,  
1985; R eiter e t a l . , 1982, Tartaglione e t a l . , 1983). Similar levels 
have also been  rep o rted  b y  Frishman et a l . ,  (1982) and Hecht et 
a l . , (1981). Thus the sustained  plasma levels of verapamil 
achievable in  the  clinic (0 .6 -1 .5  uM) are  significantly lower than  
those th a t are  known to be optimal in terms of resistance modifying 
activ ity  in  v itro  (6 uM). This problem has recen tly  been reviewed 
by  C hauffert and  colleagues (1987).
Verapamil is a racemic m ixture of the D- and L- 
stereoisom ers. It is known th a t the L-isomer of verapamil is about 
10 times more effective as a calcium antagonist than  the D-isomer 
(F e rry  e t a l . , 1985) . However the two isomers are equally potent 
blockers of the fa s t inw ard channel (Newrath et a l . , 1981). Since 
the effects of verapam il on d ru g  resistance  do not appear to be 
related  to calcium antagonism (Ramu et a l . , 1984) it is conceivable 
th a t the  D-isomer alone would be a more suitable agent to use
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clinically, in view of the potential reduction in cardiovascular side- 
effects compared to the racemic m ixture.
The resis tance  modifying activ ity  of D-verapamil was 
therefo re  s tud ied  in an MDR SCLC cell line made res is tan t to 
doxorubicin and known to show a 10-fold increase in sensitiv ity  to 
doxorubicin in the p resence of racemic verapamil (6.6 uM). 
Similarly, the effect of p re-trea tm en t as a possible way of 
increasing  the resis tance  modifying activ ity  of verapamil was 
investiga ted . Finally the use of o ther agents (quinidine and 
beprid il) as resis tan ce  modifiers was evaluated in a range of lung  
cancer cell lines. Previous work has suggested  th a t these agents 
may be used  in the clinic a t levels which are maximally active in 
terms of resis tan ce  modification in v itro  without excessive toxicity 
(T suruo  e t a l . , 1984).
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METHODS 
Cell Lines
The newly estab lished  small cell lung cancer cell lines 
(LS106, LS111, LS112, LCPH2, LCPH3, LS263, LS274, LS277 and 
LS310) and  th e ir  growth requirem ents have already been 
described . In addition a long established SCLC cell line and its  
re s is ta n t co u n te rp a rt were also used . NCI-H69 was obtained from 
Dr. D. C arney (National Cancer In s titu te , Bethesda, U .S .A .)  and 
its doxorubicin re s is ta n t coun terpart H69LX10 was a gift from D r. 
P eter Twentyman (M .R .C . Clinical Oncology and Radiotherapeutics 
U nit, C am bridge, U .K .) . These lines grow in suspension and are 
maintained in RPMI 1640 medium containing glutamine (2mM), foetal 
bovine serum  (10% v /v )  and for H69LX10 only, doxorubicin 
(1 ug /m l, 1.84 uM).
In addition four long established non-small cell lung cancer 
(NSCLC) cell lines were used in some modifier experim ents. The 
source and  grow th requirem ents of WIL, SK-MES, L-DAN and A549 
have been described  previously  (C hapter 5).
Reagents / D rugs
Racemic verapamil (V),  quinidine (Q),  bepridil (B) and 3- 
(4 ,5-dim ethylthiazol-2-yl) - 2,5-diaphenyltetrazolium  bromide 
(MTT) were obtained from Sigma Chemical Co. (Poole, D orset, 
U . K . ) .  The stereoisom ers of verapamil were a gift from Dr E.
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Schlick (Knoll A . G . ,  6700 Ludwigshaf e n , Federal Republic of 
G erm any).
Determination of Optimal MTT Concentration
Individual SCLC aggregates in 200 ul of medium were placed 
in wells, 1 aggregate  p e r round bottomed well of a 96 well 
m icrotitre p late (Nunclon; Gibco, Paisley, Scotland) using  a Gilson 
m icropipette. For cell line LS112ST, exponentially growing cells 
were try p sin ized  and diluted to give a final concentration of 5 x 
10^ cells/m l. A liquots, 200 u l, were then  placed in each well of a 
96 well m icrotitre p late (fla t bottomed; Linbro, Flow L aboratories). 
Cells were incubated  fo r 24 hours a t 37°C in an atmosphere of 2% 
CO3  in a ir . S ubsequently  MTT (a t concentrations of between 0 
and 5 mg/ml) was dissolved in PBS and 50 ul was added to each 
well, 8 wells p e r  concentration. Following a 4 hour incubation the 
plates were cen trifuged  a t 200 g for 5 minutes and the medium was 
carefully  rem oved. The formazan crysta ls  produced were dissolved 
in 200 ul DMSO and 25 ul of Sorensen’s glycine buffer (0.1M 
glycine + 0.1 M NaCl equilibrated  to a pH of 10.5 with NaOH 0.1N) 
was added . A bsorbance was recorded  as described previously 
(C hapter 5 ) .
Estimation of Growth Rates
The newly established  SCLC cell lines were plated out into 
round bottom ed 96 well p lates (Nunclon; Gibco, Paisley, Scotland),
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one agg regate  p e r  well in 200 ul of medium. In all cases duplicate 
p lates were se t u p . Plates were fed daily with fre sh  medium. 
Every 2nd day  the aggregates from one row (comprising eight 
wells) from each p late were tra n sfe rred  to another 96 well plate for 
measurement of MTT reduction . MTT (50 u l, 4 mg/ml) was added 
and the  p lates p rocessed  as described in the preceding C hapter.
Cytotoxicity Assays
D rug sen sitiv ity  was determ ined b y  the tetrazolium dye- 
based m icrotitre assay  as described  in detail in C hapter 5. For the 
SCLC cell lines, 1 aggregaate  was tra n sfe rred  into each well in 100 
ul of medium u s in g  a Gilson m icropipette. F reshly  diluted d ru g  (+ 
modifier) was added immediately in a volume of 100 ul a t twice the 
desired  final concen tra tion . It should be noted th a t when 
verapam il, the  stereoisom ers of verapamil or o ther modifiers were 
used , a serial dilution of 8 concentrations of doxorubicin was 
fre sh ly  p rep a red  a t twice the  desired  final concentration. These 
were th en  d ilu ted  50:50 with e ith er d ru g -free  medium or medium 
containing modifier a t twice the desired  final concentration (four 
times the  desired  final concentration fo r the new SCLC cell lines) 
p rio r to addition to the  wells. Four wells (adheren t cells) or 8 
wells (n o n -ad h eren t cells) were used  for each d ru g  concentration 
and when modifiers were used , the control wells were exposed to
the modifier alone.
R esults a re  ex p ressed  in term s of the d ru g  concentration 
requ ired  to kill 50% of the cells ( ID so ) estimated as the absorbance
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value equal to 50% of th a t of the cells in the control, un trea ted  
w ells.
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RESULTS
Determination of Optimal Concentration of MTT
The optimal concentration of MTT for maximal formazan 
crysta l production  varied  from 1.6 mg/ml (LS112ST, Figure 6.1A) 
to 4 mg/ml (LS111, F igure 6 .IB ). Concentrations of MTT up to 5 
mg/ml did not appear to be significantly  toxic to the new SCLC cell 
lines.
Growth Studies
R epresen tative growth curves for two of the newly 
established cell lines [LS111 (A) and LS112FL (B )] are  shown in 
Figure 6 .2 . The doubling times, measured from the growth 
cu rv es, fo r all the  newly established SCLC cell lines are  shown in 
Table 6 .1 .
Determination of Chemosensitivitjes of Newly Established SCLC Cell 
Lines
The re su lts  of a chem osensitivity assay  are  illustra ted  in 
Plate 6.1 which shows a m icrotitre plate at the end of a 
chem osensitivity assay , following a 4 hour incubation with MTT (4 
mg/ml) before (A) and a fte r  (B) solubilisation of the MTT-formazan 
crysta ls  in  DMSO. Figure 6.3 shows a represen ta tive  dose 
response curve to doxorubicin for the  newly established SCLC cell
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Figure 6.1
Determination of optimal MTT concentration in SCLC cell 
lines. For cell line LS112ST (A) cells were plated out (3 x 10^ p e r 
well) and allowed to a ttach  and grow for 2-3 days. For cell line 
LS111 (B) ag g regates  were placed in wells (1 aggregate p e r well) 
in 200 ul of cu ltu re  medium and allowed to grow for 1-2 days. 
Subsequently  50ul MTT (concentration 0-5mg/ml) was added to 
each well, 8 wells p e r  concentration. Plates were incubated for 4 
hours and then  MTT-formazan production m easured, a fte r the 
MTT-formazan c ry sta ls  had been dissolved in DMSO. Values are 
the mean + SEM of 8 observations.
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Figure 6.2
Growth curves fo r LS111 (A) and LS112FL (B ). Individual 
agg regates  were plated  out in 200ul of medium in 96-well p lates. 
The p lates were fed daily and every  second day aggregates from 
8 wells (1 row) were tra n sfe rred  to another plate for measurement 
of viable cell num ber b y  MTT reduction. Cells were incubated with 
MTT (50ul, 4mg/ml) for 4 hours and the MTT-formazan crysta ls  
dissolved in  DMSO. Values are  the mean + SEM of 8 wells.
celt Ltne
Oeubltng Times
w m )
i m
fDQXr UM)
LS106 5.5 127.0* + 10.9(3)
LS111 5.1 105.0 + 23.0(4)
LS112FL 6.2 35.5 ±  11.4(4)
LCPH2 4.5 73.5 + 10.8(4)
LCPH3 5.6 38.5 + 9.6 (4)
LS263 4.0 147.0 + 81.0(3)
LS274 5.5 220.0 + 40.0(6)
LS277 4.5 17.5 + 7.7 (3)
LS310 5.0 1050.0 + 140.0 (6)
* Mean + SEM
Table 6.1
Doubling times and chemosensitivities to doxorubicin (DOX) of newly established SCLC cell lines 
The number of observations are shown In parentheses.
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Plate 6.1
A 96-well p la te  a t the  end of a chem osensitiv ity  a ssa y , to 
determ ine th e  s e n s itiv ity  of cell line LS111 to doxorub ic in . The 
p late  was in cu b a ted  w ith MTT (50ul, 4mg/ml) fo r 4 h o u rs  and  is 
shown b e fo re  (A) and  a f te r  (B) th e  M TT-formazan c ry s ta ls  were 
d isso lved  in  DMSO.
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Figure 6.3
Chem osensitivity assay  to determine sensitiv ity  of cell line 
LCPH2 to doxorubicin. Individual aggregates were placed (1 
aggregate  p e r  well) in a 96-well plate. Cells were exposed to 
various concentrations of doxorubicin for 24 hours. A fter a 
recovery  period (w ith daily feeding) surv iv ing  cell number was 
estim ated b y  MTT reduction (50ul, 4mg/ml, 4 h o u rs) . Values are 
the mean + SEM of 8 observations.
169
line LCPH2. F igure 6.4 shows the resu lts  of 4 separate  
experim ents perform ed b y  2 individual researchers  to estimate the 
chem osensitivity of cell line LS111 to doxorubicin. As can be seen 
the experim ental re su lts  are highly reproducible. The resu lts  for 
all the  chem osensitivity assays in the newly established SCLC cell 
lines are  shown in Table 6 .1 . It can be seen th a t the cell lines 
exhibit a wide (60-fold) range of sensitiv ity  to doxorubicin. The 
in trinsic  chem osensitivity to doxorubicin did not appear to relate 
to the grow th morphology or o ther characteristics of the cell lin e , 
nor did it  re la te  to the  patien t h isto ry  from whose biopsy the  cell 
line was estab lished .
Effects of Racemic Verapamil and its Stereoisomers on Drug 
Sensitivity in H69LX10
The sen sitiv ity  of the MDR SCLC cell line H69LX10 to 
doxorubicin is shown in Table 6 .2 . H69LX10 is about 60-fold more 
resis tan t th an  NCI-H69. Also shown in Table 6.2 is the sensitiv ity  
to doxorubicin when cells were exposed to d ru g  in the presence of 
either racemic verapamil (6.6 uM) or to the individual stereoisomers 
of verapamil (6 .6  uM ). Racemic verapamil had no significant effect 
on the chem osensitivity of the p aren t cell line. However, 
verapamil increased  the sensitiv ity  to doxorubicin of the re s is tan t 
cell line b y  10-12 fold. Furtherm ore, th is effect was observed 
with bo th  the  D- and L- isomers of verapamil.
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Figure 6.4
MTT-formazan production p e r  well estimated 5 days a fte r  
exposure of individual aggregates of cell line LS111 to various 
concentrations of doxorubicin for 24 hours. Results are the mean 
of 8 wells and 4 separate experim ents are shown.
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Figure 6.5 shows the chem osensitivity to doxorubicin when 
H69LX10 m ulti-d rug  res is ta n t cells are  exposed to the d ru g  in the 
p resence of various concentrations of e ither racemic verapamil or 
the D-isomer. There is a concentration-dependent increase in 
d ru g  sen sitiv ity  in the p resence of verapamil. This is tru e  fo r 
both  racemic verapamil and the D-isomer. There is no significant 
d ifference betw een the activities of the two agents a t any  given 
concentration. The maximum activ ity  of verapamil is observed a t 
a concentration of 6-7 uM.
Effect of Pre-treatment with Verapamil
The re su lts  of experim ents in which cells were exposed to 
the resis tan ce  modifier verapamil alone for 24 h o u rs , immediately 
p rio r to s tan d a rd  co-incubation with doxorubicin for 24 hours are 
shown in Table 6 .3 .
It can be seen th a t in the case of the cell line WIL, p re ­
treatm ent w ith verapamil for 24 hours leads to a fu rth e r  significant 
increase in  resis tance  modification ( i .e .  increase in sensitiv ity  to 
doxorubicin). On the o ther hand , there  is no increase in 
resistance  modification following p re-trea tm en t of the re s is tan t 
SCLC cell line H69LX10 with verapamil.
H69LX10
|  Control 
| | Verapamil 
D - Verapamil
I
1 2 3 4 5  6 . 6
Verapamil concentration (pM)
Figure 6.5
The effect of various concentrations of e ither racemic 
verapamil or the D-isomer, on the sensitiv ity  of cell line H69LX10 
to doxorubicin. Cells were exposed to doxorubicin for 24 hours in 
the absence (solid bar) or presence of racemic verapamil (open 
b a rs)  o r D-verapamil (hatched b a rs ) . The ID ^C, is the d ru g  
concentration req u ired  to kill 50% of the cells, and resu lts  are  the 
mean + SEM of 3 observations.
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Effects of Other Resistance Modifiers in H69LX10
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Table 6.4 shows the effect of a number of resistance  
modifiers on the  chem osensitivity of H69LX10 to doxorubicin. In 
th is Table the effects of the modifier are shown by  comparing the 
IDs o  with doxorubicin alone to the IDs o  achieved with doxorubicin 
plus modifier. This gives a ratio  which may be regarded  as a 
resis tance  modifying fac to r. It may be seen th a t beprid il a t a 
concentration of 4uM (which can be achieved in the clinic) re su lts  
in a 6-fold increase in sensitiv ity  to doxorubicin. Quinidine is 
even more effective as a resistance modifier in th is cell line, 
causing a 10-fold increase in sensitiv ity  to doxorubicin a t clinically 
achievable levels. Furtherm ore for both quinidine and bepridil 
th ere  is clear evidence of a dose-response relationship.
Effects of Resistance Modifiers in Established NSCLC Cell Lines
Table 6.5 shows the effects of a number of resistance 
modifiers on the  sensitiv ity  of the NSCLC cell lines to doxorubicin. 
It may be seen th a t in these cell lines although verapamil (V) and 
the L-stereoisom er of verapamil (LV) do modulate chemosensitivity 
to doxorubicin significantly  in all cases, the D-isomer (DV) is less 
effective and  n e ith er quinidine (Q) nor bepridil (B) have any 
modulating effect.
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Effects of Verapamil in Newly Established SCLC Cell Lines
The effects of verapamil (6.6 uM) on the sensitiv ity  of the 
newly estab lished  SCLC cell lines to doxorubicin is shown in Table 
6 .6 . Also shown in th is Table are the growth characteristics of 
the cell lines and the  h isto ry  of the biopsies (p re-trea tm en t or 
post-chem otherapy) from which the cell lines were estab lished .
It can be seen th a t th ere  was a significant increase in 
sen sitiv ity  to doxorubicin in the presence of verapamil in 5 of the 
9 cell lines. This effect is illu stra ted  in Figure 6.6 which shows 
a 2.3 fold increase in sensitiv ity  to doxorubicin in the p resence of 
verapamil (6 .6  uM) in cell line LS263. The modulation of 
sensitiv ity  w ith verapamil did not appear to relate to the clinical 
h is to ry  of the patien t from whose biopsy the cell line was 
es tab lish ed , nor did it appear to relate to any p articu la r 
ch arac teris tics  of the cell line, including morphology. Nor did 
sensitisation  b y  verapamil relate  to the in trinsic  sensitiv ity  of the 
cell line to doxorubicin.
LS2630.8
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Figure 6.6
MTT-formazan production p e r  well estimated 5 days a fte r 
exposure of cell-line LS263 to doxorubicin alone for 24 hours ( • )  
or to doxorubicin and verapamil (6.6uM) for 24 hours (O ). When 
verapamil was used control wells were also exposed to verapamil 
(6.6uM) fo r 24 h o u rs. Values are mean + SEM of 8 wells.
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DISCUSSION
The resu lts  p resen ted  here are of substan tia l im portance. 
They show th a t it  is possible to accurately  measure 
chem osensitivity in the  newly established small cell lung cancer cell 
lines. A wide range of sensitiv ity  to doxorubicin has been 
dem onstrated. These re su lts  also indicate th a t verapamil has a 
m odulating effect on the chem osensitivity of a num ber of lung  
cancer cell lines - not only in the non-small cell lung cancer cell 
lines (Table 6 .5) and in the MDR SCLC cell line H69XL10 (Table 
6.2) b u t also in a num ber of the newly established SCLC cell lines 
(Table 6 .6 ).
Chemosensitivity of Newly Established SCLC Cell Lines
Having been able to accurately  measure the grow th and 
chem osensitivity of the newly established SCLC cell lines it  has 
been possible to examine w hether in v itro  chem osensitivity reflec ts  
e ither the  clinical h is to ry  of the biopsy material from which the cell 
line was estab lished  or the morphology of the cell line.
These questions have in trigued  scien tists  for many years and 
resu lts  remain conflicting. For example, Hill (1983) and Cole 
(1986) showed a correlation between the clinical response of certain  
tumour ty p es  and the response to cytotoxic d rugs in v itro  u sing  
established  cell lines of similar h isto logy. On the o ther h an d , Hug 
et a l . , (1984) found no association between the chem osensitivity of 
cell lines obtained from b reast cancer patien ts before and a fte r
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chem otherapy. More specifically in small cell lung cancer early  
work b y  C arney a t al. (1983) suggested  th a t cell lines established 
from u n tre a ted  p a tien ts  were relatively  sensitive and cell lines 
estab lished  from relapse biopsies were relatively  re s is ta n t. This 
work is , how ever, open to criticism . A cloning technique, with all 
the in h eren t problems of aggregate d isruption  described  
p rev iously , was used  to measure chem osensitivity. Furtherm ore 
the definition of sensitiv ity  or resistance used  b y  these 
re sea rch ers  as a g re a te r  or less than  70% reduction in surv ival 
must be reg a rd ed  as ra th e r  simplistic and a rb itra ry .
Work b y  Carmichael et al. (1988A) using  a tetrazolium  dye- 
based chem osensitivity assay , in a s tu d y  of 15 newly established  
SCLC cell lines (7 from p re -tre a te d  patien ts and 8 from patien ts  
a fte r  chem otherapy) also suggested  th a t small cell lung  cancer cell 
lines estab lished  from trea ted  patien ts were more res is ta n t than  cell 
lines from u n trea ted  p a tien ts. However, the chem osensitivity 
assay  described  b y  Carmichael e t al. (1988A) req u ired  the 
d isaggregation  of the SCLC cell lines p rio r to seeding, and th is  
may have led to inaccuracies.
R ecently a group of w orkers in Holland have established 3 
new small cell lung  cancer cell lines from one p a tien t, one cell line 
before treatm ent and two cell lines following relapse (B erendsen et 
a l . ,  1988). All the cell lines showed similar morphology to the 
biopsies from which th ey  were derived . Chemosensitivity was 
m easured u s in g  Weisenthal’s fa s t g reen  assay . The relapse cell 
lines showed increased  resistance  to doxorubicin, melphalan and 
etoposide compared with the cell line from the original b iopsy.
1 7 5
However, it  is w orth noting th a t the th ird  cell line, estab lished  
from a b iopsy a t a time of fu r th e r  relapse was actually  more 
sensitive than  the  cell line established from the initial relapse 
tum our. The au thors a ttrib u te  this to alterations in 
chem osensitivity in v itro .
C arney e t al. (1983) rep o rted  th a t SCLC cell lines of varian t 
morphology were ra d io -re s is tan t. I t could be hypothesised th a t 
these findings with reg a rd  to the rad io-resistance of v arian t lines 
may simply re la te  to the method used  to s tu d y  cell sensitiv ity . It 
seems likely th a t classic cell lines will requ ire  more aggressive 
physical d isaggregation  and hence will be more sensitive to the 
effects of noxious in ju ry  ( e .g .  rad ia tion ). On the o ther hand , 
more easily  d isaggregated  varian t morphology cell lines will be 
relatively  p ro tec ted  from toxic in ju ry  and so appear more re s is ta n t 
if rad io -sen sitiv ity  is m easured by  cloning. Similarly the  apparen t 
increased  chem osensitivity of the SCLC cell line H69, in comparison 
to non-sm all cell lung  cancer cell lines, repo rted  b y  Cole (1986) 
may re la te  to d isaggregation of H69 fo r counting p rio r to p la ting  
out in m icrotitre p la tes. Nonetheless th is can only p a rtly  be the  
explanation because ne ither C arney e t al. (1983) nor Carmichael et 
al. (1988A) showed a correlation between aggregate morphology 
and chem osensitivity.
In th is  s tu d y  9 cell lines, 5 from u n trea ted  pa tien ts  and 4 
from relapse  p a tie n ts , two of which have been passaged in mouse 
xenograft, have been estab lished . A lthough a 60-fold range of 
chem osensitivity has been dem onstrated no clear relationship
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betw een clinical h is to ry  of the biopsy or aggregate morphology and 
in v itro  chem osensitivity has been found (Table 6 .6 ). For example 
LS263 obtained from a relapse biopsy of a chem oresistant patien t 
was almost twice as sensitive as LS274, a cell line established from 
a p re -th e ra p y  b iopsy of a chemosensitive pa tien t. However, it 
should be noted th a t ,  fo r an individual p a tien t, chem osensitivity 
does appear to re la te  to p a tien t/b iopsy  h isto ry  and m irror clinical 
course. Thus LS310, a cell line obtained from a b iopsy of a 
relapse p a tien t is 5 times more res is ta n t than  cell line LS274, 
obtained from the  p re -trea tm en t biopsy of the same patien t who 
initially  had a chemosensitive tum our.
Resistance Modulation in NSCLC and an MDR SCLC Cell Lines
For the  re s is tan t cell line H69LX10 verapamil increased  
doxorubicin sen sitiv ity  and th is  effect was concentration dependent 
(F igure 6 .5 ) . Such an effect has been described  previously  for 
verapamil (Rogan e t a l . , 1984) and also fo r amiodarone (C hauffert 
et a l . ,  1987). In addition it was shown th a t the individual 
stereoisom ers of verapamil a re  equally effective in term s of 
resistance  modification (Table 6 .2 ). These findings have 
implications fo r resis tance  modification in the  clinic. It has already 
s ta ted  th a t levels of verapamil optimally active in v itro  (6 .6  uM) 
are not attainable in the clinic because of unacceptable 
cardiovascular tox icity . Given th a t the D-isomer of verapamil has 
been shown to be equally active in term s of resistance modification 
in the doxorubicin re s is ta n t cell line H69LX10, and given th a t D-
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verapamil is though t to be less cardiotoxic (F e rry  et a l . ,  1985) it 
may be possib le, with the use of D-verapamil alone, to achieve 
h igher levels of modifier without excess cardiovascular toxicity . 
A lthough not maximal, it is worth noting th a t some resistance 
modification was seen in the re s is tan t cell line H69LX10 with 
concentrations of verapamil th a t are achievable in the clinic (F igure 
6 .5 ).
An a lte rna tive  approach to the use of the individual 
stereoisom ers of verapamil in the clinic might be the  use of o ther 
resistance  modifying a g e n ts . C ertainly it has been shown th a t the 
use of e ith e r beprid il or quinidine can produce a 6-fold or 10-fold 
increase in  sen sitiv ity  to doxorubicin in H69LX10 cells (Table 6 .4 ) . 
Moreover th is  effect is seen with concentrations of modifier th a t 
are achievable in the  clinic. Thus these agents may be more 
suitable fo r fu tu re  clinical studies of resistance modification. 
However, it should be noted th a t n either bepridil nor quinidine, 
unlike verapam il, produce any  increase in chem osensitivity in the  
non-small cell lung  cancer cell lines (Table 6 .5 ). Since these non­
small cell lung  cancer cell lines do not express P-glycoprotein th is 
finding  su g g ests  th a t verapamil may have a d ifferen t a n d /o r 
additional mechanism of action as a modifier in these cell lines. I t 
is in te re s tin g  to note th a t the  resistance  modifying activ ity  of 
verapamil in these  cell lines appears to be related  to the L- ra th e r  
than the D-isomer (Table 6 .5 ).
It has also been shown th a t p re-trea tm en t for 24 hours with 
verapamil alone p rio r  to cytotoxic d ru g  exposure in the presence 
of verapam il can increase the resistance  modification seen in the
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non-small cell lung  cancer cell line, WIL (Table 6 .3 ). The reason 
for th is  remains unclear. A similar effect has p reviously  been 
described  b y  Radel e t al. (1988) who showed th a t a 24 hour 
exposure to the  modifier DMDP followed by  a sh o rt exposure to 
doxorubicin re su lted  in the same cytotoxicity as a 24 hour 
exposure to bo th  a g e n ts . Thus it may be th a t p re -trea tm en t with 
modifier may be a method of obtaining increased resistance  
modification in the clinic. It should be noted th a t p re -trea tm en t 
with verapam il did not increase the chem osensitivity of the 
re s is ta n t SCLC cell line H69LX10. This may be because with a 24 
hour exposure to doxorubicin plus verapamil, the maximal 
resis tance  modification th a t could be obtained had already  been 
ach ieved .
This w ork, like most of the work on resistance  modifiers to 
date , has u sed  cell lines derived from animal tum ours or long 
estab lished  cell lines derived from human tum ours. These cell 
lines have th en  been rendered  re s is ta n t in v itro  b y  chronic 
exposure to cytotoxic d ru g s , and used as models of tum our cell 
resis tan ce . What is ideally req u ired  are  new human cell lines 
estab lished  from patien ts whose tumour dem onstrates the 
phenomenon of initial chem osensitivity and subsequent re s is ta n t 
relapse in  the  clinic. This underlines the  importance of the  newly 
estab lished  SCLC cell lines.
Resistance Modulation in Newly Established SCLC Cell lin e s
The fact th a t 5 of the 9 newly established SCLC cell lines
studied  show an increase in sensitiv ity  to doxorubicin in the 
p resence of verapamil is of p articu la r note (Table 6 .6 ). Such an 
effect has not been previously  rep o rted . This increase in 
chem osensitivity with verapamil did not relate to the in trin s ic  
sensitiv ity  of the cell lines to doxorubicin or to the clinical h is to ry  
of the  p a tien t from whose biopsy the cell line was obtained. For 
example, the  most re s is tan t cell line, LS310 obtained from a relapse 
biopsy from a chem oresistant pa tien t did not show any change in 
sensitiv ity  to doxorubicin in the  presence of verapamil. On the 
o ther hand one of the most sensitive cell lines (LS112FL) 
estab lished  from a patien t who had not received any treatm ent 
showed an almost 3-fold increase in sensitiv ity  to doxorubicin in 
the p resence of verapamil.
Thus verapam il can significantly  modulate the sensitiv ity  of 
some newly estab lished  SCLC cell lines. This suggests  th a t 
verapamil may have a role in the clinical se ttin g , and th is  has 
stim ulated in te re s t and enthusiasm  fo r the randomised clinical tria l 
of verapam il given in addition to chem otherapy to patien ts with 
small cell lung  cancer. The resu lts  of th is  s tu d y  are described  in 
the nex t C hapter.
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CHAPTER 7
A RANDOMISED CLINICAL STUDY OF VERAPAMIL IN ADDITION TO 
COMBINATION CHEMOTHERAPY IN SMALL CELL LUNG CANCER
INTRODUCTION
Verapamil has been shown to increase the d ru g  sen sitiv ity  of 
MDR cells in v i tro . This effect is known to be dose dependant. At 
optimal concentrations in v itro  (6 .6  uM), verapamil has also been 
shown to have modulating activ ity  in 5 of the 9 newly estab lished  
SCLC cell lines (C hapter 6).
O vergrow th with re s is ta n t tumour is the principle cause of 
treatm ent failure in SCLC. To date th ere  have been few clinical 
s tu d ies , and  no published large scale randomised clinical stud ies to 
examine the  activ ity  of resistance  modifying d ru g s  in the 
chem otherapy of cancer patien ts.
Previous Clinical Studies
The f ir s t  s tu d y  of verapamil given in addition to chem otherapy 
was th a t rep o rted  b y  Benson III e t al. in 1985. Seventeen pa tien ts  
were tre a te d  with vinblastine (1.5 mg/m22 for 5 days) and  escalating  
doses of in travenous verapamil. Cardiovascular toxicity  was the
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dose-lim iting toxicity  fo r verapam il, and the mean verapamil level 
achieved was only 290 ng/m l (0.45 uM ). No response or su rv ival data  
was rep o rted  from th is  s tu d y .
Ozol’s group from the National Cancer In stitu te  a t B ethesda 
rep o rted  a s tu d y  of verapamil given in addition to doxorubicin in the 
treatm ent of d ru g -re s is ta n t ovarian cancer (Ozols e t a l . ,  1987A ). 
Eight p a tien ts  were trea ted  with doxorubicin (50 mg/m3 ) and 
increasing  doses of in travenous verapamil (maximum dose 15 
m g/kg/m in). With th is  dosage a mean verapamil level of 1,273 ng/m l 
[2.0uM] (range  720 - 2,767 ng/m l [1.1 - 4.3uM]) was achieved. 
However, all pa tien ts req u ired  invasive cardiac m onitoring and 
cardiovascular tox icity  was unacceptable. There were no objective 
responses seen in any  of the pa tien ts  and median surv ival was only 
4 m onths.
The few o ther studies exploring the efficacy of resis tance  
modifiers have been slightly  more encouraging. P resan t e t al. (1986) 
used verapam il (480 to 960 m gs/day orally) and observed  some 
responses in  heavily p re -tre a te d  p a tien ts . The h igher doses of oral 
verapamil were noted to cause hypotension and arrhy thm ias. Dalton 
et al. (1989) have trea ted  8 pa tien ts with multiple myeloma and non- 
Hodgkin’s lymphoma who had developed p rogressive  disease whilst 
receiving chem otherapy with v incristine and doxorubicin. They 
trea ted  these  pa tien ts  with the same chem otherapy and added in fused  
verapamil (0.15 m g/kg /hour) for 36 h o u rs . Three patien ts  received 
h igher doses of verapamil (0.30-0.45 m g /k g /h o u r). As in previous
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s tu d ies , the dose limiting toxicity  was cardiac. Three p a tien ts , two 
of whom had been trea ted  with the h igher doses of verapam il, showed 
a response , and these th ree  patien ts were all shown to have P- 
glycoprotein positive tum ours. As v incristine is known to increase 
in trace llu lar an thracycline accumulation in MDR cells (Willingham et 
a l . , 1986), the addition of th is cytotoxic d ru g  may have po ten tia ted  
the effects of verapamil on doxorubicin accumulation. However, the 
responses were only sho rt lived, and surv ival was not significantly  
im proved.
One s tu d y  has suggested  surv ival benefit from the addition of 
resis tan ce  modifier (Figueredo e t al; 1990). In th is  non-random ised 
s tu d y , verapamil (360 or 480 m g/day) and tamoxifen (80 or 100 
m g/day) were given in addition to combination chem otherapy with 
doxorubicin, v incristine and etoposide (DVE), to 58 p a tien ts  with 
ex tensive small cell lung  cancer. If patien ts  were re s is ta n t to DVE or 
re lapsed  a f te r  responding  to DVE they  were tre a ted  with 
cyclophosphamide and cisplatinum (CC) as second line th e rap y .
Cardiovascular toxicity  was not significant, presum ably re la ted  
to the  re la tive ly  modest doses of oral verapamil given. Verapamil 
plasma levels were not m easured.
The initial response ra te  was quite h igh for th is  group of 
pa tien ts  (complete 24%, overall 58%). Median surv ival was 46 weeks. 
This compares favourably  with historic controls and does su g g est th a t 
th is  combination of resistance  modifiers may be active in  conjunction 
with combination chem otherapy in extensive SCLC.
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A group from Sydney, A ustralia are  also conducting a 
random ised s tu d y  of verapamil given in addition to chem otherapy in 
small cell lung  cancer. They have rep o rted  th e ir  interm ediate re su lts  
(Wheeler e t a l . , 1988) and the s tu d y  remains in p ro g ress  (Bell, 1990, 
w ritten  communication). The total doses of chem otherapy given were 
rela tive ly  low and although response ra te s  were fa ir  (56% overall 
response r a te ) ,  median surv ival was disappointing (only 9 months in 
the limited disease patien ts and only 3 months in the  ex tensive disease 
p a t ie n ts ) . These resu lts  may relate to sub-maximal doses of 
chem otherapy. It is therefo re  difficult to estab lish  the  significance 
of these  interm ediate re su lts .
The only o ther P-glycoprotein active resistance modifier to be 
used  to date in  the clinical se ttin g  is trifluoperazine (Miller e t a l . ,  
1988). In th is  s tu d y  the au thors rep o rted  7 responses to 
chem otherapy with doxorubicin plus trifluoperazine in 36 pa tien ts  w ith 
re s is ta n t tum our. Again it was not possible to achieve levels of 
modifier in  the  clinic th a t had been found to be optimally active in 
v itro  w ithout unacceptable side effects (ex tra-pyram idal to x ic ity ). 
Plasma levels of trifluoperazine achieved in the  clinic were only 4-130 
ng/m l compared to levels optimally active in v itro  (400-2000 ng/m l, 
Ganapathi e t a l . , 1984; Ganapathi & Grabowski, 1988).
Thus th e re  has been no published large-scale  random ised s tu d y  
to assess  if g iv ing a resistance modifier in addition to chem otherapy 
is of clinical b enefit. Such a s tu d y  was therefo re  u n dertaken  to see
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if th is  approach could have an impact on the d ru g  resis tance  seen in 
the  clinic in p a tien ts  with SCLC.
A lthough pa tien ts  with re s is ta n t tum ours appear to be the  b es t 
population in whom to investigate the activ ity  of resistance  m odifiers, 
th is  is a heterogeneous group of patien ts who have been heavily 
p re tre a te d  and who have advanced d isease. Thus the  tria l design was 
inevitab ly  a compromise between the constrain ts of realistic  clinical 
p ractice  and scientific objectives, and so the activ ity  of verapamil in 
p rev iously  u n tre a ted  SCLC patien ts  was investigated . Information 
from the  prev iously  repo rted  clinical pilot stud ies of resistance  
modifiers was u tilised  in the tria l design.
A fo u r-d ru g  combination with documented efficacy in small cell 
lung  cancer was u sed . Doxorubicin, v incristine and etoposide a re  all 
active single agen ts in SCLC and have been used widely in clinical 
s tud ies (H ansen, 1987). These d rugs are  known to be involved in 
resis tan ce  in  the  MDR phenotype. Cyclophosphamide, the  fo u rth  
d ru g  used  in the  chem otherapy protocol is not associated with MDR 
(Cantwell e t a l . , 1988). Verapamil was combined with chem otherapy 
from the o u tse t, when the re s is ta n t population is expected to be 
small.
The major end-poin ts of th is  clinical s tu d y  were to assess  the 
feasability  of giving oral verapamil in conjunction with combination 
cytotoxic chem otherapy in patien ts  with SCLC, to assess any  possible 
enhanced normal tissue toxicity  and to examine for an increased  
response ra te  a n d /o r  improved su rv ival. If effective one might not
expect the resis tance  modifier to change response ra te  because of the 
presum ed initially  low proportion of re s is ta n t cells within the  tum our. 
On the  o th er h and , a relatively  small decrease in the re s is ta n t tum our 
cell population would subsequently  become apparen t as prolongation 
of time to p rogression  and improved su rv ival. The s tru c tu re  of the 
c u rre n t s tu d y  com prising 226 patien ts is described .
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METHODS 
Patient Selection
Patien ts w ith histologically proven small cell lung  cancer aged 
70 or less and with ECOG perform ance s ta tu s  of 0,1 or 2 were 
eligible. Initially  the s tu d y  was re s tr ic ted  to pa tien ts  with only 
limited disease, b u t a f te r  the f ir s t  60 patien ts  had been en te red , 
pa tien ts  with extensive disease suitable fo r in tensive combination 
induction chem otherapy were also elig ible. All patien ts had adequate 
bone marrow and hepatic function and had had no previous 
chem otherapy or rad io therapy . Eligible patien ts  had no active cardiac 
d isease , and  had  not been on beta-b locker or p rio r calcium an tagon ist 
th e rap y . All p a tien ts  gave informed consent.
R egistration, Stratification, Randomisation and Data Collection
Patien ts were reg is te red  a t the  clinical tria ls  office and were 
s tra tified  according to disease ex ten t p rio r to random isation. Nine 
C entres from the  West of Scotland, one from A berdeen and also one 
from N orthern  Ireland  en tered  pa tien ts  into th is s tu d y  u n d e r the  
auspices of the  West of Scotland Lung Cancer Research Group. 
Following e n try  to the s tu d y , detailed treatm ent and follow-up record  
forms were completed and collected a t the West of Scotland Clinical 
Trials Office a t the  Beatson Oncology C entre (W estern Infirm ary ,
Glasgow) fo r subsequen t analysis.
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Pre-Treatm ent Studies
These included a full clinical examination, including pulse and 
ly ing and s tand ing  blood p re ssu re . A full blood count and 
biochemical screen  (u rea , electro lytes and liver function te s ts )  were 
checked along with a p re-trea tm en t chest x - ra y  and bronchoscopy.
Treatment D esign
P atien ts who were randomised to receive verapam il, were given 
oral verapam il 120 mg 6 hourly  ( i .e .  480 m g/day) fo r a to tal of five 
days, beg inn ing  two days p rio r to chem otherapy to achieve s teady- 
s ta te  levels of verapamil a t the time of cytotoxic treatm ent. Capsules 
were not counted to check compliance. However, blood samples were 
obtained d u rin g  verapamil treatm ent from 18 p a tien ts . (See below ).
P atien ts were trea ted  with cyclophosphamide (750 mg/m3  b y  
i .v .  b o lu s), doxorubicin (40 mg/m3  b y  i .v .  b o lu s), v incristine  
(1 .4 /m 3  b y  i .v .  bolus) on Day 1 and etoposide (75 mg/m3 , as a  one 
hour in travenous infusion) on Days 1,2 and 3. Verapamil was 
continued (120 mgs 6 hourly) fo r Days 1,2 and 3 of chem otherapy. 
The control patien ts  (trea ted  with the same in travenous 
chem otherapy) were not trea ted  with placebo capsules and th u s  the 
s tu d y  was not placebo controlled.
1 8 8
P atien ts received 4 courses of chem otherapy repeated  a t 3 
weekly in te rv a ls  unless th ere  was significant toxicity  n ecessita ting  
withdrawal or th ere  was evidence of disease p rog ression . Patien ts 
who, a t re s tag in g  a f te r  4 courses were felt to have en tered  complete 
rem ission (see below ), received consolidative rad io therapy  com prising 
4000 cGy in 3 weeks given to the prim ary s ite (s )  of thoracic disease 
and 3000 cGy in 2 weeks given sim ultaneously to the whole b ra in  (as 
prophylaxis against cerebral re la p se ) .
Dose Modification
Chem otherapy was given a t the  doses listed  above, if on Day 1 
the white cell count (wbc) was >3.0 x 10^/1 and p latelets were >100 
x 10®/1. If these  param eters had not been a tta ined , treatm ent was 
postponed fo r 1 week and full doses given when param eters were 
sa tisfac to ry . Treatm ent was postponed fo r a fu r th e r  week if 
n ecessary , b u t if delay was longer than  2 weeks, protocol 
chem otherapy was discontinued.
If the  n ad ir (mid-cycle) wbc, measured on Day 10, was <1.0 x 
10^/1 or if n ad ir p latelets were <30 x 10^/1, the doses of cytotoxic 
d ru g  in  su b sequen t courses of chem otherapy were reduced  to 
cyclophosphamide 600 mg/m3 , doxorubicin 30 mg/m3  on day  1, and 
etoposide 50 mg/m3  on days 1,2 and 3.
Follow-up Studies and Restaging
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For p a tien ts  in the verapamil treatm ent arm, pulse and blood 
p re ssu re  were checked immediately p rio r to s ta r tin g  the  f ir s t  course 
of verapamil and again on Day 1 of chem otherapy, ( i .e .  the  th ird  day 
of oral verapam il tre a tm e n t) . In addition an ECG was checked a t th is  
time, and  subsequen tly  checked with every  course of chem otherapy 
in p a tien ts  on the verapamil arm.
Full re s tag in g  was perform ed a fte r  4 cycles of chem otherapy 
had been completed. This comprised repeat clinical (including rep eat 
haematological and biochemical param eters) and radiological 
exam inations. In those patien ts thought to have en tered  complete 
rem ission, re -s ta g in g  bronchoscopy was perform ed to confirm the  
absence of any  residual endobronchial tum our. Response was divided 
into complete (C R ), partia l (PR) and none (NR) as defined b y  WHO 
c rite ria . Survival was measured as time from randomisation to time of 
d e a th .
Verapamil Levels
A to tal of 72 blood samples were obtained from 18 patien ts  
(range 1-11 samples p e r  p a tien t) , selected from the verapamil 
treatm ent g roup . Verapamil concentrations in plasma were estim ated 
b y  an HPLC assay  with fluorescence detection (Cole e t a l . , 1981).
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Confirmation of Response
Because the  s tu d y  was not blinded or placebo controlled, and 
because it was the individual clinicians who were responsib le fo r 
a ssessin g  response a t re stag in g , observer bias in assessm ent of 
response was possib le. T herefore , a toted of 64 p re - th e ra p y  and 
res tag in g  x -ra y s  from 7 partic ipa ting  institu tions were examined b y  
an independent radiologist. The re -s tag in g  x -ra y s  from the  p a ir  were 
always examined f ir s t ,  and only if en tire ly  normal was a complete 
radiological response accepted.
Statistical Methods
The s tu d y  was s tra tified  fo r disease ex ten t. A p a tien t was 
random ised b y  a telephone call to the West of Scotland Clinical T rials 
U n it. The random isation list was constructed  using  random perm uted 
blocks of leng th  6. Comparisons of p re treatm en t charac teris tics  and 
su rv ival were based  on all random ised eligible p a tien ts . All o ther 
comparisons used  randomised eligible pa tien ts  who s ta r te d  protocol 
trea tm en t. Categorical variables were compared mainly u sin g  
P earson 's ch i-sq u are  te s t (with no continuity  co rrec tio n ). Categories 
were combined if necessary  to make all expected values g rea te r  than  
or equal to 5. If it was not possible to combine categories to make all 
expected values g rea te r  than  or equal to 5 then  F ish er's  exact te s t  
was u sed  on the appropriate  2 x 2  tab le . When overall response was
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compared s tra tifica tion  according to disease ex ten t was included in the 
analysis and  the  p -values were calculated u sing  the  M antel-Haenszel 
te s t .  The Mann-Whitney U -test was used for the comparison of 
continuous variables such as age and to tal cumulative dose. When 
pulse and blood p re ssu re  measurements were compared before and 
a f te r  verapam il, Wilcoxon's signed rank  sum te s t was u sed . Kaplan - 
Meier estim ates were used  fo r surv ival c u rv e s . Survival cu rves were 
term inated when 5 pa tien ts  were a t r isk . Survival was m easured from 
time of random isation and all causes of death  have been included. 
Comparison of su rv iva l was by  the M antel-Haenszel s tra tified  lo g -rank  
te s t ,  w ith s tra tifica tion  based on ex ten t of d isease.
192
RESULTS
Patient Demography
Recruitm ent to th is s tu d y  is complete and a total of 226 patien ts  
have been en te red . Of these , six patien ts  were found to be ineligible 
soon a f te r  random isation because they  were found to have extensive 
disease a t a time when the s tu d y  was only open to pa tien ts with 
limited disease (Table 7 .1 ). One patien t aged 73 was also s tr ic tly  
ineligible b u t was trea ted  according to protocol and has been included 
in the  analysis.
In term s of disease stage , similar num bers of ex tensive and 
limited disease pa tien ts  were randomised to each group (p = 0 .815). 
An even sp read  of perform ance s ta tu s  at randomisation was found 
between the  two treatm ent arms (p = 0.752). No significant difference 
was found between the two arms of the  s tu d y  with re g a rd  to the  
prognostic  indicators described b y  Souhami e t al. (1985) (p  = 0.827) 
(Table 7 .2 ).
Total Drug Doses and Number of Cycles of Protocol Treatment
Table 7.3 indicates th a t similar num bers of cycles of protocol 
treatm ent were adm inistered in the verapamil and control arms (p  = 
0.918). Considering the total cumulative doses of cytotoxic d ru g s  
adm inistered, the  only suggestion of a difference was with
Verapamil Control
R andom ised 113 113
R andom ised  + eligible 111(a) 109(b)
R andom ised , eligible 
and  started  
protocol trea tm en t
107(c) 107(d)
a. Two patients excluded b ecau se  found to have extensive d isease  before
such  patients were eligible.
b. Four patients excluded b ecau se  found to have extensive d isease  before
such  patients were eligible.
c. O ne patient refused treatm ent. O ne patient died before receiving any
chem otherapy . O ne patient on beta-blockers and not given verapam il. 
O ne patient hypotensive and not given verapam il.
d. O ne patient already on verapam il. O ne patient given verapam il
in error.
Table 7.1
Details of patients en tered  into study.
A n ft m n *  «** P m P m m
A ge Verapamil
Control
35
37
53 59 
55 59
64
65
73
69
111
109
.495
Cwrfro* P-value
P erform ance s ta tu s  (ECOG) 0
1
2
22.5% (25) 
85.8% (73) 
11.7% (13) 
100.0% (111)
25.7% (28) 
65.1% (71) 
9.2% (10) 
100.0% (109)
.752
Sex Male
Fem ale
55.9% (62) 
44.1% (49) 
100.0% (111)
59.6% (65) 
40.4% (44) 
100.0% (109)
.571
D isease  extent Limited
Extensive
75.7% (84) 
24.3% (27) 
100.0% (111)
74.3% (81) 
25.7% (28) 
100.0% (109)
.815
S ouham i ca teg o ries G ood
M oderate
Poor
28.1% (27) 
43.8% (42) 
28.1% (27) 
100.0% (96)
29.5% (28) 
46.3% (44) 
24.2% (23) 
100.0% (65)
.827
*25% lie a n d  75% lie refer to the  lower and  u pper quartiles.
T ab le  7 .2
Details of pre-treatm ent patient characteristics. F igures In p a ren th eses  a re  actual num ber of patients.
Min. 26%Ha« Madian 75%Ha** Max. P-valua
VarapamH 38 123 154 160 175 0.586
Control 38 118 158 160 175
fb ttH ftto tfttft*  do t*  oTvtariaftoa*
Min. 25%Ha Madian 75%Ha Max. P-vatuo
VarapamH 1.1 3.7 4.4 4.8 8.0 0.422
Control 0.8 4.0 4.4 5.0 6.8
to t t t  Cuinuia^a dfcta 4>r«yd<Wi«4>MIMtt*
Min. 25%Ha Madian 76%Ha Max. P-valua
VarapamH 281 2084 2500 2883 3428 0.106
Confrd 571 2188 2738 2873 3222
t d t t t  <MMUteUv*4t6ht dfatopaanto*'
Min. 25%Ha Madtan 75%Ha Max. P-valua
VarapamH 75 800 668 875 843 0.472
Control 73 828 880 688 800
VarapamH Contol P-valua
No. of cydaa of 1 8.4% W 8.4% (8) 0.816
Protocol taatm ant 2 3.7% (4) 5.6% (6)
3 8.4% (10) 10.3% (11)
4 78.5% (84) 75.7% (81)
100.0% (107) 100.0% (107)
* Total cumulatlva doaa axpraatad a t  mg par m ata  aquarad.
** 25%Ha and 75%Ha rafar to lowar and uppar quartHaa.
Tabla 7.8
Total cumulatlva doaaa of cytotoxic cfruga admlnlatarad and numbar of cydaa of 
protocol taatm ant glvan In aach arm of tha atudy.
193
cyclophospham ide, where the median cumulative dose in the verapamil 
arm was lower (2500mg cf: 2738mg; p = 0.106). This may have 
re la ted  to the  h ig h er incidence (p  = 0.031) of dose reductions a f te r  
course 1 in the  verapamil treatm ent arm (see Toxicity, Table 7.9 
below ).
Reasons for Discontinuing Chemotherapy
T here were a similar num ber of pa tien ts  who stopped 
chem otherapy a f te r  2 courses in both  treatm ent arm s. T here were a 
similar num ber of deaths du rin g  treatm ent in each arm . Reasons fo r 
discontinuing  chem otherapy and the  causes of death  d u rin g  treatm ent 
in each treatm ent arm are  listed  in Table 7 .4 . It can be seen th e re  
were no significant d ifferences in the num ber of pa tien ts  who did not 
complete chem otherapy or the  reasons fo r d iscontinuing 
chem otherapy.
Toxicity
The w orst toxicity  d u rin g  any  one p a tien t's  treatm ent was 
reco rded . T here were no s ta tis tica lly  significant d ifferences in 
general toxicities between the  two arm s, except fo r more severe  
alopecia in  the verapamil treatm ent group (p = 0.045) (Table 7 .5 ) .
A part from a small, b u t s ta tistica lly  significant fall in systolic 
and diastolic blood p re ssu re  following the f ir s t  course of treatm ent
Verapamil Control
Progressive disease 7 10
Patient refusal 2 2
Excessive toxicity 3 2
Dead (drug toxicity) 5 3
Dead (non-cancer cause) 2 4
Dead (cause unknown) 2 3
Other reasons 2 * 2**
* One patient developed phobic reaction to i.v. line.
In the other case clinician decided that the tumour was 
chemoresistant and switched to XRT.
**  One patient stopped because of general deterioration 
in health. The other patient developed an empyema.
Table 7.4
Reasons for discontinuing treatment before 4th cycle 
of chemotherapy.
WHO grade Verapamil Control P-Vafue
Nausea 0 9.9% (10) 5.7% 6) .553
1 29.7% (30) 30.5% 32)
2 25.7% (26) 23.8% 25)
3 33.7% (34) 36.2% 38
4 1.0% ( D 3.8% 4)
100.0% (101) 100.0% 05)
Oral 0 71.0% (71) 77.7% 80) .528
1 19.0% (19) 15.5% 16)
2* 6.0% ( 6) 3.9% 4)
3* 3.0% ( 3) 2.9% 3)
4* 1.0% ( 1) 0.0% 0)
100.0% (100) 100.0% 03)
Haemorrhage 0 98.0% (98) 98.1% 01) 1.000**
1* 1.0% ( D 0.0% 0)
2* 1.0% ( 1) 1.0% 1)
3* 0.0% ( 0) 0.0% 0)
4* 0.0% ( 0) 1.0% 1)
100.0% (100) 100.0% 03)
Alopecia 0 7.1% ( 7) 9.5% 10) .045
1 1.0% ( 1) 5.7% 6)
2 11.1% (11) 20.0% 21)
3 80.8X (80) 64.8% 8)
4 O.OX ( 0) O.OX 0)
100.0%^ (99) 100.0% 05)
Fever 0 88.0% (88) 93.2% 96) .203
1* 9.0% (9 ) 1.9% 2)
2* 3.0% (3 ) 4.9% 5)
100.0% (100) 100.0% 03)
Neurotoxicity 0 64.7% (64) 64.1% 66) .978
1 29.3% (29) 29.1% 30)
2* 5.1% ( 5) 4.9% 5)
3* 1.1% ( 1) 1.9% 2)
100.0% (99) 100.0% 03)
Cardiac 0 98.0% (98) 96.1% 99) .683**
1* 0.0% ( 0) 2.9% 3)
2* 1.0% ( 1) 0.0% 0)
3* 1.0% ( 1) 0.0% 0)
4* 0.0% ( 0) 1.0% 1)
100.0% (100) 100.0% 03)
* These categories combined for calculating the P-value.
** This P-value obtained from Fisher’s exact test. 
T able 7 .5
Toxicity (based on all randomised eligible patients who received at least one course of 
protocol treatment). Figures in parentheses refer to the actual number of patients.
194
with verapam il [p = <0.001 (systolic BP); p = 0.005 (diastolic BP)] 
th ere  was no evidence of increased cardiovascular toxicity  in the 
verapamil arm (Table 7 .6 ). One patien t in the control arm died of an 
acute myocardial in farction . One pa tien t in the  verapamil treatm ent 
arm developed tra n s ien t 1st degree A-V block d u rin g  the f ir s t  course 
of verapam il, b u t th is did not p rev en t fu r th e r  treatm ent with 
verapamil and the  h ea rt block did not recu r.
With re g a rd  to m yelosuppression Table 7.7 shows th a t the 
median n ad ir white cell count a f te r  cycle 1 of chem otherapy was lower 
in the verapamil arm than in the control arm. This did not quite 
reach  s ta tis tica l significance (p=0.065) and overall th e re  was no 
significant difference in haematological toxicity  (Table 7 .8 ). Since 
th e re  was a suggestion  of a difference in nad ir white cell counts a f te r  
course 1 betw een the verapamil and control arm s, the incidence of 
dose reductions in the two treatm ent arms a f te r  course 1 and a f te r  
subsequen t courses of chem otherapy was investigated . There were 
significantly  more dose reductions a f te r  course 1 in the  verapam il 
treatm ent arm (p = 0.031) (Table 7 .9 ).
Response
Response da ta , for all the patien ts in each treatm ent arm are  
shown in Table 7.10. No statis tically  significant d ifferences in overall 
response were seen . Patients with extensive disease had a b ig g er 
gain in overall response ra te  in the  verapamil arm (87% cf: 70% for
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WHO Grade Verapamil Control
Haemoglobin 0 37.0% (34) 35.5% (33) .289
1 43.5% (40) 35.5% (33)
2* 15.2% (14) 23.7% (22)
3* 2.2% ( 2) 3.2% ( 3)
4* 2.2% ( 2) 2.2% ( 2)
100.0% (92) 100.0% (93)
WBC 0* 5.4% ( 5) 5.4% ( 5) .392
1* 4.4% ( 4) 5.4% ( 5)
2 16.3% (15) 18.3% (17)
3 42.4% (39) 50.5% (47)
4 31.5% (29) 20.4% (19)
100.0% (92) 100.0% (93)
Platelets 0 71.7% (66) 75.3% (70) .777
1 14.1% (13) 14.0% (13)
2* 8.7% ( 8) 6.5% ( 6) ,
3* 5.4% ( 5) 4.3% ( 4)
100.0% (92) 100.0% (93)
* These categories combined for calculating the P-value.
T able 7 .8
Worst recorded haematological toxicity, estimated from nadir blood counts after all courses of 
chemotherapy. Figures in parentheses refer to actual number of patients.
Verapamil Control P-value
Chemotherapy 
Dose Reductions 
(after course 1)
Delays in 
Chemotherapy 
(after course 1)
Reduced
Not
Reduced
Delayed
Not
Delayed
21.4% (21) 
78.6% (77) 
100.0% (98)
19.4% (19) 
80.6% (79) 
100.0% (98)
10.2% (10) 
89.8% (88) 
100.0% (98)
13.3% (13) 
86.7% (85) 
100.0% (98)
0.031
0.246
Chemotherapy 
Dose Reductions 
(ever)
Delays in
Chemotherapy
(ever)
Reduced
Never
Reduced
Delayed
Never
Delayed
29.9% (32) 
70.1% (75)
100.0% (107)
31.8% (34) 
68.2% (73)
100.0% (107)
19.6% (21) 
80.4% (86)
100.0% (107)
28.0% (30) 
72.0% (77
100.0% (107)
0.082
0.550
Table 7.9
Incidence of dose reductions and delays after course 1 of chemotherapy and during the 
entire treatment period. Figures in parentheses refer to actual number of patients.
Control Pwefua
Response* CR 38.5% (37) 27.1% (28)
PR 44.8% (43) 53.1% (51)
No change 7.3% (7) 7.3% (7)
Progressive 9.4% (9) 12.5% (12)
Disease
100.0% (96) 100.0% (98)
CR + PR 83.3% (80) 80.2% (77) .582
Estimated difference in percentage of overall (CR+PR)
responders (Verapamil - Control) “ 3.1%**
85% c.i. for above difference = -8.1%-14.3%
Vwapamtf
Unevaluable Dead before 12 weeks 2 4
(non-cancer cause)
Dead before 12 weeks 2 3
(cause unknown)
Dead before 12 weeks 5 3
(drug toxicity)
Assessment not done 2 1
Did not start on
protocol treatment 4 2
* Expressed as  percentage of evaluable patients.
** This difference is calculated allowing for the strattflcalon on disease extent. 
&M a7JP
Response data a t 12 weeks as  defined by WHO criteria for all patients. (CR-complete response, P R - partial response). 
The actual number of patients are shown in parentheses. Unevaluable patients and reasons for this are also shown.
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controls) compared to patien ts with limited disease (82.2%, verapamil 
cf: 83.3% fo r co n tro ls ) . This however was not s ta tis tica lly  significant 
and could easily  relate  to random fluctuation .
Confirmation of Response
T here was agreem ent between the  clinicians1 and the  
rad io log ist's  assessm ent of response in  40 of 64 cases (Table 7 .11 ). 
T here were a total of 11 "downgrades" [5/27 in the verapamil arm 
(18.5%) and 6/37 in the control arm (16.2%)]. In the  case of the 
"upgrades" i .e .  an improvement in response ra tin g  a f te r  independent 
radiological assessm ent, th ere  were more in the control arm (24.3%) 
than  in the  verapamil treatm ent arm (14.8%). Overall th e re  was no 
s ta tis tica lly  significant difference in the  d istribu tion  of reg rad in g s  
betw een the  two treatm ent arms (p  = 0.646).
Survival
Survived curves fo r the p a tien ts , divided according to disease 
ex ten t a t p resen ta tion  and according to treatm ent group (verapam il 
or control) are  shown in F igure 7 .1 . As expected , p a tien ts  w ith 
ex tensive disease show a worse su rv ival p a tte rn . T here is no 
significant difference in the su rv ival cu rves between the  control and 
the  verapam il treatm ent arms in limited disease p a tie n ts . In ex tensive 
disease p a tien ts  verapamil does appear to confer some su rv iva l
Verapamil Control
Downgrades 18.5% (5) 16.2% (6)
Sam e 66.7% (18) 59.5% (22)
Upgrades 14.8% (4) 24.3% (9)
Table 7.11
Re-evaluation of radiological response assessm en t by an independent radiologist. 
Figures in parentheses refer to actual numbers of x-ray pairs examined.
1 0 0
Extensive disease 
□  Verapamil 
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■  Verapamil 
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Figure 7.1
A ctuarial su rv ival curves fo r pa tien ts  in the clinical s tu d y . 
P atien ts have been divided according to disease ex ten t (limited or 
ex tensive) and treatm ent group (verapam il or con tro l).
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advan tage, b u t th is  does not approach sta tis tica l significance.
The analysis of the surv ival curves in term s of median su rv ival 
and death  ra te  is shown in Table 7.12. This confirms th a t th e re  is 
no significant d ifference in su rv ival betw een the  verapamil treatm ent 
and the  control arms for the group as a whole (p=0.943). Also listed  
in Table 7.12 are  the  causes of death . There were no significant 
d ifferences betw een the verapamil and control a rm s. The m ajority of 
pa tien ts  have died of tum our p rogression .
Verapamil Levels
Median verapamil concentration fo r the 18 p a tien ts  s tud ied  was 
252 ng/m l (0.38 uM) with wide in te r-p a tien t variation .
Am* Dtseaee
Status
N& of 
Patianta
No* of 
Deaths
i i i i i i i
Survival
95% &f. for 
mecBan survival
Verapamil
Control
Limited
Limited
84
81
75
62
45 weeks 
48 weeks
36-52 weeks 
44-56 weeks
Verapamil
Control
Extensive
Extensive
27
28
25
24
32 weeks 
23 weeks
24-48 weeks 
18-31 weeks
Verapamil
Control
All
All
111
109
100
86
41 weeks 
44 weeks
36-48 weeks 
36-49 weeks
Relative death rate (Verapamil/Control) 
95% c.i. for relative death rate
= 1.17
0.87-1.57
P =  .290
Gattesa of Death
Verapamil Control
Drug Toxicity 6 3
Tumour progression 86 73
Non-cancer cause 
(without tumour)
0 1
Non-cancer casue 
(with tumour)
3 4
Not known 5 5
Table 7.12
Survival data and causes of death.
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DISCUSSION
This is the  f ir s t  large-scale  random ised s tu d y  to examine the  
feasib ility  and effec ts , in term s of tox icity , response and su rv iv a l, 
of adding  a resis tance  modifier to combination cytotoxic chem otherapy.
The s tu d y  population was well balanced in  term s of disease 
ex ten t and the prognostic  indices defined b y  Souhami ( Souhami e t a l . ,  
1985). A lthough th e re  was not a significant effect on response and 
su rv ival from the addition of verapamil to chem otherapy, the  regime 
was well to lera ted .
Toxicity
Toxicity was quite pred ictab le  and accep tab le , w ith no evidence 
of increased  tox icity , except fo r a tre n d  to more severe alopecia and  
a tendency  to g rea te r  m yelosuppression following the f ir s t  course of 
chem otherapy in the  verapamil treatm ent arm. The reasons fo r th is  
are  u n certa in . Indeed these  findings may simply re la te  to chance 
d iffe ren ces .
As P -glycoprotein  has been shown to be p re se n t in normal 
tissu es  (Fojo e t a l . ,  1987B; Thiebaut e t a l . ,  1987) th is  has possible 
implications fo r the  use of verapamil in addition to chem otherapy. In 
p a rticu la r  th e re  is theoretical concern th a t bone marrow cells might 
become more sensitive to the m yelosuppressive effects of cytotoxic 
d ru g s . However, a t least in v itro , th is  does not appear to be the
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case. Fine e t al. (1987) showed no increase in cy totoxicity  with 
doxorubicin in normal human marrow cells in v itro . Similarly, 
Yalowich e t al. (1985) failed to dem onstrate an increase in cy totoxicity  
in normal bone marrow if verapamil was given in addition to 
doxorubicin or v incris tine , although th is  group did dem onstrate some 
enhanced toxicity  when verapamil was combined with etoposide.
In the  small num ber of pilot clinical stud ies rep o rted  (Benson 
III e t a l . , 1985; Dalton e t a l . , 1989; Miller e t a l . , 1988; Ozols e t a l . , 
1987A; P resan t e t a l . , 1986) th e re  was no evidence of increased  
marrow tox icity  with modifier. However, recen tly  Figueredo e t al. 
(1990) have suggested  th a t the increased  m yelosuppression (w hite cell 
and  p latelet counts not m easured in all cases) and h igh serious 
infection r isk  th ey  encountered in th e ir  non-random ised s tu d y  may 
re la te  to the  addition of resistance modifier to chem otherapy.
It has prev iously  been rep o rted  th a t verapamil can increase 
plasma levels of doxorubicin and reduce doxorubicin clearance (K err 
e t a l . , 1986). Thus a pharm acokinetic effect might explain the  
increased  alopecia and lower nad ir white cell counts a f te r  the f ir s t  
course of chem otherapy in the p a tien ts  tre a ted  w ith verapam il. In 
th is  re g a rd  the  g rea te r  incidence of dose reductions a f te r  the  f ir s t  
course of chem otherapy in the verapam il arm patien ts  is notew orthy. 
This in p a r t  re la tes to the lower n ad ir white cell counts in the  
verapam il tre a ted  p a tien ts , b u t may also be an indication of the 
p resc rib in g  clinicians' heightened caution in the  management of those 
p a tien ts  receiv ing  verapam il. A lthough the  c rite ria  fo r dose reduction
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were clearly  specified in the protocol, and the m ajority of dose 
reductions a f te r  course 1 were confirmed to be on the basis of low 
Day 10 white cell counts, th e re  may have been a tendency  b y  the 
clinicians to e r r  on the  side of caution in those p a tien ts  tre a ted  with 
verapam il.
T here was no evidence of card iovascular toxicity  caused b y  
verapamil in th is  s tu d y  and th is  presum ably re la tes  to the re la tive ly  
low oral doses, w ith consequently  low plasma verapam il levels. The 
verapamil levels achieved in pa tien ts  in th is  s tu d y  (median 252 ng/m l) 
are  well below those optimally active in v itro  (over 3000 ng /m l). In 
those clinical s tud ies where h ig h er verapamil levels were achieved b y  
large doses of in travenous verapam il, th e re  was an unacceptable 
incidence of cardiovascular tox icity  (Benson III e t a l . ,  1985; Dalton 
et a l . ,  1989; Ozols et a l . ,  1987A). T here was no evidence of 
increased  doxorubicin cardiac tox icity  in the  verapamil tre a te d  
p a tien ts . However, the  total doses of doxorubicin u sed  in th is  s tu d y  
(maximum cumulative dose less than  320 mg) would not be expected  to 
lead to cardiac toxicity .
Response
T here were no sta tis tica lly  significant differences in response  
in the  two arms of the  s tu d y . However, in  the ex tensive disease 
p a tien ts  th e re  was an 87% overall response ra te  in the  verapam il 
treatm ent arm , compared with only 71% in the  control arm . The
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reasons fo r th is  remain unclear. These observations could quite 
easily  re la te  to random fluctuation . A lternatively  th ey  may re la te  to 
the pharm acokinetic effect a lready  d iscussed  (K err e t a l . ,  1986). 
Indeed if verapamil was acting  solely on re s is ta n t tum our su b ­
populations (presum ably relatively  small in num ber a t p resen ta tio n ) 
one would not expect any  difference in response ra te s  betw een the  
verapamil and control arm s.
Because the  s tu d y  was not placebo-controlled and blinded an 
independent radiologist reviewed in  a b lind fashion a selection of p re -  
th e rap y  and res tag in g  chest x - ra y s . The res tag in g  x -ra y s  were 
always examined f ir s t  of the p a ir , and only if th is  was en tire ly  normal 
did the  radiologist re g a rd  the  response as complete. As mentioned 
p rev iously , if the patien t was reg ard ed  as having  had a complete 
response on the  x - ra y , a restag in g  bronchoscopy to confirm a CR was 
perform ed. Table 7.11 shows th a t the  concordance ra te  betw een the  
clinicians’ assessm ent of response and th a t of the  radiologist was fa ir , 
w ith agreem ent in 40 out of 64 cases (62.5%). With re g a rd  to those 
p a tien ts  whose radiological response was reg rad ed  following 
independent asessm ent no significant difference in the  d istrib u tio n  of 
reg rad in g s  betw een the  two treatm ent groups was found.
Survival
T here was no difference in su rv ival noted betw een the  
treatm ent (verapam il) and control arms in th is  s tu d y . However, in
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patien ts  with ex tensive disease th e re  was a difference in median 
su rv ival between the verapamil arm (32 weeks) and the control arm 
(23 w eeks). This would be a n a tu ra l consequence of the  h ig h er 
overall response ra te  a lready  noted in ex tensive disease pa tien ts  
tre a ted  with verapam il. However the difference does not approach 
sta tis tica l significance. Indeed the median survived of only 23 weeks 
in the  control arm is ra th e r  d isappoin ting , ra th e r  than  the  median 
su rv ival in  the  verapamil treatm ent arm being  s trik in g ly  good (as 
d iscussed  in Figueredo e t a l . , 1990).
Criticism of Study Design
A num ber of criticism s of the  s tu d y  design have become 
ap p aren t d u rin g  analysis. These concern the  s tu d y  population, the  
failure to placebo-control or blind the tr ia l, the  failure to assess  
response independently  and the failure to consider the  im portance of 
achieving adequate levels of modifier in  the clinic.
To rap id ly  assess clinical ac tiv ity  of a resis tance  modifier, the 
p a tien ts  being  studied  should ideally have relapsed  disease. 
However, th is  is a heterogeneous group of pa tien ts  who have been 
p re - tre a te d  and who have advanced disease. P reviously  u n tre a ted  
p a tien ts  fe lt suitable fo r in tensive combination chem otherapy were 
th erefo re  s tu d ied . Although the m ajority (75%) of pa tien ts  had  limited 
disease only 29% fell into Souhami’s (1985) good prognosis category . 
Thus th e  median su rv ival of only 45-48 weeks in the  limited disease
2 0 2
p a tien ts  in th is  s tu d y  is not unexpected .
As the  clinician who trea ted  the p a tien t and assessed  response 
was aware of p a tien t random isation and as th e re  were no dummy 
p rep ara tio n s u sed , the s tu d y  was n e ith e r blinded or placebo- 
controlled. Moreover compliance with treatm ent in the verapamil arm 
was not checked b y  capsule counting.
In an attem pt to overcome these  shortcom ings an independent 
assessm ent of response was u n dertaken  in conjunction with an 
independent radiologist. In general, agreem ent was found betw een 
the clinicians’ and the  rad io logist's assessm ent of resp o n se , although 
a tendency  to underestim ate response in  the control arm was no ted . 
In addition , in a group of 18 selected p a tie n ts , plasma levels of 
verapam il were m easured. A lthough levels were more than  10-fold 
below those which are  known to be maximally active in SCLC in v i tro , 
sa tisfac to ry  verapam il levels were achieved, considering  th e  oral 
dosage regime th a t was adm inistered. This re la tive ly  low dose of 
verapamil was chosen to avoid excessive card iovascular toxicity .
Summary
This s tu d y  has shown it is possible to tre a t pa tien ts  undergo ing  
chem otherapy fo r small lung  cancer with verapam il. T here was no 
evidence of increased  toxicity  save fo r sligh tly  more severe  alopecia 
and a lower median nad ir white cell count following the  f ir s t  course of 
chem otherapy in the verapamil tre a ted  p a tien ts . W hether these
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effects re late  to a pharm acokinetic phenomenon (K err a t a l . , 1986) or 
w hether th ey  re la te  to heightened normal tissue  toxicity  because of 
the possible p resence of P -glycoprotein  in  h a ir  follicles and  normal 
bone marrow cells or w hether th ey  simply re la te  to chance remains 
u n c lea r.
In term s of response and su rv iva l, re su lts  in bo th  treatm ent 
arms a re  similar. However, th e re  were more dose reductions in the 
verapam il tre a ted  patien ts  a f te r  the  f ir s t  course of chem otherapy. 
Thus it appears th a t verapamil may be having some effect desp ite  
achieving plasma levels of verapamil in the  clinic th a t were 
substan tia lly  lower than  levels optimally active in the  SCLC cell lines 
in v i tro . A lthough no clear dose-response has been dem onstrated  in 
term s of the  resistance  modifying ac tiv ity  of verapamil in the  clinic, 
such  a relationship  does ex ist in the  laborato ry  (C hap ter 6 ). Thus 
one could speculate th a t with h igher plasma levels of verapam il one 
might an ticipate g rea te r  resis tance  modifying ac tiv ity , b u t such  an 
approach is limited b y  cardiovascular tox icity  (Ozols e t a l . , 1987A ) .
In summary, the addition of verapamil to cytotoxic 
chem otherapy in patien ts  with small cell lung  cancer is quite feasib le , 
w ithout undue toxicity  with the dose of verapamil u sed . However no 
improvement in response or su rv ival has been noted . At b es t it 
appears th a t the  addition of verapamil reduces the  death  ra te  b y  only 
13%. This may re la te  to failing to achieve blood levels of verapam il 
in the  clinic th a t might be expected to be maximally  active in term s of 
resis tance  modification. These find ings, coupled with evidence of
resis tance  modification with verapamil in newly estab lished  small cell 
lung  cancer cell lines in the laborato ry  su g g est th a t fu r th e r  stud ies 
aimed a t achieving h igher levels of modifier to t r y  and manipulate the  
MDR phenotype in the  clinic merit fu r th e r  investigation .
CHAPTER 8
2 0 5
GENERAL DISCUSSION
The original aims of th is  thesis  have, on the  whole, been 
achieved. Nine SCLC biopsies have been established  as continuous 
cell lines in v itro . These cell lines were derived  from both  
u n trea ted  and from trea ted  pa tien ts  and include 2 p a irs  of cell 
lines each estab lished  from the  same patien t before and a f te r  a 
course of chem otherapy. There is a 60-fold range in the  
sensitiv ities of the cell lines to doxorubicin and fo r 5 of the  cell 
lines d ru g  sen sitiv ity  is increased  b y  verapam il. A lthough the  
addition of verapamil to chem otherapy fo r p a tien ts  with SCLC did 
not significantly  improve su rv iv a l, the  combination was well 
to lera ted  and no adverse  toxicity  was o b se rv ed . The re su lts  have 
been d iscussed  in detail in the individual chap ters  and only the  
main points will be reviewed in th is  ch ap te r.
Establishment and Characterisation of SCLC Cell Lines
A ran g e  of cell lines have been successfu lly  estab lished  in  
tissu e  cu ltu re  from biopsies of p a tien ts  bo th  p rio r to chem otherapy 
and also a t time of re lapse , both  from the  prim ary site  and  from a 
v a rie ty  of m etastatic deposits.
A g rea t deal was lea rn t about the  establishm ent of cell lines 
from fre sh  b iopsy m aterial. In p a rticu la r the  im portance of
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m aintaining a high tum our cell density  in the early  stages became 
ev iden t. A lthough a num ber of rep o rts  have described  the use of 
enzymatic d isaggregation , feeder lay e rs , conditioned medium and 
serum -free medium none of these methods proved  n ecessary  fo r the  
successfu l establishm ent of a SCLC biopsy in cu ltu re .
A p articu la rly  im portant p a ir  of cell lines (LS274 and LS310) 
have been estab lished , rep resen tin g  a cell line from a p re ­
treatm ent tum our biopsy (LS274) and  a cell line estab lished  from 
the same p atien t a t time of relapse (LS310). This p a ir  of cell lines 
may th erefo re  be reg ard ed  as a model of d ru g  resis tance  in v itro  
w here d ru g  resis tance  developed in the clinic.
These cell lines have been fully  charac terised  and 
dem onstrate typical fea tu res  of SCLC in v itro , including 
ch arac te ris tic  appearances on pathological exam ination, the  
possession of certain  m arker enzyme ac tiv ities, and the typical 3- 
p deletion seen on karyotypic analysis.
In co n trast to a num ber of ex isting  SCLC cell lines these  
lines a re  all a t an early  passage num ber and are  th u s  less subject 
to phenotypic d rif t as a re su lt of long term  cu ltu re . T h u s, 
although the  clinical relevance of such  tissu e  cu ltu re  models 
remains u n c lear, these early  passage newly estab lished  SCLC cell 
lines re p re se n t an im portant tool fo r stud ies of d ru g  resis tance  in 
SCLC in v i tro .
Chemosensitivity Testing
Considerable difficulties were encountered  when conventional
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techniques were used  to m easure the chem osensitivity of these  cell 
lines. In p a rtic u la r, initial s tud ies u s in g  sphero id  grow th 
m easurem ents proved unhelpfu l. This re la ted  to the fact th a t only 
a few of the  cell lines grew successfu lly  in the  agar-coated  p la te s . 
The time req u ired  fo r and labour in tensive n a tu re  of any  one 
experim ent was also a significant obstac le . This technique had  the 
advantage th a t the  in tac t aggregate  could be stud ied  and th is  was 
a major consideration fo r these cell lines since the  m ajority could 
not be d ispersed  into a viable single cell suspension .
Subsequently  a tetrazolium  dye-based  chem osensitivity assay  
was investiga ted  as a possible means of s tu d y in g  d ru g  sen sitiv ity . 
A num ber of im portant deficiencies in  th e  basic assay  were 
iden tified . The major fault associated w ith p rev iously  published  
assays was the  failure to dem onstrate a linear relationship  betw een 
cell num ber and MTT-formazan p roduction . This resu lted  in a 
g ross underestim ation of cell num bers a t h igh cell densities. This 
problem was overcome b y  u sing  an  increased  su b s tra te  (MTT) 
concentration d u rin g  the final incubation and b y  controlling the  pH 
of the  MTT-formazan p roduct. Doxorubicin was shown to p en e tra te  
th roughou t the aggregates of the SCLC cell lines and MTT was 
reduced  b y  the viable cell population of the  ag g reg a te . Thus the 
en tire  aggregate  was exposed to the  cytotoxic d ru g  and hence 
MTT-formazan production could be used  to m easure su rv iv in g  cell 
num bers in en tire  tum our ag g reg a tes . The basic assay  was th u s  
shown to be suitable for m easuring chem osensitivity in the  newly 
estab lished  SCLC cell lines.
U sing th is  assay  the chem osensitivities of the  new cell lines
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to doxorubicin were m easured. Such stud ies revealed a wide (60- 
fold) range of sen sitiv ity  to doxorubicin. This did not appear to 
re la te  to morphology or any  o th er charac teris tics  of the cell lin e s . 
N either did chem osensitivity appear to re la te  to the p a tien t h is to ry  
from whose biopsy the  cell line was estab lished . However, 
considering  the p a ir of cell lines LS274 and LS310, it does appear 
th a t in cell lines obtained from the  same p a tien t sen sitiv ity  to 
doxorubicin might m irror the clinical h is to ry  of the  p a tien t from 
whose biopsies the  cell lines had been estab lished .
S ubsequently  the activ ity  of verapam il in these  cell lines was 
in vestiga ted . A 2-3 fold increase in sen sitiv ity  to doxorubicin in 
the p resence of verapamil was found in 5 of the 9 cell lines te s ted . 
Increased  sen sitiv ity  to doxorubicin in the  p resence of verapam il 
did not appear to re late  to the in trin s ic  chem osensitivity of th e  cell 
line o r the  clinical h is to ry  of the  p a tien t from whose biopsy  th e  cell 
line had  been estab lished . Similarly increased  sen sitiv ity  in  the  
p resence of verapamil did not appear to re la te  to cell line 
morphology or any  o ther cellular ch arac te ris tic s . Nonetheless 
th ere  was clear evidence of increased  sen sitiv ity  to doxorubicin in 
the p resence of verapamil in newly estab lished  SCLC cell lines. 
This find ing  has not been prev iously  rep o rted .
The mechanism of action of verapamil in the SCLC cell lines 
remains u nclear. More recen t work with these  SCLC cell lines has 
failed to dem onstrate the p resence of P -glycoprotein  e ith e r b y  
W estern blot or b y  immunocytochemistry. P reviously , Cole e t al. 
(1989) rep o rted  th a t verapamil can increase the  sen sitiv ity  to
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doxorubicin of an MDR varian t of the SCLC cell line NCI-H69 which 
does not overexpress P -glycoprotein . Thus it appears th a t 
verapamil can modulate d ru g  sensitiv ity  via a mechanism th a t does 
not involve P-glycoprotein . A lthough th is  mechanism has not y e t 
been identified  it  is known th a t verapam il can a lte r  th e  en erg y  
metabolism of d ru g  re s is ta n t cells (B roxterm an e t a l . , 1989) and 
of non-MDR cell lines (Plumb et a l . , 1989). An alteration  of the 
ATP pool in the cell could influence the cy totoxicity  of compounds 
such  as doxorubicin. This clearly  req u ires  fu r th e r  detailed 
investigation . To date u sing  a re s is ta n t human SCLC tum our model 
it has been shown th a t the resis tance  modifying ac tiv ity  of 
verapam il is dose-dependent. The concentration of verapamil th a t 
is optimally active in v itro  appears to be about 6 uM. This is in 
co n trast to the levels of verapamil which are  achievable in the  
clinic w ithout excessive card iovascular tox icity  (up  to lu M ). 
These re su lts  have implications fo r the  application of verapam il as 
a resis tan ce  modifier in the clinic.
Clinical Study of Verapamil Plus Chemotherapy in SCLC
T his , the  only large-scade random ised clinical s tu d y  of 
verapam il given in addition to combination chem otherapy in pa tien ts  
w ith SCLC, does not suggest an improvement in su rv iva l in  the  
verapam il treatm ent arm. However, th e re  are  indications th a t 
verapam il has some activ ity  in the clinical con tex t. In p a rtic u la r  
following the  f ir s t  course of chem otherapy the  median n ad ir white 
cell count was lower in the verapamil treatm ent arm . This resu lted
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in a significantly  increased  num ber of dose reductions a f te r  the  
f ir s t  cycle of chem otherapy in the  verapam il arm , compared with 
con tro l. Despite th is , response ra te s  and su rv ival were similar in 
both  arms of the  s tu d y .
These effects of verapamil in the  clinic have been produced 
with plasma levels of modifier substan tia lly  lower th an  those 
optimally active in SCLC in v itro  (0 .3  uM cf: 6.6 uM ). In th is  
reg a rd  it  is w orth considering th a t verapamil may have activ ities 
in the  clinic, o ther than  those which a re  ap p aren t in v i tro . For 
exam ple, verapamil may a lte r tum our blood flow (Kaelin e t a l . ,  
1982) or may a lte r  the handling and  pharm acokinetics of the  
doxorubicin used  to tre a t these  p a tien ts  (K err e t a l . ,  1986). 
T hus, although the levels obtained in the clinic were sub-optim al, 
some clinical ac tiv ity  was seen.
The addition of verapamil to combination chem otherapy in 
pa tien ts  with SCLC is en tire ly  feasible in term s of p a tien t 
acceptability  and without undue increased  tox icity . T herefo re , it 
seems reasonable to suggest th a t fu r th e r  stud ies  of resis tan ce  
modifiers should be p u rsu ed . These stud ies  should aim to achieve 
levels of modifier in the clinic, similar to those levels known to be 
active in the  laboratory . Indeed recen tly  C habner & Fojo (1989) 
have s ta ted  th a t clinical tria ls  aimed a t re v e rs in g  m ultidrug 
resis tan ce  should be p u rsu ed  as a h igh  p rio r ity . A gents of 
in te re s t include the less cardiotoxic D-isomer of verapamil and 
modulators such as quinidine and  beprid il w here clinically 
achievable levels are  comparable to those active in the labo ra to ry .
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Possible Mechanisms of Resistance in SCLC ; P-Glycoprotein 
Reviewed
The function of P- glycoprotein in normal cells and its  
regulation  b y  su b s tra te s  or inh ib ito rs is as y e t unknow n. The 
question remains as to how im portant or re levan t P-glycoprotein  
ac tiv ity  is to the d ru g  resistance  seen in SCLC in the clinic.
Recently Lai e t al. (1989) published  th e ir  work which 
examined MDR-1 gene expression in lung  cancer (24 fre sh  b iopsies, 
67 cell lines and  10 non-tum ourous lung  sam ples). In 58% of lung  
tum our b iopsies, including 3 of 6 SCLC biopsies significant 
a lthough relatively  low levels of MDR-1 gene expression  were 
found , as was the case in 7 of 10 non-tum ourous lung  samples. 
In the  lung  cancer cell lines, 33% dem onstrated sign ifican t, 
a lthough again relatively  low levels of MDR-1 gene expression . 
Only 4 of the  27 SCLC cell lines exhib ited  MDR-1 gene exp ression . 
The au th o rs  did not find an association betw een MDR-1 gene 
expression  and chem osensitivity in v itro , m easured u s in g  a 
tetrazolium  dye-based  assay . They concluded th a t the clinical 
m ultidrug resis tance  of many lung  cancers could not be explained 
exclusively  on the basis of expression  of the  MDR-1 gene. Thus 
it seems likely th a t in SCLC, recu rren ce  of chem oresistant tum our 
does not re la te  solely to the  repopulation /pro liferation  of cells 
ex p ress in g  h igher levels of P -g lycoprotein . N onetheless, Shen e t 
al. (1986B) have pointed out th a t increased  levels of MDR-1 gene 
expression  may precede gene amplification in the  development of 
d ru g  re s is ta n c e , and so the finding  of low b u t detectable levels of
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MDR-1 mRNA in these  clinical specimens may be re lev an t. 
C ertainly  th is  s tu d y  does not exclude the possib ility  of 
he terogeneity  of expression  of MDR-1 mRNA in individual tum our 
cells .
A recen t clinical s tu d y  published  b y  Cantwell and colleagues 
(1988) has also suggested  th a t P-glycoprotein  and the MDR 
phenotype may not be the major cause of clinical resis tan ce  in 
SCLC. In th is  s tu d y  88 p a tien ts  w ith SCLC were tre a te d  with the 
MDR d ru g s  v in cris tin e , doxorubicin and  etoposide fo r 3 cycles. 
Those pa tien ts  only showing a p artia l response or no response to 
th is  treatm ent were then  tre a ted  with the  non-MDR d ru g  ifosfamide 
(5 gm/m3 ) . Only 6 of the 14 p a tien ts  (43%) tre a ted  with Ifosfamide 
showed any  response to th is non c ro ss -re s is ta n t regimen and none 
of the  responses were complete. A g re a te r  response to Ifosfamide 
might have been expected if MDR was the  basis of the  re s is tan ce , 
given th a t resis tance  to Ifosfamide th ro u g h  the  MDR phenotype has 
not been dem onstrated to date (Cantwell e t a l . , 1988).
The recen t laborato ry -based  re p o rt b y  Lai e t al. (1989) and  
th is  clinical s tu d y  (Cantwell e t a l . ,  1988) bo th  su g g est th a t o v er­
expression  of P-glycoprotein  is unlikely to be the  main cause of 
resis tan ce  in SCLC. Their re su lts  would su p p o rt the  find ings in 
our clinical s tu d y  which failed to dem onstrate any  significant 
benefit from the addition of verapamil to chem otherapy in the  
treatm ent of pa tien ts  with SCLC, although the low levels of 
verapam il achieved in the clinic may also have been co n trib u to ry .
T hus the  role of MDR-1 gene expression  and P -g lycoprotein  
in clinical resis tan ce  in SCLC needs to be more clearly  defined .
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Several lines of evidence su g g est th a t o ther mechanisms of 
resis tance  may be involved in the resis tance  of lung  cancer seen 
in the clinic.
Alternative Mechanisms of Resistance
A num ber of enzyme ch an g es , including alterations in 
g lutathione tra n sfe ra ses  and certa in  topoisom erases, have been 
implicated as alternative  mechanisms of d ru g  res is tan ce . In 
addition o ther enzyme alterations (Bosmann & Kessel, 1970; 
Bosmann, 1971) as well as a lte red  membrane flu id ity  and  o ther 
membrane changes (Holleran e t a l . ,  1986; Ramu et a l . ,  1983; 
Wheeler e t a l . , 1982), a ltered  sub -cellu lar d ru g  d istribu tion  (Klohs 
& Steinkam pf, 1988; Sehested e t a l . , 1987A,B), and ionic changes 
[reduced  sodium pump activ ity  (Bose & Lam, 1988) and a lte red  
calcium levels (T suruo  et a l . , 1984)] have also all been implicated 
in d ru g  resis tan ce . Finally reduced  d ru g  influx has also been 
su ggested  as an alternative  mechanism of resis tan ce  (S kovsgaard , 
1978A,B). Most of th is  work was based  on laborato ry  models of 
d ru g  resis tan ce  and has been review ed in detail b y  R iordan & Ling
(1985).
Glutathione and Glutathione - S -  Transf erases
G lutath ione-S -transferase  (GST) comprises a t least 12 iso­
enzymes . This phase II enzyme has long been known to b ind  and 
detoxify  cellular poisons (Jakoby, 1978) and  comprises a family of
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dimeric p ro te ins which conjugate electrophilic su b s tra te s  w ith the  
trip ep tid e  glutathione (GSH), thus making a less toxic and more 
read ily  excreted  metabolite. The anionic isoenzyme of GST, a form 
found in placenta and usually  p re sen t only in low levels in liver is 
o v er-ex p ressed  both  in ra t  h yperp lastic  nodules (Cowan e t a l . , 
1986; Rushmore et a l . , 1987; Satoh et a l . , 1985) and in
doxorub ic in -resis tan t human b re a s t (MCF-7) cancer cells (B atist 
e t a l . , 1986; Cowan e t a l . , 1986). A num ber of cytotoxic ag en ts , 
including melphalan, have been shown to act as su b s tra te s  fo r 
GST, and the ra te  of cytotoxic detoxification is increased  
significantly  in the p resence of GST catalysis (Dulik e t a l . , 1986). 
Thus increased  GST activ ity  appears  to be a component of 
resis tan ce  in some cellular system s.
R ecently Moscow’s and Cowan's laborato ry  a t the  National 
C ancer In s titu te , Bethesda has cloned the  cDNA encoding placental 
GST (G STpi). Using th is  cDNA probe th ey  found a marked 
h eterogeneity  in GSTpi expression . In te res tin g ly , as well as in 
p lacen ta , th is  enzyme is also normally ex p ressed  in lung  tissu e  
(Moscow & Cowan, 1988). Increased  amounts of GSTpi and GSTpi 
mRNA have been found in colon cancers compared with "normal” 
tissu e  a t the  resection  margin (Kodate e t a l . , 1986). Since colon 
carcinoma exhib its in trin sic  resis tance  it  may be th a t GSTpi is a 
m arker fo r such  resis tan ce . O ther classes of GST isoenzymes may 
also p lay  a role in resistance  to an tineoplastic ag en ts . For 
example, two d iffe ren t isoenzymes in the  basic class of GST have 
been implicated in resistance  to mechlorethamine (B uller e t a l . ,
1987) and  a lk y l a t i n g  agents (Manoharan e t a l . , 1987). Furtherm ore
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levels of g lu tath ione, the  su b s tra te  fo r all GSTs have been shown 
to be elevated in cells re s is tan t to melphalan (G reen e t a l . , 1984A; 
Suzukake e t a l . ,  1982, 1983). L ittle is known about GST 
expression  in SCLC. Carmichael e t al. (1988B) dem onstrated GST 
ac tiv ity  in a panel of lung  tum ours and rep o rted  th a t the  levels of 
g lutathione and GST were h ig h er in NSCLC, an in h eren tly  
re s is ta n t tum our ty p e , than  in SCLC cell lines.
Thus the  role of GSTpi in clinical d ru g  resis tan ce  remains 
unclear. In term s of doxorubicin re s is tan ce , some isoenzymes of 
GST possess peroxidase ac tiv ity , increased  levels of which could 
p ro tec t the  tum our cell from doxorubicin tox icity , assum ing th a t 
free  radical generation is an im portant mechanism of action of 
doxorubicin toxicity . The peroxidase could "mop up" free  radicals 
(S inha e t a l . , 1987). Thus GSTs hav ing  peroxidase ac tiv ity  could 
reduce various potential tox ins, including  free  rad icals.
It is possible to modulate GST ac tiv ity  bo th  in v itro  and in 
v ivo . Buthionine sulfoximine (BSO ), a sy n th e tic  amino acid 
analogue which inhib its the  f ir s t  enzyme in the  GSH b iosynthesis 
pathw ay, depletes in tracellu lar g lutathione which is the  su b s tra te  
fo r GST isoenzymes and glutathione peroxidase (M eister, 1983). 
T reatm ent w ith BSO has been shown to re s to re  sen sitiv ity  in 
d oxorub ic in -resis tan t tum our ce lls , p e rhaps b y  perm itting  
generation  of toxic free  radicals in cells which had p rev iously  been 
p ro tec ted  b y  glutathione (Hamilton e t a l . , 1985). Similarly several 
s tud ies  of d ifferen t re s is tan t tum our cell lines have shown rev e rsa l 
of d ru g  resis tance  a fte r  treatm ent w ith BSO, correspond ing  with 
decreases in in tracellu lar GSH concentrations (Kramer e t a l . , 1987;
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Ozols e t a l . ,  1987B; Russo & Mitchell, 1985).
Of p a rticu la r in te re s t is recen t work from Tew’s group which 
has shown th a t to tal GST ac tiv ity  is elevated 4-fold in re s is ta n t 
compared with sensitive tum our cells (Tew & C lapper, 1988). 
F urtherm ore, u sing  non-cytotoxic concentrations of e thacryn ic  acid 
in combination with chlorambucil, a su b stan tia l increase in the 
sen sitiv ity  of bo th  sensitive and re s is ta n t r a t  b re a s t carcinoma 
cells and human colon cancer cells was produced (Tew e t a l . ,
1988). E thacrynic acid acts as a su b s tra te  fo r GST, and  is known 
to form a glutathione conjugate th ro u g h  a catalytic reaction  with 
GST (Ahokas e t a l . ,  1984). M oreover, Tew et al. (1988) 
dem onstrated evidence of a dose-dependent decrease in GST 
ac tiv ity  w ith ethacryn ic  acid.
Topoisomerases
C ertain topoisomerase enzymes have been identified  as 
im portant ta rg e ts  fo r cytotoxic d ru g s , especially an thracyclines 
and  podophyllotoxins. Topoisomerase II, an  ATP dependent 
enzyme a ttaches to DNA and produces a d o ub le-stranded  b reak  
which allows unkno tting  and rep a ir  of th e  DNA. A nthracyclines 
and podophyllotoxins form stable complexes with topoisom erase II 
and  p re v e n t it  rep a irin g  DNA. In some cell lines, p a rticu la rly  
those exh ib iting  ra th e r  atypical p a tte rn s  of MDR, a lte red  
topoisom erase II ac tiv ity  has been m echanistically linked to 
resis tan ce  (Pommier et a l . ,  1986).
An etoposide re s is ta n t CHO cell line th a t showed an atypical
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MDR p a tte rn  of c ro ss-resis tan ce  to the  s tru c tu ra lly  dissim ilar 
agen ts m-AMSA, m itoxantrone and doxorubicin dem onstrated 
alte red  topoisomerase II ac tiv ity  (Glisson e t a l . , 1986). In addition 
a lte red  topoisomerase II ac tiv ity  has been seen in a CHO cell line 
selected fo r resistance  to ellipticine which was c ro ss -re s is tan t to 
m-AMSA and etoposide (Pommier e t a l . , 1986). M ultidrug re s is ta n t 
cells with a lte red  levels of topoisomerase II continue to be isolated 
(Deffie e t a l . , 1989; Ferguson e t a l . ,  1988). Indeed it may be 
th a t MDR cells with increased  P-glycoprotein  levels may also have 
a component of resistance mediated via a lterations in topoisomerase 
II.
Topoisomerases may re p re se n t the  final common pathw ay of 
cytotoxicity  of several d ifferen t classes of an tineoplastic ag en ts . 
However, no s tu d y  has y e t determ ined w hether a lte red  
topoisom erase activ ity  plays a role in  d ru g  resis tan ce  in  the  clinical 
se ttin g .
Thus the  mechanisms relevan t to clinical resis tan ce  in SCLC 
have y e t to be defined. C ertainly once the re levan t mechanisms 
have been elucidated, exciting opportunities fo r modulation in  the  
laborato ry  and the clinic will become possib le.
Future Direction of Clinical Research
The ultim ate goal of th is  laborato ry  re sea rc h , a t least from 
a clinician 's point of view, is to enable changes in th e ra p y  th a t will 
improve median and long term  su rv ival in p a tien ts  w ith SCLC.
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Various opportunities ex ist fo r the application of what is a lready  
known about d ru g  resistance  in SCLC to be ex tended  to the  clinical 
se ttin g .
In p a rtic u la r, if increased  MDR-1 gene expression  and P- 
glycoprotein levels are  an im portant com ponent, then  refinem ent of 
c u rre n t modifier s tud ies with verapam il, p erh ap s  making use of the  
fact th a t verapamil is a racemic m ixture of two stereoisom ers, or 
perhaps u sin g  alternative  m odifiers, would seem ap p ro p ria te . If 
on the  o th er hand alterations in cellular glutathione p lay  a major 
component, th en  clinical s tud ies aimed a t in te rfe rin g  with GST 
enzyme ac tiv ity  are  indicated.
P -  glycoprotein Blockers
The main obstacle is achieving serum  verapam il levels in the  
clinic similar to those shown to be optimally active in  v itro  ( g re a te r  
than  6 uM). Given th a t a dose-response effect fo r verapam il in 
term s of resis tance  modifying ac tiv ity  w ith doxorubicin in SCLC in 
v itro  has been dem onstrated (C hap ter 6) it  seems reasonable to 
speculate th a t b y  increasing  serum  verapam il levels it might be 
possible to increase the activ ity  of verapam il in  SCLC in  the  clinic. 
However such  dose increases with verapam il a re  limited b y  
card iovascular tox icity . A possible solution to th is  problem lies 
in the  fact th a t verapamil is a racemic m ixture of the  D- and L- 
stereo isom ers. The L-isomer is about 10-fold more active in term s 
of effects on cardiac conduction than  the D-isomer (C u rtis  & 
Walker, 1986; Echizen e t a l . ,  1985; T riggle & Swamy, 1983).
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Using a m ulti-d rug  re s is ta n t SCLC tum our model it has been shown 
th a t the resis tance  modifying ac tiv ity  of the  individual 
stereoisom ers is similar. Thus the use of D-verapamil alone might 
allow h ig h er serum  levels to be achieved in SCLC p atien ts  w ithout 
undue cardiotoxicity . Clinical stud ies of D-verapamil in addition 
to cytotoxic chem otherapy in cancer p a tien ts  a re  now underw ay.
A nother possible approach to the problem of achieving levels 
of modifier in the clinic th a t a re  known to be optimally active in 
v itro  might be to use an a lternative  modifier, such as quinidine or 
bep rid il. Using a re s is ta n t tum our model in the  laborato ry  it has 
been shown th a t quinidine and beprid il a re  capable of re v e rs in g  
d ru g  resis tan ce  a t concentrations th a t can be a tta ined  in  the  clinic 
w ithout undue toxicity . With an oral dose of quinidine of lgm . 
B . D . , plasma levels of quinidine of 2-4 ug/m l are  achievable, and 
th is  is the  concentration th a t is optimally active in v itro . Clinical 
stud ies u s in g  quinidine in addition to an  an thracycline in b re a s t 
cancer p a tien ts  are  cu rren tly  underw ay.
A final, exciting  possibility  fo r therapeu tic  in terven tion  
rem ains. This theo ry  suggests  th a t,  in tum our cells where 
resis tan ce  is indeed due to P -g lycopro tein , i t  may be possible to 
ta rg e t monoclonal antibodies, conjugated with tox ins, against the  
P -glycoprotein  of re s is ta n t cells (F itzgerald  e t a l . ,  1987) and so 
use the  actual mechanism th a t causes re sis tan ce , to overcome th a t 
re s is ta n c e .
2 2 0
GST Antagonists
Two agen ts may be of clinical use in term s of overcoming 
GST mediated resis tan ce , namely BSO and ethacryn ic  acid. Phase 
I clinical tria ls  of BSO, given with the  antineoplastic ag en t, L- 
phenylalanine m u sta rd , are  now underw ay a t the Fox Chase Cancer 
C enter in the  United S tates (O’Dwyer, 1989, w ritten  
communication). In addition a t least two cen tres  (The Fox Chase 
Cancer C entre and the  U niversity  of California, Irv ine) in the 
United S tates have s ta r te d  phase I s tud ies u sing  ethacryn ic  acid 
in combination with antineoplastic d ru g s  including thioTEPA 
(N agourney, 1989, w ritten  communcation; O 'Dwyer, 1989, w ritten  
communcation).
Concluding Comment
The difficulties of p revention  and early  detection mean th a t 
lung  cancer will continue to be a significant clinical problem in  the  
coming decades. Relapse with re s is ta n t tum our in small cell lung  
cancer remains the major obstacle in im proving long-term  su rv iva l 
in pa tien ts  with th is  d isease. In th is  con tex t, it is im portant th a t 
s tud ies such  as those described  in th is  thesis  are  ex tended in the 
p u rsu it of the  tan talizing  goal of overcoming d ru g  resis tan ce  in 
small cell lung  cancer.
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